Page last updated: 2024-10-22

aspirin and Brain Ischemia

aspirin has been researched along with Brain Ischemia in 798 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL."9.69Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol. ( Aguilar-Pérez, M; Ainz-Gómez, L; Amaya Pascasio, L; Baena-Palomino, P; Bravo Rey, I; Cabezas-Rodríguez, JA; Castellanos Rodrigo, MDM; de Albóniga-Chindurza, A; Delgado-Acosta, F; Díaz Pérez, J; Escudero-Martínez, I; Fernandez Prudencio, L; Freijo Guerrero, MDM; Gamero-García, MÁ; González Díaz, E; González García, A; Hidalgo, C; Jiménez Jorge, S; Jiménez-Gómez, E; Medina-Rodríguez, M; Moniche, F; Montaner, J; Morales Caba, L; Mosteiro, S; Ortega-Quintanilla, J; Oteros Fernández, R; Pardo-Galiana, B; Ramirez Moreno, JM; Rosso Fernández, C; Sanz-Fernandez, G; Vielba-Gomez, I; Zamora, A; Zapata-Arriaza, E, 2023)
"Aspirin is recommended for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke but can lead to gastrointestinal intolerance and bleeding."9.69Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial. ( Bath, PM; Dong, Q; Feng, Y; Huang, X; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, X; Li, Z; Lin, J; Liu, B; Liu, L; Liu, Q; Meng, X; Pan, Y; Suo, Y; Wang, Y; Xie, X; Xiong, Y; Xu, A; Yang, H; Yuan, B; Zhao, J; Zhao, X; Zhou, Y; Zhu, H, 2023)
"Aspirin and unfractionated heparin are often used during endovascular stroke treatment to improve reperfusion and outcomes."9.51Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial. ( Beenen, LFM; Berkhemer, O; Boiten, J; Bokkers, RPH; Boukrab, I; Chalos, V; Coutinho, JM; de Laat, KF; de Ridder, I; den Hertog, HM; Dippel, DWJ; Elgersma, O; Emmer, BJ; Gerrits, D; Gons, RAR; Hammer, S; Hofmeijer, J; Jenniskens, SFM; Kerkhoff, H; Koudstaal, PJ; Krietemeijer, M; Lingsma, HF; Lycklama, G; Majoie, CBLM; Manschot, S; Martens, J; Meijer, FJA; Nieboer, D; Postma, AA; Remmers, M; Roos, YBWEM; Roosendaal, SD; Roozenbeek, B; Rozeman, A; Schonewille, W; Staals, J; Tolhuisen, M; Truijman, MTB; Tuladhar, AM; Uyttenboogaart, M; van de Graaf, RA; van den Berg, R; van den Wijngaard, I; van der Hoorn, A; van der Lugt, A; van der Schaaf, I; van der Sluijs, PM; van der Steen, W; van der Worp, HB; van Dijk, LC; van Doormaal, PJ; van Es, ACGM; van Hasselt, B; van Oostenbrugge, RJ; van Tuijl, J; van Voorst, H; van Zwam, W; Vos, D; Vos, JA; Wolff, L; Yo, LSF; Yoo, AJ; Zinkstok, S, 2022)
"To test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke."9.51Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. ( Bath, PM; Chen, W; Dong, Q; Jiang, Y; Jing, J; Johnston, SC; Li, H; Lin, J; Meng, X; Pan, Y; Wang, Y; Xu, AD, 2022)
"The study aimed to evaluate the clinical efficacy of the Huo Xue Hua Yu method combined with aspirin in the treatment of patients with acute cerebral infarction (ACI)."9.41Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis. ( Chen, C; Liu, X; Ma, F; Tang, Q; Wen, X; Wu, Y, 2023)
"Clopidogrel and aspirin are key intervention for acute ischemic stroke (AIS) and transient ischemic attack (TIA)."9.41Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial. ( Chen, J; Gao, P; Han, M; Jia, W; Kuang, J; Peng, C; Starcevich, K; Tu, J; Wang, J; Wu, Y; Yi, Y; Yin, S; Zhang, X, 2021)
" Patients with newly diagnosed ischemic stroke who are just about to start Aspirin were assessed for eligibility and inclusion in our trial."9.34An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS). ( Abdallah, IM; Ahmed, MS; Ali, M; AlSaud, AE; Danjuma, MI; Elshafei, MN; Imam, Y; Mohamed, MFH; Obeidat, K; Parray, AS; Saeid, R, 2020)
"Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone."9.30Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019)
"Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases."9.30Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019)
"Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4."9.30Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. ( Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC, 2019)
" The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days."9.27Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018)
"Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding."9.27Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. ( Amarenco, P; Ameriso, SF; Arauz, A; Bangdiwala, SI; Benavente, OR; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Davalos, A; De Vries Basson, MM; Eckstein, J; Endres, M; Gagliardi, RJ; Hankey, GJ; Hart, RG; Joyner, C; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Sheridan, P; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, D; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, JI; Yoon, BW, 2018)
"The PRISMS trial was designed as a 948-patient, phase 3b, double-blind, double-placebo, multicenter randomized clinical trial of alteplase compared with aspirin for emergent stroke at 75 stroke hospital networks in the United States."9.27Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. ( Broderick, J; Chatterjee, A; Devenport, J; Devlin, T; Jauch, EC; Khatri, P; Kleindorfer, DO; Levine, SR; Mejilla, J; Pavlov, A; Purdon, B; Romano, JG; Saver, JL; Sawyer, RN; Starr, M; Vagal, A; Yeatts, SD, 2018)
"To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA."9.24Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. ( Chen, W; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Zhao, X, 2017)
"In order to evaluate the impact of cilostazol on endothelial function, we compared the changes of flow-mediated dilation (FMD) between aspirin and cilostazol groups in patients with acute cerebral ischemia."9.24Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. ( Choi, MH; Hong, JM; Lee, JS; Lee, SE; Lee, SJ; Shin, DH, 2017)
"A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin."9.22Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016)
"In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia."9.22Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016)
"We analysed the rates of stroke and systemic embolism in 6563 aspirin-treated patients with AF from the ACTIVE-A/AVERROES databases."9.20Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. ( Alings, M; Avezum, A; Connolly, SJ; Díaz, R; Eikelboom, JW; Hart, RG; Healey, JS; Hohnloser, SH; Lauw, MN; Lewis, BS; Shestakovska, O; Vanassche, T; Wang, J, 2015)
"Aspirin is a primary antiplatelet agent for the secondary prevention of ischemic stroke."9.20Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions. ( Cho, KH; Choi, KH; Choi, MJ; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, JS; Lee, SH; Nam, TS; Park, MS, 2015)
"We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined)."9.20Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. ( Anker, SD; Buchsbaum, R; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015)
"This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source."9.19Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014)
"Ancillary analysis of the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, comparing aspirin and apixaban, focused on sex differences."9.19Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2014)
"The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated."9.17Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Flaker, G; Hart, R; Lanas, F; Lip, GY; Shestakovska, O; Xavier, D; Yusuf, S, 2013)
"Recent randomized trials have shown that cilostazol is superior to aspirin for secondary stroke prevention."9.16Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. ( Nakamura, T; Tsuruta, S; Uchiyama, S, 2012)
"The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease."9.16Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012)
"Dizziness was significantly improved in the cilostazol group versus the aspirin group (P<0."9.16Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. ( Johkura, K; Kudo, Y; Kuroiwa, Y; Momoo, T; Nakae, Y; Yoshida, TN, 2012)
"It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm."9.16Warfarin and aspirin in patients with heart failure and sinus rhythm. ( Ammon, SE; Anker, SD; Buchsbaum, R; del Valle, ML; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Gabriel, AP; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Massie, BM; Mejia, V; Mohr, JP; Ponikowski, P; Pullicino, PM; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2012)
"Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs."9.16Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012)
"Apixaban reduces stroke with comparable bleeding risks when compared with aspirin in patients with atrial fibrillation who are unsuitable for vitamin k antagonist therapy."9.16Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K ( Budaj, A; Connolly, SJ; Eikelboom, JW; Flaker, GC; Hart, RG; Husted, S; Kaatz, S; Lip, GY; Shestakovska, O; Yusuf, S, 2012)
"Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia."9.15Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. ( Emoto, M; Fukumoto, S; Inaba, M; Koyama, H; Mima, Y; Nishizawa, Y; Shoji, T; Tanaka, S; Ueno, H, 2011)
"To explore whether triflusal may modulate those pathways in human stroke, evolution of several inflammation markers (pro-inflammatory, adhesion molecules, chemokines, metalloproteinases, apoptosis and angiogenesis-related biomarkers) and neurological outcome were evaluated at baseline, and at days 1, 3, 7 and 90 in a pilot study in which 30 patients with acute ischemic stroke were randomly allocated to receive triflusal or aspirin."9.14Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke. ( Alvarez-Sabín, J; García-Bonilla, L; Krupinski, J; Montaner, J; Penalba, A; Quintana, M, 2009)
"The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed in patients previously treated with aspirin for the prevention of ischemic stroke."9.14Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. ( Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G, 2009)
"In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo."9.14Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. ( Cha, JK; Ha, SW; Kwon, SU; Lee, JH; Lee, SJ, 2010)
"During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found."9.14Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009)
"In spite of the fact that the null hypothesis was not supported by our data, we found results supporting the safety (and potential efficacy) of ASA and tirofiban when used in the first hours of acute ischemic stroke."9.14Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. ( Boiti, C; Borutti, G; Cazzaniga, M; Falaschi, F; Maestroni, A; Mandelli, C; Manganaro, D; Monzani, V; Rossi, P; Torgano, G; Zecca, B; Zilioli, E, 2010)
"The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)."9.14Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010)
"The 160 patients with acute ischemic stroke were divided into two groups randomly: treatment group 85 cases (Songling Xuemaikang + Shuxuetong + Aspirin enterie coated tablets), control group 75 cases (Shuxuetong + Aspirin enterie ccoated tablets)."9.14[Changes of plasma fibrinogen level among acute ischemic stroke subtypes according to TOAST criteria and effects of Songling Xuemaikang]. ( Chen, Y; Huang, J; Liu, G; Liu, X; Lu, N; Xu, Y; Yang, D, 2010)
"Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%."9.13Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. ( Karepov, V; Kuliczkowski, W; Serebruany, V; Tolpina, G, 2008)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."9.13Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
"All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance."9.13Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008)
"Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community."9.13Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008)
"Patients experiencing acute ischemic stroke or transient ischemic attack are commonly treated with clopidogrel and/or aspirin (mono- and dual-antiplatelet therapy) to minimize the risk for recurrent stroke."9.12Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis. ( Huang, Z; Yang, Y; Zhang, X, 2021)
"A large number of patients experience ischemic stroke despite treatment with aspirin (acetylsalicylic acid, ASA)."9.12Variable platelet response to aspirin in patients with ischemic stroke. ( Boucher, M; Hohlfeld, T; Junghans, U; Schrör, K; Schumacher, M; Siebler, M; Weber, AA, 2007)
"In the majority of patients with acute ischemic stroke, ASA and acetaminophen are insufficient for reducing an elevated BT to a state of normothermia."9.11Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. ( De Keyser, J; Elting, JW; Luijckx, GJ; Luyckx, GJ; Maurits, N; Sulter, G, 2004)
"The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone."9.11Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004)
" Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials."9.11Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005)
"Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study."9.11Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. ( Alberts, MJ; Bhatt, DL; Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL; Ziai, W, 2005)
"This pilot study enrolled ischemic stroke patients within 48 hours and randomized to aspirin 300 mg/d or combination (aspirin 300 mg/d+ standard release dipyridamole 75 mg thrice a day) and followed up for 6 months."9.11Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005)
"In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks."9.10Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. ( Buggle, F; Grau, AJ; Lichy, C; Reiners, S; Ruf, A, 2003)
" In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke."9.10Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002)
"In this study, 591 patients with recent cerebral ischemia of arterial origin were randomly allocated to treatment with aspirin 30 to 325 mg/d or with the combination of aspirin and dipyridamole 400 mg/d in the European/Australian Stroke Prevention in Reversible Ischemia Trial."9.10Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003)
"We performed multivariate logistic regression analysis of 2012 participants given aspirin alone or in combination with low, inefficacious doses of warfarin in the Stroke Prevention in Atrial Fibrillation I-III trials followed for a mean of 2."9.09Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. ( Asinger, RW; Hart, RG; McBride, R; Pearce, LA; Rothbart, RM, 1999)
"Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation."9.09Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000)
" We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding."9.09Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000)
"We sought to compare different antithrombotic secondary treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to the risk of stroke recurrence."9.09Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. ( Heller, C; Kurnik, K; Luigs, P; Nowak-Göttl, U; Schobess, R; Sträter, R, 2001)
"Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage."9.09A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. ( Adams, HP; Albers, GW; Furie, KL; Jackson, CM; Kistler, JP; Lazar, RM; Levin, B; Mohr, JP; Pettigrew, LC; Pullicino, P; Sacco, RL; Thompson, JL, 2001)
"Aspirin is only modestly effective in the secondary prevention after cerebral ischemia."9.08A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. ( , 1997)
"Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention."9.01Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019)
"The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin."9.01Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019)
"Background and Purpose- The role of aspirin plus clopidogrel (A+C) therapy compared with aspirin monotherapy in patients presenting with acute ischemic stroke (IS) or transient ischemic attack remains uncertain."9.01Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. ( Hammad, T; Kaluski, E; Khan, SU; Meyer, MA; Nasir, F; Rahman, H, 2019)
"To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)."8.98Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018)
"Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke."8.93Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016)
" We found no evidence that the net benefit of aspirin increased with increasing risk of thrombosis, haemorrhage or poor functional outcome in all three trials."8.91Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials. ( Candelise, L; Chen, Z; Murray, GD; Sandercock, PA; Thompson, DD; Whiteley, WN, 2015)
" The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0."8.89Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013)
"This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions."8.89Aspirin and clopidogrel for prevention of ischemic stroke. ( Anderson, DC; Thomson, RM, 2013)
"Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide."8.88Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012)
"Aspirin is widely used for secondary prevention after stroke."8.87Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011)
"Aspirin is used to prevent ischemic stroke and other types of cardiovascular disease."8.87Gender differences in the primary prevention of stroke with aspirin. ( Adelman, EE; Brown, DL; Lisabeth, L, 2011)
"The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD)."8.84Clopidogrel in secondary ischemic stroke prevention. ( Belvís, R; Kulisevsky, J; Pagonabarraga, J; Santamaría, A, 2008)
"Individual patient data of patients who received aspirin or placebo after cerebral ischemia were obtained from 9 clinical trials."8.82Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials. ( Algra, A; Ariesen, MJ; Koudstaal, PJ; Rothwell, PM; van Walraven, C, 2004)
"The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)."8.82Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004)
"Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results."8.82Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005)
"In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage."8.82Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005)
"This paper will examine how cerebral perfusion deficits in cocaine abusers may be a target for pharmacotherapy."8.80Pharmacotherapy of cerebral ischemia in cocaine dependence. ( Kosten, TR, 1998)
"A retrospective analysis was performed on 75 patients with cancer and mild to moderate ischemic stroke, 34 of whom received tirofiban treatment and 41 aspirin treatment."8.31Tirofiban in the treatment of cancer-associated ischemic stroke. ( Lin, ZH; Zhang, ZM; Zhu, GL, 2023)
"This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin."8.12Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022)
"Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins."8.12Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022)
"We investigated (1) the associations of pre-stroke aspirin use with thrombus burden, infarct volume, hemorrhagic transformation, early neurological deterioration (END), and functional outcome, and (2) whether stroke subtypes modify these associations in first-ever ischemic stroke."8.02Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, KH; Han, MK; Hong, KS; Jeong, SW; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Lee, BC; Lee, J; Lee, KB; Lee, SJ; Nahrendorf, M; Oh, MS; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Schellingerhout, D; Yu, KH, 2021)
"We recruited 293 ischemic stroke patients, taking aspirin for more than seven days, and performed LTA to classify them."8.02Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy. ( Chandra, SR; Christopher, R; Ramanujam, N; Sundaravadivel, P, 2021)
"Ticagrelor plus aspirin could reduce the risks of major adverse cardiac events in diabetic patients with stable coronary artery disease (SCD), and yet it also increases bleeding risk."8.02Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. ( Shi, L; Wu, B, 2021)
"Patients with ischemic stroke receiving aspirin (100 mg/day) for three months were recruited for a multicenter, prospective, cohort study."8.02Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions. ( Chen, Y; Deng, W; Huang, W; Jiang, H; Li, J; Liang, Z; Liu, Q; Ou, Z; Ouyang, F; Wu, Z; Xing, S; Zeng, J; Zhang, Y, 2021)
"This study provides supporting evidence that aspirin use is associated with reduced ischaemic events after pneumonia in a primary care setting."8.02Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database. ( Arnold, D; Hamilton, F; Henley, W; Payne, RA, 2021)
" Here we assessed the contribution of clopidogrel versus aspirin to the development of pneumonia during an acute ischemic stroke admission."8.02Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients. ( Feng, Q; Fu, J; Jin, X; Shan, B; Shen, R; Yu, Z; Zhou, H; Zhu, H, 2021)
" The aim of this study was to assess the safety and efficacy of the p48 MW HPC (phenox, Bochum, Germany) to treat distal intracranial aneurysms under the use of aspirin monotherapy."8.02Aspirin monotherapy in the treatment of distal intracranial aneurysms with a surface modified flow diverter: a pilot study. ( Abud, DG; Abud, TG; de Castro-Afonso, LH; de Freitas, RK; Monsignore, LM; Nakiri, GS, 2021)
" Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups."7.96Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020)
"In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention."7.96Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020)
"Several clinical trials reported that clopidogrel was superior to aspirin in secondary stroke prevention by reducing the risk of major adverse cardiovascular events (MACE)."7.91Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. ( Chan, L; Chen, YC; Hsu, CY; Hu, CJ; Lin, CL; Muo, CH; Vidyanti, AN; Wu, D, 2019)
"This study aimed to investigate the effectiveness of monotherapy acetylsalicylic acid (ASA) and warfarin for stroke prevention in low-risk atrial fibrillation (AF) by using a population- -based cohort study in Taiwan."7.91Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study. ( Chen, HC; Liu, CY, 2019)
"To evaluate the effect of prestroke aspirin (PA) use on initial stroke severity, early neurologic deterioration (END), stroke recurrence, hemorrhagic transformation (HT), and functional outcome in patients with ischemic stroke (IS)."7.91Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. ( Han, Z; Lin, J; Luo, H; Yi, X; Zhou, J; Zhou, Q, 2019)
"To investigate the association of aspirin resistance (AR) with mortality in a cohort of Chinese patients with acute ischemic stroke (AIS)."7.91Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke. ( Jing, Y; Li, S; Yang, S; Yue, X, 2019)
"High plasma level of HbA1c is involved in enhanced platelet aggregability in acute atherothrombotic stroke patients, and prestroke administration of aspirin may be beneficial to clinical outcomes."7.91Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke. ( Hagii, J; Harima, K; Honda, S; Kitajima, M; Metoki, H; Mikami, K; Osanai, T; Tomisawa, T; Urushizaka, M; Yasujima, M, 2019)
"To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients."7.88Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018)
"To investigate the prognostic value of aspirin reaction units (ARU) in a 3-month follow-up study in a cohort of Chinese patients with first-ever ischemic stroke."7.88Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients. ( Fan, YN; He, Y; Hua, QJ; Ji, SB; Liu, YX; Su, LL; Wang, CW; Xi, TT; Yuan, B, 2018)
"WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG."7.88Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018)
"Prostaglandin-Endoperoxide Synthase 1 (PTGS1) and smoking may play important roles in aspirin nonresponsiveness, but the effect of their interaction on stroke outcomes remains largely unknown."7.85Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: Interaction with smoking. ( Cai, B; Cai, H; Cao, L; Davis, SM; Guo, H; Liu, X; Sun, L; Sun, W; Yan, B; Zhang, H; Zhang, Z; Zhou, S, 2017)
"Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS."7.85Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017)
"This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy."7.85Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017)
"To investigate the prevalent of aspirin resistance (AR) in stroke and its association with recurrent stroke in 214 patients with ischemic stroke who were receiving aspirin before the stroke onset."7.85Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( Wang, Z; Zhang, N; Zhou, L, 2017)
"BACKGROUND To investigate the combination of beraprost sodium (BPS) and aspirin in the treatment of acute ischemic stroke (AIS)."7.85Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke. ( Chen, S; Chen, W; He, W; Li, S; Wei, D; Xie, S, 2017)
"Aspirin and statin are recommended for the treatment of acute ischemic stroke."7.85Statin and Aspirin Pretreatment Are Associated with Lower Neurological Deterioration and Platelet Activity in Patients with Acute Ischemic Stroke. ( Han, Z; Lin, J; Wang, C; Yi, X; Zhou, Q, 2017)
"Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin."7.85Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017)
"Admission National Institutes of Health Stroke Scale (NIHSS) score, ischemic lesion volumes on diffusion-weighted imaging (DWI), and in vitro aspirin resistance, in addition to other pertinent stroke features, were determined in a series of ischemic stroke patients."7.83The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance in Ischemic Stroke. ( Agayeva, N; Arsava, EM; Topcuoglu, MA, 2016)
"We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)."7.83Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016)
"Selecting among different antiplatelet strategies when patients experience a new ischemic stroke while taking aspirin is a common clinical challenge, currently addressed by a paucity of data."7.83Different Antiplatelet Strategies in Patients With New Ischemic Stroke While Taking Aspirin. ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Han, MK; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Ko, YC; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Nah, HW; Oh, MS; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Saver, JL; Shin, DI; Yeo, MJ; Yu, KH, 2016)
"The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain."7.83Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Gorelick, PB; Han, MK; Hong, KS; Kang, K; Kim, DE; Kim, DH; Kim, JT; Ko, Y; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, JM; Park, TH; Yu, KH, 2016)
" Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment."7.83Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. ( Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016)
"To investigate whether aspirin resistance is associated with initial stroke severity and infarct volume, using diffusion-weighted imaging (DWI) in patients with acute ischemic stroke that occurred while taking aspirin."7.83Aspirin resistance is associated with increased stroke severity and infarct volume. ( Jang, MU; Jung, S; Kim, C; Lee, BC; Lee, J; Lee, JH; Oh, MS; Yu, KH, 2016)
"A higher loading dose of aspirin (160-325 mg) can be beneficial in treating acute ischemic stroke, although there is an increased risk of minor bleeding."7.83To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. ( Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016)
"miR-145 is involved in the anti-proliferation and anti-inflammation effects of aspirin on VSMCs by inhibiting the expression of CD40."7.83miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40. ( Chen, M; Guo, R; Guo, X; Peng, X; Wu, T; Yu, L; Zhang, B, 2016)
"Aspirin is known to reduce stroke risk; however, its role in reducing severity of ischemic syndrome is not clear."7.83Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke. ( Cloonan, L; Fitzpatrick, KM; Furie, KL; Kanakis, AS; Nelson, S; Perilla, AS; Rost, NS; Shideler, KI, 2016)
"Aspirin resistance has an incidence of 5%-65% in patients with ischemic stroke, who receive the standard dose of aspirin, but the platelet function is inadequately inhibited, thereby leading to thrombotic events."7.83Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. ( Cai, YF; Chen, LY; Chen, XM; Huang, M; Jin, J; Li, JL; Peng, LL; Zhao, M; Zhao, YQ; Zhou, ZY, 2016)
"A significant proportion of ischemic strokes occur while using aspirin and therefore can be considered as clinical aspirin resistance."7.81Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke. ( Agayeva, N; Arsava, EM; Gungor, L; Topcuoglu, MA, 2015)
" Therefore, we sought to evaluate the time-dependent changes in platelet reactivity to aspirin during the acute stage after ischemic stroke and the clinical implications of variable patient responses to aspirin in acute ischemic stroke."7.81Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin Over Time in Acute Ischemic Stroke. ( Cho, KH; Choi, KH; Choi, SM; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, SH; Nam, TS; Park, MS; Saver, JL, 2015)
"Some patients with a recent ischemic stroke who are being treated with aspirin as an antiaggregant suffer a new ischemic stroke."7.80Aspirin resistant patients with recent ischemic stroke. ( Castilla-Guerra, L; Fernández-Moreno, MC; Navas-Alcántara, MS, 2014)
"This study was designed to test the pre-treatment doses of guggulipid (50 mg/kg), aspirin (100 mg/kg) per orally and co-administration of both drugs for 28 days followed by middle cerebral artery occlusion - a model of focal cerebral ischemia in rats."7.80Neuroprotective effect of guggulipid alone and in combination with aspirin on middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia in rats. ( Ahmad, MA; Akhtar, M; Mujeeb, M; Najmi, AK, 2014)
"Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)."7.80Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014)
"To analyze the potential impact of aspirin therapy for long-term secondary prevention after stroke of undetermined etiology in resource-limited settings without access to neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH)."7.80Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings. ( Berkowitz, AL; Bianchi, MT; Chou, SH; Westover, MB, 2014)
"Aspirin resistance is common in the population of patients with hemodynamic cerebral ischemia scheduled for cerebral revascularization."7.79Aspirin resistance in patients with hemodynamic cerebral ischemia undergoing extracranial-intracranial bypass surgery. ( Horn, P; Jussen, D; Vajkoczy, P, 2013)
"A prospective study included 35 patients admitted with ischemic stroke and commenced on 300 mg aspirin."7.79"Aspirin resistance" in ischemic stroke: insights using short thrombelastography. ( Curzen, N; Englyst, N; Radhakrishnan, A; Sambu, N; Weir, N, 2013)
"The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths."7.79Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013)
"Among patients with stroke, the phenomenon of resistance to treatment with low-dose aspirin acetylsalicylic acid (ASA) is quite common."7.79Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. ( Chełstowski, K; Clark, J; Jastrzębska, M; Nowacki, P; Siennicka, A; Wódecka, A, 2013)
"The prognostic value of occurrence of ischemic stroke in a patient despite aspirin treatment (aspirin treatment failure) is not known."7.79Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke. ( Adams, HP; Cordina, SM; Georgiadis, AL; Lakshminarayan, K; Qureshi, AI; Suri, MF; Tariq, N; Vazquez, G, 2013)
"This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day)."7.79Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. ( Chichelli, T; Ching, M; Farooq, O; Janicke, D; Li, F; Mehta, B; Munschauer, FE; Radovic, V; Sawyer, RN; Sternberg, Z, 2013)
"Of the 82 patients with recurrent cerebral ischemia included in this study, 37 (45%) patients were poor compliant with aspirin."7.79Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia. ( Abu-Hegazy, M; Azzam, H; El-Mitwalli, A; Gomaa, M; Wasel, Y, 2013)
"Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone."7.78Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012)
"The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects."7.78Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012)
"Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably myocardial infarction and stroke."7.78Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes. ( Al-Hazzani, A; Dadheech, S; Jyothy, A; Kaul, S; Munshi, A; Prabha, TS; Rao, PP; Sharma, V, 2012)
" In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques."7.78Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012)
"A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update."7.76Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. ( Ellrodt, G; Fonarow, GC; Frankel, MR; Hernandez, AF; Labresh, KA; Liang, L; Menon, BK; Schwamm, LH; Smith, EE, 2010)
"In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding."7.76Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010)
"A considerable proportion of patients discontinue dipyridamole therapy because of headache."7.75Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009)
"There are very limited data on the influence of pretreatment with aspirin (ASA) on the etiology of subsequent first-ever ischemic stroke."7.75Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients. ( Kouperberg, E; Sprecher, E; Telman, G; Yarnitsky, D, 2009)
" We tested the hypothesis that combined pre-treatment with aspirin and clopidogrel is a risk factor for thrombolysis-related symptomatic intracerebral hemorrhage (sICH)."7.75Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? ( Dzialowski, I; Gahn, G; Hermann, A; Koch, R, 2009)
"Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke."7.74ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. ( Cha, JK; Jeon, HW; Kang, MJ, 2008)
"The results suggest that triflusal and aspirin appear to be equally neuroprotective against middle cerebral artery occlusion-induced cerebral ischemia."7.74Effects of triflusal and aspirin in a rat model of cerebral ischemia. ( Allen, GV; Bayona, NA; Cechetto, DF; Cheng, G; Hachinski, VC; Whitehead, SN, 2007)
"To report a case of cerebral ischemia in a patient receiving oral isotretinoin for severe acne."7.74Cerebral ischemia probably related to isotretinoin. ( Laroche, ML; Macian-Montoro, F; Merle, L; Vallat, JM, 2007)
"The present study was carried out to investigate the effect of the combination of an endothelin antagonist TAK-044 and an antiinflammatory agent aspirin in middle cerebral artery (MCA) occlusion model of acute ischemic stroke in rats."7.74Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats. ( Briyal, S; Gulati, A; Gupta, YK, 2007)
"A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included."7.74Can aspirin resistance be clinically predicted in stroke patients? ( Bang, OY; Choi, YJ; Huh, K; Joo, IS; Lee, PH; Seok, JI; Yoon, JH, 2008)
"We aimed to study the timing of aspirin prescription in ischaemic stroke comparing patients admitted to an acute stroke unit (ASU) directly or via a general medical ward."7.73Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units. ( MacLeod, MJ; Reid, J; Williams, D, 2005)
"To study the discontinuation of aspirin therapy as a risk factor for ischemic stroke (IS)."7.73Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. ( Bezerra, DC; Bogousslavsky, J; Maulaz, AB; Michel, P, 2005)
"We studied outpatients of 5 neurological ambulatory centers in an urban city, Valencia, all with a history of ischemic stroke who had received aspirin for at least 6 months."7.73Adherence to aspirin in secondary prevention of ischemic stroke. ( Ferrer, JM; Lago, A; Pareja, A; Ponz, A; Santos, MT; Tembl, JI; Vallés, J, 2006)
"The purpose of this study was to determine safety and tolerability of clopidogrel in children with arterial ischemic stroke (AIS)."7.73The risks and safety of clopidogrel in pediatric arterial ischemic stroke. ( Allen, A; deVeber, G; Hune, S; MacGregor, D; Rafay, MF; Soman, T, 2006)
"Millions of people around the world regularly consume aspirin, but its value in determining stroke severity is still not clear."7.73Does prior aspirin use reduce stroke mortality? ( Demirkaya, M; Karlikaya, G; Orken, C; Tireli, H; Varlbas, F, 2006)
"The authors describe course and outcome of eight patients with ischemic stroke as the first thrombotic manifestation of antiphospholipid syndrome who received low-dose aspirin as prophylactic treatment."7.72Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. ( de Groot, PG; Derksen, RH; Kappelle, LJ, 2003)
"To investigate the protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion rats."7.72[Protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion in rats]. ( Chen, CH; Qiu, LY; Yu, J; Zhou, Y, 2003)
"The potential neuroprotective effects of the novel nitro-derivate of aspirin (NCX4016) on permanent focal cerebral ischemia in spontaneously hypertensive rats (SHRs) was investigated."7.71Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat. ( Ambrosini, MV; Del Soldato, P; Fredduzzi, S; Mariucci, G; Tantucci, M, 2001)
"Large intervention studies suggest that aspirin may reduce mortality when given to patients who present with strokes or transient ischemic attacks."7.70Does prior use of aspirin affect outcome in ischemic stroke? ( Kalra, L; Perez, I; Smithard, DG; Sulch, D, 2000)
"This follow-up study was designed to evaluate whether the use of aspirin either before or after aneurysm rupture affects the occurrence of delayed cerebral ischemia."7.69Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Juvela, S, 1995)
"The primary outcome is IS recurrence."6.80Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015)
"Despite improvements in treatment, stroke still carries a high death toll and disability in Asia."6.76The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011)
" These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke."6.76Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. ( Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011)
" It is impossible to exclude that long term administration of warfarin in strategy of sinus rhythm maintenance attenuated advantages of normal rhythm in relation of lowering of stroke risk in AFFIRM study and other similar works."6.73[Prevention of ischemic stroke in middle aged patients with atrial fibrillation. Effect of sinus rhythm maintenance, aspirin, warfarin, and simvastatin]. ( Kanorskiĭ, SG; Shevelev, VI; Zafiraki, VK; Zingilevskiĭ, KB, 2007)
"Patients with minor ischemic stroke or transient ischemic attack represent a high-risk population for recurrent stroke."6.72Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G, 2021)
"Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke."6.61Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019)
"Stroke is one of the leading causes of death."6.55Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance. ( Chaurasia, P; Munshi, A; Singh, S; Vasudeva, K, 2017)
"Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal."6.42Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. ( Michiels, JJ, 2003)
"To assess the balance of benefits and risks of aspirin in particular categories of patient with acute stroke (eg, the elderly, those without a CT scan, or those with atrial fibrillation), a prospectively planned meta-analysis is presented of the data from 40 000 individual patients from both trials on events that occurred in the hospital during the scheduled treatment period (4 weeks in CAST, 2 weeks in IST), with 10 characteristics used to define 28 subgroups."6.19Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. ( Chen, ZM; Collins, R; Counsell, C; Liu, LS; Pan, HC; Peto, R; Sandercock, P; Warlow, C; Xie, JX, 2000)
"A review is given on the clinical studies performed with aspirin in patients with chronic vascular occlusions of the limbs and on studies in cerebral ischemia using aspirin and sulfinpyrazone."6.14Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders. ( Breddin, K, 1977)
"Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL."5.69Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol. ( Aguilar-Pérez, M; Ainz-Gómez, L; Amaya Pascasio, L; Baena-Palomino, P; Bravo Rey, I; Cabezas-Rodríguez, JA; Castellanos Rodrigo, MDM; de Albóniga-Chindurza, A; Delgado-Acosta, F; Díaz Pérez, J; Escudero-Martínez, I; Fernandez Prudencio, L; Freijo Guerrero, MDM; Gamero-García, MÁ; González Díaz, E; González García, A; Hidalgo, C; Jiménez Jorge, S; Jiménez-Gómez, E; Medina-Rodríguez, M; Moniche, F; Montaner, J; Morales Caba, L; Mosteiro, S; Ortega-Quintanilla, J; Oteros Fernández, R; Pardo-Galiana, B; Ramirez Moreno, JM; Rosso Fernández, C; Sanz-Fernandez, G; Vielba-Gomez, I; Zamora, A; Zapata-Arriaza, E, 2023)
"Aspirin is recommended for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke but can lead to gastrointestinal intolerance and bleeding."5.69Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial. ( Bath, PM; Dong, Q; Feng, Y; Huang, X; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, X; Li, Z; Lin, J; Liu, B; Liu, L; Liu, Q; Meng, X; Pan, Y; Suo, Y; Wang, Y; Xie, X; Xiong, Y; Xu, A; Yang, H; Yuan, B; Zhao, J; Zhao, X; Zhou, Y; Zhu, H, 2023)
"The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied."5.69Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion. ( Cai, T; Cao, M; Chen, X; Chen, Z; Cheng, D; Geng, W; Guo, C; He, P; He, W; Hu, J; Huang, F; Huang, J; Huang, W; Huang, X; Kong, W; Li, B; Li, F; Li, H; Li, L; Li, Z; Liang, H; Liu, C; Liu, J; Liu, S; Liu, W; Liu, Z; Luo, J; Miao, J; Mu, J; Nogueira, RG; Peng, Y; Qiu, Z; Saver, JL; Shi, Q; Shi, Z; Song, J; Tan, X; Tang, M; Tang, Y; Tian, Y; Wan, Y; Wang, D; Wang, M; Wang, P; Wu, Y; Xie, S; Xie, W; Yang, D; Yang, J; Yang, Q; Yang, S; Yao, L; Yu, Y; Yu, Z; Yue, C; Zhang, B; Zhao, H; Zheng, J; Zi, W, 2023)
"Aspirin and unfractionated heparin are often used during endovascular stroke treatment to improve reperfusion and outcomes."5.51Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial. ( Beenen, LFM; Berkhemer, O; Boiten, J; Bokkers, RPH; Boukrab, I; Chalos, V; Coutinho, JM; de Laat, KF; de Ridder, I; den Hertog, HM; Dippel, DWJ; Elgersma, O; Emmer, BJ; Gerrits, D; Gons, RAR; Hammer, S; Hofmeijer, J; Jenniskens, SFM; Kerkhoff, H; Koudstaal, PJ; Krietemeijer, M; Lingsma, HF; Lycklama, G; Majoie, CBLM; Manschot, S; Martens, J; Meijer, FJA; Nieboer, D; Postma, AA; Remmers, M; Roos, YBWEM; Roosendaal, SD; Roozenbeek, B; Rozeman, A; Schonewille, W; Staals, J; Tolhuisen, M; Truijman, MTB; Tuladhar, AM; Uyttenboogaart, M; van de Graaf, RA; van den Berg, R; van den Wijngaard, I; van der Hoorn, A; van der Lugt, A; van der Schaaf, I; van der Sluijs, PM; van der Steen, W; van der Worp, HB; van Dijk, LC; van Doormaal, PJ; van Es, ACGM; van Hasselt, B; van Oostenbrugge, RJ; van Tuijl, J; van Voorst, H; van Zwam, W; Vos, D; Vos, JA; Wolff, L; Yo, LSF; Yoo, AJ; Zinkstok, S, 2022)
"To test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke."5.51Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. ( Bath, PM; Chen, W; Dong, Q; Jiang, Y; Jing, J; Johnston, SC; Li, H; Lin, J; Meng, X; Pan, Y; Wang, Y; Xu, AD, 2022)
"HPR-aspirin was persistent 75days later in 36% patients."5.43High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016)
"The study aimed to evaluate the clinical efficacy of the Huo Xue Hua Yu method combined with aspirin in the treatment of patients with acute cerebral infarction (ACI)."5.41Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis. ( Chen, C; Liu, X; Ma, F; Tang, Q; Wen, X; Wu, Y, 2023)
" We sought to determine whether the presence of carotid stenosis was associated with increased risk of ischemic stroke and whether the addition of clopidogrel to aspirin was associated with more benefit in patients with versus without carotid stenosis."5.41Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial. ( de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, AS; Kvernland, A; Mac Grory, B; Rostanski, S; Yaghi, S, 2021)
"In patients with a minor ischaemic stroke or transient ischaemic attack (TIA), separate trials have shown that dual antiplatelet therapy with clopidogrel plus aspirin (clopidogrel-aspirin) or ticagrelor plus aspirin (ticagrelor-aspirin) are more effective than aspirin alone in stroke secondary prevention."5.41Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial. ( Bath, PM; Dong, Q; Jing, J; Johnston, C; Li, H; Li, Z; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Zhao, X, 2021)
"Clopidogrel and aspirin are key intervention for acute ischemic stroke (AIS) and transient ischemic attack (TIA)."5.41Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial. ( Chen, J; Gao, P; Han, M; Jia, W; Kuang, J; Peng, C; Starcevich, K; Tu, J; Wang, J; Wu, Y; Yi, Y; Yin, S; Zhang, X, 2021)
"Focal cerebral ischemia was induced by MCA occlusion for 2 hours followed by reperfusion for 22 hours."5.37Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats. ( Ahmad, SJ; Akhtar, M; Islam, F; Khanam, R; Pillai, KK; Pratap, R, 2011)
" Patients with newly diagnosed ischemic stroke who are just about to start Aspirin were assessed for eligibility and inclusion in our trial."5.34An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS). ( Abdallah, IM; Ahmed, MS; Ali, M; AlSaud, AE; Danjuma, MI; Elshafei, MN; Imam, Y; Mohamed, MFH; Obeidat, K; Parray, AS; Saeid, R, 2020)
" In this study, we compared three major platelet function tests to assess their performance and found better methods for platelet function evaluation after aspirin or clopidogrel treatment in ischemic stroke patients by comparative study."5.34A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy. ( Cheng, Y; Ge, W; Han, Z; Huang, L; Jin, J; Luo, C; Shao, T; Wang, Z; Xu, Y; Yang, D, 2020)
"(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke."5.33Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005)
"Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events."5.30Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial. ( Adamopoulos, D; Asimakopoulos, C; Bourdakis, A; Chantzichristos, VG; Darmanis, P; Dimitriadou, A; Gkiokas, S; Goudevenos, JA; Ipeirotis, K; Kalantzi, KI; Kitikidou, K; Klonaris, I; Kostaki, A; Logothetis, D; Mainas, K; Mais, T; Maragiannis, A; Martiadou, K; Mavronasos, K; Michelongonas, I; Mitropoulos, D; Ntalas, IV; Panagiotakos, DB; Papadimitriou, G; Papadopoulos, A; Papaioakeim, M; Sofillas, K; Stabola, S; Stefanakis, E; Stergiou, D; Thoma, M; Tselepis, AD; Tsoumani, ME; Zenetos, A; Zisekas, S, 2019)
" The aim was to assess whether the effect of clopidogrel plus aspirin versus aspirin alone on recurrent stroke would be affected by admission activated partial thromboplastin time (aPTT)."5.30Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time. ( Laskowitz, DT; Li, H; Liu, L; Meng, X; Miao, Z; Wang, X; Wang, Y; Xie, X; Zhao, X, 2019)
"Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone."5.30Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019)
"Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases."5.30Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019)
"Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4."5.30Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. ( Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC, 2019)
" The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days."5.27Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018)
"Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding."5.27Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. ( Amarenco, P; Ameriso, SF; Arauz, A; Bangdiwala, SI; Benavente, OR; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Davalos, A; De Vries Basson, MM; Eckstein, J; Endres, M; Gagliardi, RJ; Hankey, GJ; Hart, RG; Joyner, C; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Sheridan, P; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, D; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, JI; Yoon, BW, 2018)
"In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke."5.27Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. ( Ahn, SH; Heo, SH; Hong, KS; Hwang, YH; Jung, JM; Kang, DW; Kim, BJ; Kim, YJ; Kwon, JH; Kwon, SU; Lee, EJ; Lee, J; Lee, JH; Lee, JS; Navarro, JC; Park, JH; Park, JM; Rha, JH; Seo, WK; Sohn, SI; Wong, LKS; Yu, S, 2018)
"The PRISMS trial was designed as a 948-patient, phase 3b, double-blind, double-placebo, multicenter randomized clinical trial of alteplase compared with aspirin for emergent stroke at 75 stroke hospital networks in the United States."5.27Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. ( Broderick, J; Chatterjee, A; Devenport, J; Devlin, T; Jauch, EC; Khatri, P; Kleindorfer, DO; Levine, SR; Mejilla, J; Pavlov, A; Purdon, B; Romano, JG; Saver, JL; Sawyer, RN; Starr, M; Vagal, A; Yeatts, SD, 2018)
"Clinical studies results show that policosanol (20 mg/day) + aspirin therapy had benefits versus placebo + aspirin to patients with recent non-cardioembolic ischemic stroke."5.27Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients. ( Fernandez-Dorta, L; Fernandez-Travieso, JC; Illnait-Ferrer, J; Mas-Ferreiro, R; Mendoza-Castano, S; Mesa-Angarica, M; Reyes-Suarez, P; Sanchez-Lopez, J, 2018)
"To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA."5.24Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. ( Chen, W; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Zhao, X, 2017)
"In order to evaluate the impact of cilostazol on endothelial function, we compared the changes of flow-mediated dilation (FMD) between aspirin and cilostazol groups in patients with acute cerebral ischemia."5.24Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. ( Choi, MH; Hong, JM; Lee, JS; Lee, SE; Lee, SJ; Shin, DH, 2017)
"Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, significantly decreased death and dependency, and reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved."5.22Oral antiplatelet therapy for acute ischaemic stroke. ( Barnes, SC; Beishon, LC; Chithiramohan, T; Clough, RH; Kadicheeni, M; Minhas, JS; Robinson, T; Wang, X, 2022)
"It was found that the effectiveness of dual antiplatelet therapy in patients with minor ischaemic stroke or high risk transient ischaemic attack does not significantly differ in patients with prior aspirin exposure; therefore there should be no influence on the decision to use dual antiplatelet therapy."5.22Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta-analysis. ( Clarke, A; Murphy, R; O'Donnell, MJ; Reddin, C, 2022)
"A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin."5.22Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016)
"In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia."5.22Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016)
" In a previous study, we found that the number of MESs is associated with stroke recurrence and that clopidogrel plus aspirin more effectively reduce the number of MESs than does aspirin alone."5.22The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. ( Chen, C; Deng, QQ; Fu, JH; Huang, YN; Markus, H; Ratanakorn, D; Tang, J; Wong, KS; Zhao, H, 2016)
"We analysed the rates of stroke and systemic embolism in 6563 aspirin-treated patients with AF from the ACTIVE-A/AVERROES databases."5.20Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. ( Alings, M; Avezum, A; Connolly, SJ; Díaz, R; Eikelboom, JW; Hart, RG; Healey, JS; Hohnloser, SH; Lauw, MN; Lewis, BS; Shestakovska, O; Vanassche, T; Wang, J, 2015)
"Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke."5.20Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. ( Bath, PM; Dineen, R; Pocock, S; Robson, K; Sprigg, N; Woodhouse, LJ, 2015)
"Aspirin is a primary antiplatelet agent for the secondary prevention of ischemic stroke."5.20Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions. ( Cho, KH; Choi, KH; Choi, MJ; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, JS; Lee, SH; Nam, TS; Park, MS, 2015)
"We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined)."5.20Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. ( Anker, SD; Buchsbaum, R; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015)
"PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage was designed to compare cilostazol and aspirin and to assess the effect of adding probucol, a lipid-lowering and anti-oxidative agent, in patients at high risk of haemorrhagic stroke."5.20Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial. ( Hong, KS; Kim, BJ; Kwon, SU; Lee, JY, 2015)
"In this study, patients taking 100 mg aspirin daily (orally) were examined after admittance to the stroke unit due to a stroke or stroke recurrence."5.19[Acetylsalicylic acid non-responders after ischemic insult in geriatric patients]. ( Kolb, GF; Nosul, M, 2014)
"We performed a secondary analysis from the Cilostazol in Acute Ischemic Stroke Treatment (CAIST) trial, which was a double-blinded, randomized, multicenter trial, assessing the noninferiority of cilostazol over aspirin within 48 hours of an acute ischemic stroke."5.19Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. ( Bae, HJ; Kang, DW; Kwon, HM; Lee, YS, 2014)
"We evaluated the efficacy of low-molecular-weight heparin (LMWH) relative to aspirin in preventing early neurologic deterioration (END), venous thromboembolism (VTE), and outcomes at 6 months."5.19Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014)
"This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source."5.19Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014)
"Ancillary analysis of the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, comparing aspirin and apixaban, focused on sex differences."5.19Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2014)
" Its aim was to investigate the potential effects of terutroban in patients with atherothrombotic disorders, in comparison to aspirin, on the evolution of magnetic resonance imaging (MRI) lesions after a recent ischemic stroke or transient ischemic attack (TIA)."5.17Results of the PERFORM magnetic resonance imaging study. ( Bracoud, L; Chabriat, H; Gass, A; Hennerici, M; Maeder, P; Michel, P, 2013)
"Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably stroke and myocardial infarction."5.17Association of COX-2 rs20417 with aspirin resistance. ( Al-Hazzani, A; Alshatwi, AA; Jyothy, A; Kaul, S; Munshi, A; Sharma, V, 2013)
"We selected all patients with a CHADS(2) score of 1 from the AVERROES and ACTIVE trials who were treated with acetylsalicylic acid with or without clopidogrel and calculated the incidences of ischaemic or unspecified stroke or systemic embolus (SSE) according to their CHA(2)DS(2)-VASc score."5.17The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. ( Connolly, SJ; Coppens, M; Dorian, P; Eikelboom, JW; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2013)
"The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated."5.17Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Flaker, G; Hart, R; Lanas, F; Lip, GY; Shestakovska, O; Xavier, D; Yusuf, S, 2013)
"Recent randomized trials have shown that cilostazol is superior to aspirin for secondary stroke prevention."5.16Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. ( Nakamura, T; Tsuruta, S; Uchiyama, S, 2012)
"The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease."5.16Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012)
"Dizziness was significantly improved in the cilostazol group versus the aspirin group (P<0."5.16Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. ( Johkura, K; Kudo, Y; Kuroiwa, Y; Momoo, T; Nakae, Y; Yoshida, TN, 2012)
"We identified 9 independent risk factors for SICH: baseline National Institutes of Health Stroke Scale, serum glucose, systolic blood pressure, age, body weight, stroke onset to treatment time, aspirin or combined aspirin and clopidogrel, and history of hypertension."5.16Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. ( Ahmed, N; Egido, JA; Ford, GA; Lees, KR; Mazya, M; Mikulik, R; Toni, D; Wahlgren, N, 2012)
"We analyzed MRI of 133 patients admitted consecutively for intra- and extracranial stenting for symptomatic large artery atherosclerosis who received aspirin and clopidogrel."5.16Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention. ( Abrigo, J; Ahuja, AT; Leung, TW; Ng, N; Siu, DY; Soo, YO; Wong, LK; Yu, S, 2012)
"It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm."5.16Warfarin and aspirin in patients with heart failure and sinus rhythm. ( Ammon, SE; Anker, SD; Buchsbaum, R; del Valle, ML; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Gabriel, AP; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Massie, BM; Mejia, V; Mohr, JP; Ponikowski, P; Pullicino, PM; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2012)
"Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs."5.16Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012)
"Apixaban reduces stroke with comparable bleeding risks when compared with aspirin in patients with atrial fibrillation who are unsuitable for vitamin k antagonist therapy."5.16Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K ( Budaj, A; Connolly, SJ; Eikelboom, JW; Flaker, GC; Hart, RG; Husted, S; Kaatz, S; Lip, GY; Shestakovska, O; Yusuf, S, 2012)
"Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia."5.15Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. ( Emoto, M; Fukumoto, S; Inaba, M; Koyama, H; Mima, Y; Nishizawa, Y; Shoji, T; Tanaka, S; Ueno, H, 2011)
"TAIST was a randomized controlled trial assessing 10 days of treatment with tinzaparin versus aspirin in 1489 patients with acute ischemic stroke (<48 hr) with admission BP of 5.14The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST). ( Bath, PM; Christensen, H; De Deyn, PP; England, T; Geeganage, C; Gray, LJ; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2009)
"We evaluated the location, type (lacunar vs nonlacunar), cause, and severity of stroke in patients who had an ischemic stroke endpoint in the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial."5.14Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis. ( Chimowitz, MI; Famakin, BM; George, MG; Lynn, MJ; Stern, BJ, 2009)
"To explore whether triflusal may modulate those pathways in human stroke, evolution of several inflammation markers (pro-inflammatory, adhesion molecules, chemokines, metalloproteinases, apoptosis and angiogenesis-related biomarkers) and neurological outcome were evaluated at baseline, and at days 1, 3, 7 and 90 in a pilot study in which 30 patients with acute ischemic stroke were randomly allocated to receive triflusal or aspirin."5.14Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke. ( Alvarez-Sabín, J; García-Bonilla, L; Krupinski, J; Montaner, J; Penalba, A; Quintana, M, 2009)
"The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed in patients previously treated with aspirin for the prevention of ischemic stroke."5.14Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. ( Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G, 2009)
"We present the protocol of a multicenter randomized clinical trial (n = 800) investigating the effects of immediate addition of aspirin to rt-PA on poor outcome (modified Rankin score >2) in ischemic stroke patients."5.14Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial. ( de Haan, RJ; Roos, YB; Stam, J; Vermeulen, M; Zinkstok, SM, 2010)
"In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo."5.14Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. ( Cha, JK; Ha, SW; Kwon, SU; Lee, JH; Lee, SJ, 2010)
"During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found."5.14Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009)
"In spite of the fact that the null hypothesis was not supported by our data, we found results supporting the safety (and potential efficacy) of ASA and tirofiban when used in the first hours of acute ischemic stroke."5.14Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. ( Boiti, C; Borutti, G; Cazzaniga, M; Falaschi, F; Maestroni, A; Mandelli, C; Manganaro, D; Monzani, V; Rossi, P; Torgano, G; Zecca, B; Zilioli, E, 2010)
"The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)."5.14Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010)
" Our objective is to investigate whether immediate addition of aspirin to rt-PA thrombolysis improves functional outcome in ischemic stroke."5.14A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial. ( de Haan, RJ; Roos, YB; Stam, J; Vermeulen, M; Zinkstok, SM, 2010)
"The 160 patients with acute ischemic stroke were divided into two groups randomly: treatment group 85 cases (Songling Xuemaikang + Shuxuetong + Aspirin enterie coated tablets), control group 75 cases (Shuxuetong + Aspirin enterie ccoated tablets)."5.14[Changes of plasma fibrinogen level among acute ischemic stroke subtypes according to TOAST criteria and effects of Songling Xuemaikang]. ( Chen, Y; Huang, J; Liu, G; Liu, X; Lu, N; Xu, Y; Yang, D, 2010)
"Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%."5.13Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. ( Karepov, V; Kuliczkowski, W; Serebruany, V; Tolpina, G, 2008)
"The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel."5.13Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008)
"All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance."5.13Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008)
"Thirty chronic ischemic stroke patients taking aspirin alone followed by aspirin-clopidogrel combined therapy had platelet reactivity tests performed over 3 months: ex vivo platelet aggregation, platelet recruitment and urinary 11-dehydro-thromboxane B(2) (11-dhTxB(2))excretion."5.13Platelet aggregation and recruitment with aspirin-clopidogrel therapy. ( Brace, LD; Cursio, J; Grossi, E; Helgason, CM; Pandey, D; Valika, A, 2008)
"Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community."5.13Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008)
"Patients experiencing acute ischemic stroke or transient ischemic attack are commonly treated with clopidogrel and/or aspirin (mono- and dual-antiplatelet therapy) to minimize the risk for recurrent stroke."5.12Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis. ( Huang, Z; Yang, Y; Zhang, X, 2021)
" The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily."5.12ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007)
"A large number of patients experience ischemic stroke despite treatment with aspirin (acetylsalicylic acid, ASA)."5.12Variable platelet response to aspirin in patients with ischemic stroke. ( Boucher, M; Hohlfeld, T; Junghans, U; Schrör, K; Schumacher, M; Siebler, M; Weber, AA, 2007)
"We examined the outcomes of 627 noncardioembolic stroke patients who were double-blindly assigned to either warfarin or aspirin therapy and assessed VaT using transesophageal echocardiography."5.12Impact of valvular thickness on stroke recurrence in medically treated patients with stroke. ( Abe, Y; Di Tullio, MR; Homma, S; Jin, Z; Mohr, JP; Okajima, K; Sacco, RL; Salameh, MJ; Suzuki, K, 2007)
"TAIST was a randomized, controlled trial assessing the safety and efficacy of tinzaparin versus aspirin in 1484 patients with acute ischemic stroke."5.12Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). ( Bath, PM; Boysen, G; De Deyn, PP; Gray, LJ; Leys, D; O'Neill, D; Ringelstein, EB; Sprigg, N, 2007)
"In the majority of patients with acute ischemic stroke, ASA and acetaminophen are insufficient for reducing an elevated BT to a state of normothermia."5.11Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. ( De Keyser, J; Elting, JW; Luijckx, GJ; Luyckx, GJ; Maurits, N; Sulter, G, 2004)
"We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel."5.11Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004)
"The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone."5.11Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004)
" Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials."5.11Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005)
"Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study."5.11Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. ( Alberts, MJ; Bhatt, DL; Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL; Ziai, W, 2005)
"This pilot study enrolled ischemic stroke patients within 48 hours and randomized to aspirin 300 mg/d or combination (aspirin 300 mg/d+ standard release dipyridamole 75 mg thrice a day) and followed up for 6 months."5.11Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005)
"In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks."5.10Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. ( Buggle, F; Grau, AJ; Lichy, C; Reiners, S; Ruf, A, 2003)
" In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke."5.10Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002)
"In this study, 591 patients with recent cerebral ischemia of arterial origin were randomly allocated to treatment with aspirin 30 to 325 mg/d or with the combination of aspirin and dipyridamole 400 mg/d in the European/Australian Stroke Prevention in Reversible Ischemia Trial."5.10Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003)
"We performed multivariate logistic regression analysis of 2012 participants given aspirin alone or in combination with low, inefficacious doses of warfarin in the Stroke Prevention in Atrial Fibrillation I-III trials followed for a mean of 2."5.09Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. ( Asinger, RW; Hart, RG; McBride, R; Pearce, LA; Rothbart, RM, 1999)
"Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation."5.09Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000)
" We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding."5.09Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000)
" We assessed three schemes for stroke risk stratification in these patients who were treated with aspirin and who did not have prior cerebral ischemia."5.09Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. ( Halperin, JL; Hart, RG; Pearce, LA, 2000)
"We sought to compare different antithrombotic secondary treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to the risk of stroke recurrence."5.09Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. ( Heller, C; Kurnik, K; Luigs, P; Nowak-Göttl, U; Schobess, R; Sträter, R, 2001)
"Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage."5.09A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. ( Adams, HP; Albers, GW; Furie, KL; Jackson, CM; Kistler, JP; Lazar, RM; Levin, B; Mohr, JP; Pettigrew, LC; Pullicino, P; Sacco, RL; Thompson, JL, 2001)
"To determine the effectiveness of aspirin in preventing ischemic events in patients with asymptomatic carotid stenosis."5.08Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. ( Abrahamowicz, M; Battista, RN; Bourque, F; Côté, R; Langlois, Y; Mackey, A, 1995)
"Aspirin is only modestly effective in the secondary prevention after cerebral ischemia."5.08A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. ( , 1997)
") for secondary prevention of cerebral ischemia were compared with the effects of low-dosage aspirin (300 mg/die)."5.07[Clinical efficacy of picotamide]. ( de Falco, FA; Mastroroberto, G; Montariello, A; Visconti, OS, 1991)
"We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years."5.06European Stroke Prevention Study. ESPS Group. ( , 1990)
" An updated meta analysis was done to determine the effect of the various dual antiplatelets vs aspirin alone on recurrence rate of ischemic stroke, cardiovascular morbidity and mortality, and its safety profile as reported through major bleeding."5.05Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis. ( Albay, CEQ; Cheng, FC; Leyson, FGD, 2020)
"Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention."5.01Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019)
"The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin."5.01Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019)
"Background and Purpose- The role of aspirin plus clopidogrel (A+C) therapy compared with aspirin monotherapy in patients presenting with acute ischemic stroke (IS) or transient ischemic attack remains uncertain."5.01Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. ( Hammad, T; Kaluski, E; Khan, SU; Meyer, MA; Nasir, F; Rahman, H, 2019)
"To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)."4.98Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018)
"Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke."4.93Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016)
" We found no evidence that the net benefit of aspirin increased with increasing risk of thrombosis, haemorrhage or poor functional outcome in all three trials."4.91Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials. ( Candelise, L; Chen, Z; Murray, GD; Sandercock, PA; Thompson, DD; Whiteley, WN, 2015)
"Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved."4.90Oral antiplatelet therapy for acute ischaemic stroke. ( Cecconi, E; Counsell, C; Sandercock, PA; Tseng, MC, 2014)
"Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0."4.89Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013)
" The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0."4.89Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013)
"This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions."4.89Aspirin and clopidogrel for prevention of ischemic stroke. ( Anderson, DC; Thomson, RM, 2013)
" In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3."4.88Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012)
"Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide."4.88Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012)
"Aspirin is widely used for secondary prevention after stroke."4.87Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011)
"Aspirin is used to prevent ischemic stroke and other types of cardiovascular disease."4.87Gender differences in the primary prevention of stroke with aspirin. ( Adelman, EE; Brown, DL; Lisabeth, L, 2011)
"To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease."4.87Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011)
"In primary prevention trials conducted in low-risk subjects, aspirin is associated with a small reduction in ischemic strokes in women."4.85Antiplatelet drugs for ischemic stroke prevention. ( Balucani, C; Cordonnier, C; Leys, D, 2009)
" Currently, aspirin is generally prescribed for the primary prevention of stroke despite a number of trial results on effectiveness proving inconclusive."4.85Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease? ( Beckman, JA, 2009)
"The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD)."4.84Clopidogrel in secondary ischemic stroke prevention. ( Belvís, R; Kulisevsky, J; Pagonabarraga, J; Santamaría, A, 2008)
"In this paper, an overview is given of trials with oral anticoagulants and dipyridamole in the secondary prevention after transient ischaemic attack or minor stroke."4.84Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient? ( Algra, A; Halkes, PH, 2007)
"The current evidence suggests that aspirin is treatment of choice when compared to anticoagulants for patients with non-cardioembolic stroke."4.83Antithrombotic agents in cerebral ischaemia. ( Bhat, P; Bhattacharjee, M; Dalal, PM; Mishra, NK, 2006)
"Individual patient data of patients who received aspirin or placebo after cerebral ischemia were obtained from 9 clinical trials."4.82Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials. ( Algra, A; Ariesen, MJ; Koudstaal, PJ; Rothwell, PM; van Walraven, C, 2004)
"The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)."4.82Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004)
"Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results."4.82Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005)
"In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage."4.82Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005)
"This paper will examine how cerebral perfusion deficits in cocaine abusers may be a target for pharmacotherapy."4.80Pharmacotherapy of cerebral ischemia in cocaine dependence. ( Kosten, TR, 1998)
"Aspirin has been widely used to prevent myocardial infarction and ischemic stroke but some studies have suggested it increases risk of hemorrhagic stroke."4.80Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. ( He, J; Klag, MJ; Vu, B; Whelton, PK, 1998)
" Aspirin modestly reduces the risk for subsequent ischemic stroke after a transient ischemic attack or initial stroke."4.80Antithrombotic and thrombolytic therapy for ischemic stroke. ( Fisher, M, 1999)
" In primary prevention, the benefit of aspirin has been established only for patients with non-valvular atrial fibrillation and a low risk of cardioembolism, or as an alternative choice of warfarin, and in subjects at high risk of atherosclerosis."4.80[Prevention of cerebral ischemia: anti-platelet agents]. ( Leys, D, 1999)
"A vast consensus exists in defining a narrow range of recommended daily doses of aspirin, ie, 75 to 160 mg, for the prevention of myocardial infarction, stroke, and vascular death in patients with different manifestations of coronary hearth disease."4.79Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? ( Patrono, C; Roth, GJ, 1996)
"Our study aimed to explore the effectiveness and safety of intravenous t-PA compared with dual antiplatelet therapy (DAPT) and aspirin alone for minor stroke with National Institutes of Health Stroke Scale (NIHSS) score ≤5 and large vessel occlusion (LVO)."4.31Intravenous thrombolysis versus antiplatelet therapy in minor stroke patients with large vessel occlusion. ( Duan, C; Feng, X; Gu, H; Hao, M; Meng, X; Wang, S; Wang, Y; Xiong, Y; Yang, KX; Zhao, X, 2023)
"Aspirin is widely used as secondary prophylaxis for acute ischemic stroke."4.31In-Hospital Aspirin Dose as a Risk Factor for Hemorrhagic Transformation in Patients Not Treated With Thrombolysis. ( Clares de Andrade, JB; de Abreu, GQ; de Carvalho, JJF; Lima, FO; Maia Barros, LC; Mohr, JP; Pontes-Neto, OM; Silva, GS, 2023)
"A retrospective analysis was performed on 75 patients with cancer and mild to moderate ischemic stroke, 34 of whom received tirofiban treatment and 41 aspirin treatment."4.31Tirofiban in the treatment of cancer-associated ischemic stroke. ( Lin, ZH; Zhang, ZM; Zhu, GL, 2023)
" OAC prescribing status was explored for patients at risk for stroke and classified into the following: OAC, aspirin only, or no treatment."4.12Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. ( Ajabnoor, AM; Ashcroft, DM; Carr, MJ; Doran, T; Kontopantelis, E; Mamas, MA; Parisi, R; Rutter, MK; Zghebi, SS, 2022)
"This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin."4.12Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022)
"Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins."4.12Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022)
"We investigated (1) the associations of pre-stroke aspirin use with thrombus burden, infarct volume, hemorrhagic transformation, early neurological deterioration (END), and functional outcome, and (2) whether stroke subtypes modify these associations in first-ever ischemic stroke."4.02Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, KH; Han, MK; Hong, KS; Jeong, SW; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Lee, BC; Lee, J; Lee, KB; Lee, SJ; Nahrendorf, M; Oh, MS; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Schellingerhout, D; Yu, KH, 2021)
"We recruited 293 ischemic stroke patients, taking aspirin for more than seven days, and performed LTA to classify them."4.02Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy. ( Chandra, SR; Christopher, R; Ramanujam, N; Sundaravadivel, P, 2021)
"Ticagrelor plus aspirin could reduce the risks of major adverse cardiac events in diabetic patients with stable coronary artery disease (SCD), and yet it also increases bleeding risk."4.02Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. ( Shi, L; Wu, B, 2021)
"Patients with ischemic stroke receiving aspirin (100 mg/day) for three months were recruited for a multicenter, prospective, cohort study."4.02Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions. ( Chen, Y; Deng, W; Huang, W; Jiang, H; Li, J; Liang, Z; Liu, Q; Ou, Z; Ouyang, F; Wu, Z; Xing, S; Zeng, J; Zhang, Y, 2021)
"This study provides supporting evidence that aspirin use is associated with reduced ischaemic events after pneumonia in a primary care setting."4.02Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database. ( Arnold, D; Hamilton, F; Henley, W; Payne, RA, 2021)
" Here we assessed the contribution of clopidogrel versus aspirin to the development of pneumonia during an acute ischemic stroke admission."4.02Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients. ( Feng, Q; Fu, J; Jin, X; Shan, B; Shen, R; Yu, Z; Zhou, H; Zhu, H, 2021)
" The aim of this study was to assess the safety and efficacy of the p48 MW HPC (phenox, Bochum, Germany) to treat distal intracranial aneurysms under the use of aspirin monotherapy."4.02Aspirin monotherapy in the treatment of distal intracranial aneurysms with a surface modified flow diverter: a pilot study. ( Abud, DG; Abud, TG; de Castro-Afonso, LH; de Freitas, RK; Monsignore, LM; Nakiri, GS, 2021)
"We selected newly diagnosed ischemic stroke patients aged ≥20years who were newly treated with aspirin or clopidogrel from 2003-2010 Korean National Health Insurance Service-National Sample Cohort, a random sample of 2."4.02Non-persistence with anti-platelet therapy and long-term mortality after ischemic stroke: A nationwide study. ( Cho, B; Choi, HC; Kim, SJ; Kwon, OD; Lee, EJ, 2021)
" Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups."3.96Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020)
"In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention."3.96Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020)
"Several clinical trials reported that clopidogrel was superior to aspirin in secondary stroke prevention by reducing the risk of major adverse cardiovascular events (MACE)."3.91Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. ( Chan, L; Chen, YC; Hsu, CY; Hu, CJ; Lin, CL; Muo, CH; Vidyanti, AN; Wu, D, 2019)
"Treatment of patients with stroke presenting with minor deficits remains controversial, and the recent Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) trial, which randomized patients to thrombolysis vs aspirin, did not show benefit."3.91MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS. ( Benson, RT; Hsia, AW; Kalaria, CP; Latour, LL; Leigh, R; Luby, M; Lynch, JK; Majidi, S; Nadareishvili, Z, 2019)
"This study aimed to investigate the effectiveness of monotherapy acetylsalicylic acid (ASA) and warfarin for stroke prevention in low-risk atrial fibrillation (AF) by using a population- -based cohort study in Taiwan."3.91Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study. ( Chen, HC; Liu, CY, 2019)
"Of 149 subjects (mean age 57; 48% female; median NIH stroke scale (NIHSS) 19; 46% ischemic stroke; 54% hemorrhagic), implementation of treatments included: dysphagia screening (80%), deep venous thrombosis prophylaxis (0%), aspirin (83%), antihypertensives (89%) and statins (95%)."3.91Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania. ( Biseko, MR; Grundy, SJ; Kharal, GA; Klein, JP; Mateen, FJ; Mmbando, TN; Okeng'o, K; Parker, R; Regenhardt, RW; Saadi, A; Shayo, AF; Wibecan, L; Xu, A, 2019)
"To evaluate the effect of prestroke aspirin (PA) use on initial stroke severity, early neurologic deterioration (END), stroke recurrence, hemorrhagic transformation (HT), and functional outcome in patients with ischemic stroke (IS)."3.91Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. ( Han, Z; Lin, J; Luo, H; Yi, X; Zhou, J; Zhou, Q, 2019)
"To investigate the association of aspirin resistance (AR) with mortality in a cohort of Chinese patients with acute ischemic stroke (AIS)."3.91Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke. ( Jing, Y; Li, S; Yang, S; Yue, X, 2019)
"Background and Purpose- Two large-scale randomized controlled trials of recurrent stroke prevention suggest that dual antiplatelet therapy with clopidogrel plus aspirin is beneficial for prevention of subsequent ischemic events."3.91Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Choi, KH; Gorelick, PB; Han, MK; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, D; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Nah, HW; Oh, MS; Park, JM; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Yu, KH, 2019)
"High plasma level of HbA1c is involved in enhanced platelet aggregability in acute atherothrombotic stroke patients, and prestroke administration of aspirin may be beneficial to clinical outcomes."3.91Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke. ( Hagii, J; Harima, K; Honda, S; Kitajima, M; Metoki, H; Mikami, K; Osanai, T; Tomisawa, T; Urushizaka, M; Yasujima, M, 2019)
" After multivariate logistic regression, 10 variables remained independent predictors of sICH to compose the STARTING-SICH (systolic blood pressure, age, onset-to-treatment time for thrombolysis, National Institutes of Health Stroke Scale score, glucose, aspirin alone, aspirin plus clopidogrel, anticoagulant with INR ≤1."3.88STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke. ( Bonetti, B; Bovi, P; Cappellari, M; Forlivesi, S; Toni, D; Turcato, G; Zivelonghi, C, 2018)
"We used nationwide population-based registries to identify all first-time hospitalizations for stroke and subsequent mortality in patients treated with aspirin and clopidogrel in Denmark during 2004-2012."3.88Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study. ( Christiansen, CF; Grove, EL; Henderson, VW; Horváth-Puhó, E; Schmidt, M; Sørensen, HT; Würtz, M, 2018)
"To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients."3.88Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018)
"To investigate the prognostic value of aspirin reaction units (ARU) in a 3-month follow-up study in a cohort of Chinese patients with first-ever ischemic stroke."3.88Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients. ( Fan, YN; He, Y; Hua, QJ; Ji, SB; Liu, YX; Su, LL; Wang, CW; Xi, TT; Yuan, B, 2018)
"WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG."3.88Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018)
"Prostaglandin-Endoperoxide Synthase 1 (PTGS1) and smoking may play important roles in aspirin nonresponsiveness, but the effect of their interaction on stroke outcomes remains largely unknown."3.85Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: Interaction with smoking. ( Cai, B; Cai, H; Cao, L; Davis, SM; Guo, H; Liu, X; Sun, L; Sun, W; Yan, B; Zhang, H; Zhang, Z; Zhou, S, 2017)
" A substantial proportion of patients with stroke on ASA were "resistant", and the treatment with Clopidogrel was accompanied by even higher rates of unresponsiveness."3.85Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study. ( Bigliardi, G; Dell'Acqua, ML; Ferraro, D; Lelli, N; Mimmi, S; Nichelli, P; Pentore, R; Picchetto, L; Rosafio, F; Trenti, T; Vandelli, L; Zini, A, 2017)
"Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS."3.85Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017)
"This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy."3.85Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017)
"To investigate the prevalent of aspirin resistance (AR) in stroke and its association with recurrent stroke in 214 patients with ischemic stroke who were receiving aspirin before the stroke onset."3.85Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( Wang, Z; Zhang, N; Zhou, L, 2017)
"BACKGROUND To investigate the combination of beraprost sodium (BPS) and aspirin in the treatment of acute ischemic stroke (AIS)."3.85Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke. ( Chen, S; Chen, W; He, W; Li, S; Wei, D; Xie, S, 2017)
"Aspirin and statin are recommended for the treatment of acute ischemic stroke."3.85Statin and Aspirin Pretreatment Are Associated with Lower Neurological Deterioration and Platelet Activity in Patients with Acute Ischemic Stroke. ( Han, Z; Lin, J; Wang, C; Yi, X; Zhou, Q, 2017)
"This study aimed to know how frontline physicians in France, Belgium, and Switzerland implement guidelines regarding the secondary prevention of childhood arterial ischemic stroke and to introduce physicians' point of view on a clinical trial assessing the efficacy of aspirin as a preventive strategy."3.85Secondary Prevention of Childhood Arterial Ischemic Stroke. ( Bertoletti, L; Chabrier, S; Darteyre, S; Fluss, J; Laporte, S; Renaud, C, 2017)
"Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin."3.85Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017)
" Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months."3.85Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. ( Apruzzese, PK; Cannon, CP; Cohen, DJ; Cutlip, DE; D'Agostino, RB; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017)
"Admission National Institutes of Health Stroke Scale (NIHSS) score, ischemic lesion volumes on diffusion-weighted imaging (DWI), and in vitro aspirin resistance, in addition to other pertinent stroke features, were determined in a series of ischemic stroke patients."3.83The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance in Ischemic Stroke. ( Agayeva, N; Arsava, EM; Topcuoglu, MA, 2016)
"We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)."3.83Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016)
"Selecting among different antiplatelet strategies when patients experience a new ischemic stroke while taking aspirin is a common clinical challenge, currently addressed by a paucity of data."3.83Different Antiplatelet Strategies in Patients With New Ischemic Stroke While Taking Aspirin. ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Han, MK; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Ko, YC; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Nah, HW; Oh, MS; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Saver, JL; Shin, DI; Yeo, MJ; Yu, KH, 2016)
"The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain."3.83Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Gorelick, PB; Han, MK; Hong, KS; Kang, K; Kim, DE; Kim, DH; Kim, JT; Ko, Y; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, JM; Park, TH; Yu, KH, 2016)
" Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment."3.83Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. ( Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016)
"To investigate whether aspirin resistance is associated with initial stroke severity and infarct volume, using diffusion-weighted imaging (DWI) in patients with acute ischemic stroke that occurred while taking aspirin."3.83Aspirin resistance is associated with increased stroke severity and infarct volume. ( Jang, MU; Jung, S; Kim, C; Lee, BC; Lee, J; Lee, JH; Oh, MS; Yu, KH, 2016)
"A higher loading dose of aspirin (160-325 mg) can be beneficial in treating acute ischemic stroke, although there is an increased risk of minor bleeding."3.83To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. ( Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016)
"miR-145 is involved in the anti-proliferation and anti-inflammation effects of aspirin on VSMCs by inhibiting the expression of CD40."3.83miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40. ( Chen, M; Guo, R; Guo, X; Peng, X; Wu, T; Yu, L; Zhang, B, 2016)
"Aspirin is known to reduce stroke risk; however, its role in reducing severity of ischemic syndrome is not clear."3.83Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke. ( Cloonan, L; Fitzpatrick, KM; Furie, KL; Kanakis, AS; Nelson, S; Perilla, AS; Rost, NS; Shideler, KI, 2016)
"Aspirin resistance has an incidence of 5%-65% in patients with ischemic stroke, who receive the standard dose of aspirin, but the platelet function is inadequately inhibited, thereby leading to thrombotic events."3.83Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. ( Cai, YF; Chen, LY; Chen, XM; Huang, M; Jin, J; Li, JL; Peng, LL; Zhao, M; Zhao, YQ; Zhou, ZY, 2016)
"Plasma anticoagulation with warfarin during the early postoperative phase was shown statistically to be inferior to platelet aggregation inhibition by aspirin with regards to postoperative bleeding risk, cerebral ischemic events, and survival."3.83Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen? ( Breuer, M; Fuchs, J; Hüter, L; Kuntze, T; Lauer, B; Owais, T; Rouman, M, 2016)
"A significant proportion of ischemic strokes occur while using aspirin and therefore can be considered as clinical aspirin resistance."3.81Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke. ( Agayeva, N; Arsava, EM; Gungor, L; Topcuoglu, MA, 2015)
" The aim of this study was to evaluate the protective potential of implanted human umbilical cord mesenchymal stem (hUCMs) cells with/without aspirin (ASA) against focal cerebral ischemia."3.81Coadministration of the Human Umbilical Cord Matrix-Derived Mesenchymal Cells and Aspirin Alters Postischemic Brain Injury in Rats. ( Eslaminejad, T; Esmaeilpour, K; Nematollahi-Mahani, SN; Shams ara, A; Sheibani, V, 2015)
" Therefore, we sought to evaluate the time-dependent changes in platelet reactivity to aspirin during the acute stage after ischemic stroke and the clinical implications of variable patient responses to aspirin in acute ischemic stroke."3.81Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin Over Time in Acute Ischemic Stroke. ( Cho, KH; Choi, KH; Choi, SM; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, SH; Nam, TS; Park, MS; Saver, JL, 2015)
"In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke."3.81Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015)
"Some patients with a recent ischemic stroke who are being treated with aspirin as an antiaggregant suffer a new ischemic stroke."3.80Aspirin resistant patients with recent ischemic stroke. ( Castilla-Guerra, L; Fernández-Moreno, MC; Navas-Alcántara, MS, 2014)
"We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke."3.80Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. ( Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014)
"This study was designed to test the pre-treatment doses of guggulipid (50 mg/kg), aspirin (100 mg/kg) per orally and co-administration of both drugs for 28 days followed by middle cerebral artery occlusion - a model of focal cerebral ischemia in rats."3.80Neuroprotective effect of guggulipid alone and in combination with aspirin on middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia in rats. ( Ahmad, MA; Akhtar, M; Mujeeb, M; Najmi, AK, 2014)
"Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)."3.80Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014)
"To analyze the potential impact of aspirin therapy for long-term secondary prevention after stroke of undetermined etiology in resource-limited settings without access to neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH)."3.80Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings. ( Berkowitz, AL; Bianchi, MT; Chou, SH; Westover, MB, 2014)
"Aspirin resistance is common in the population of patients with hemodynamic cerebral ischemia scheduled for cerebral revascularization."3.79Aspirin resistance in patients with hemodynamic cerebral ischemia undergoing extracranial-intracranial bypass surgery. ( Horn, P; Jussen, D; Vajkoczy, P, 2013)
"A prospective study included 35 patients admitted with ischemic stroke and commenced on 300 mg aspirin."3.79"Aspirin resistance" in ischemic stroke: insights using short thrombelastography. ( Curzen, N; Englyst, N; Radhakrishnan, A; Sambu, N; Weir, N, 2013)
"The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths."3.79Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013)
"Among patients with stroke, the phenomenon of resistance to treatment with low-dose aspirin acetylsalicylic acid (ASA) is quite common."3.79Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. ( Chełstowski, K; Clark, J; Jastrzębska, M; Nowacki, P; Siennicka, A; Wódecka, A, 2013)
"The prognostic value of occurrence of ischemic stroke in a patient despite aspirin treatment (aspirin treatment failure) is not known."3.79Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke. ( Adams, HP; Cordina, SM; Georgiadis, AL; Lakshminarayan, K; Qureshi, AI; Suri, MF; Tariq, N; Vazquez, G, 2013)
"This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day)."3.79Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. ( Chichelli, T; Ching, M; Farooq, O; Janicke, D; Li, F; Mehta, B; Munschauer, FE; Radovic, V; Sawyer, RN; Sternberg, Z, 2013)
" The patient was subsequently found to have incomplete inhibition of platelet activity despite being on clopidogrel 150 mg and aspirin 81 mg daily and having a normal CYP-2C19 genotype, suggesting that suboptimal antiplatelet inhibition, secondary to morbid obesity, contributed to his in-stent thrombosis."3.79Obesity and intracranial in-stent thrombosis. ( Koch, S; Reyes-Iglesias, Y; Rose, DZ; Yavagal, DR, 2013)
"Of the 82 patients with recurrent cerebral ischemia included in this study, 37 (45%) patients were poor compliant with aspirin."3.79Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia. ( Abu-Hegazy, M; Azzam, H; El-Mitwalli, A; Gomaa, M; Wasel, Y, 2013)
"Most ischemic strokes due to TCVI are embolic in nature and occur prior to screening CTA and initiation of treatment with aspirin."3.79Timing and mechanism of ischemic stroke due to extracranial blunt traumatic cerebrovascular injury. ( Alexandrov, AV; Barlinn, K; Cava, LP; Curé, JK; Fleming, JB; Griessenauer, CJ; Harrigan, MR; Richards, BF; Taylor, T; Younan, DS; Zhao, L, 2013)
"Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone."3.78Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012)
"The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects."3.78Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012)
"Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably myocardial infarction and stroke."3.78Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes. ( Al-Hazzani, A; Dadheech, S; Jyothy, A; Kaul, S; Munshi, A; Prabha, TS; Rao, PP; Sharma, V, 2012)
" In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques."3.78Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012)
"We enrolled patients within 24 h of ischemic stroke and a group of controls taking aspirin who had never suffered a vascular event on therapy."3.77Aspirin resistance and compliance with therapy. ( Dawson, J; Higgins, P; Lees, KR; Quinn, T; Rafferty, M; Ray, G; Walters, MR, 2011)
"A total of 85 patients with acute ischemic stroke on 160mg aspirin daily were prospectively included."3.77Aspirin non-responder status and early neurological deterioration: a prospective study. ( Bugnicourt, JM; Canaple, S; Garcia, PY; Godefroy, O; Lamy, C; Roussel, B, 2011)
"The accuracy of the NHIRD in recording ischemic stroke diagnoses and aspirin prescriptions was high, and the NHIRD appears to be a valid resource for population research in ischemic stroke."3.77Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. ( Cheng, CL; Kao, YH; Lai, ML; Lee, CH; Lin, SJ, 2011)
" The aim of the present study is to investigate the effects of cilostazol and aspirin on endothelial nitric oxide synthase (eNOS) phosphorylation in the cerebral cortex, endothelial function, and infarct size after brain ischemia in spontaneously hypertensive rats (SHR)."3.77Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. ( Kawamura, M; Kitagawa, K; Omura-Matsuoka, E; Oyama, N; Sasaki, T; Sugiyama, Y; Terasaki, Y; Yagita, Y, 2011)
"In AF patients with CHADS(2) score 1, warfarin was better to prevent ischemic stroke than aspirin without increasing the incidence of major bleeding complications."3.76The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. ( Choi, DH; Hwang, ES; Kim, SK; Kim, YH; Kwak, JJ; Lee, BH; Pak, HN; Park, JH; Park, JS, 2010)
"Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization."3.76Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010)
"A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update."3.76Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. ( Ellrodt, G; Fonarow, GC; Frankel, MR; Hernandez, AF; Labresh, KA; Liang, L; Menon, BK; Schwamm, LH; Smith, EE, 2010)
"In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding."3.76Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010)
" We replicated the observation of the Atherosclerosis Risk in Communities Study and observed an interaction of rs20417 with aspirin use on myocardial infarction risk (p for interaction=0."3.75Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. ( Bis, JC; Heckbert, SR; Lemaitre, RN; Lumley, TS; Marciante, K; Psaty, BM; Rice, K; Smith, NL; Wiggins, KL, 2009)
"A considerable proportion of patients discontinue dipyridamole therapy because of headache."3.75Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009)
"Encourage men age 45 to 79 years to use aspirin when the potential benefit of a reduction in myocardial infarctions outweighs the potential harm of an increase in gastrointestinal hemorrhage."3.75Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. ( , 2009)
"There are very limited data on the influence of pretreatment with aspirin (ASA) on the etiology of subsequent first-ever ischemic stroke."3.75Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients. ( Kouperberg, E; Sprecher, E; Telman, G; Yarnitsky, D, 2009)
" We tested the hypothesis that combined pre-treatment with aspirin and clopidogrel is a risk factor for thrombolysis-related symptomatic intracerebral hemorrhage (sICH)."3.75Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? ( Dzialowski, I; Gahn, G; Hermann, A; Koch, R, 2009)
"Aspirin remains the most commonly used antithrombotic agent for the prevention of recurrent stroke among antithrombotic naive patients with a first-ever ischemic stroke in our institution."3.75The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke. ( Hseuh, IH; Lin, YJ; Po, HL, 2009)
" Ischemic stroke was predicted by hypertension, myocardial infarction, low-dose aspirin, comorbidity score, Health Assessment Questionnaire score, and presence of total joint replacement, but not by diabetes, smoking, exercise, or body mass index."3.74Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. ( Hallenbeck, JM; Michaud, K; Nadareishvili, Z; Wolfe, F, 2008)
"Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke."3.74ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. ( Cha, JK; Jeon, HW; Kang, MJ, 2008)
"Based on the risk-benefit analysis, warfarin prophylaxis for cardioembolic stroke in Chagas' disease is recommended for patients with a score of 4-5 points, in whom the risk of CE overweighs the risk of a major bleeding."3.74Prevention strategies of cardioembolic ischemic stroke in Chagas' disease. ( Freitas, GR; Hasslocher-Moreno, A; Sousa, AS; Xavier, SS, 2008)
"The results suggest that triflusal and aspirin appear to be equally neuroprotective against middle cerebral artery occlusion-induced cerebral ischemia."3.74Effects of triflusal and aspirin in a rat model of cerebral ischemia. ( Allen, GV; Bayona, NA; Cechetto, DF; Cheng, G; Hachinski, VC; Whitehead, SN, 2007)
"To report a case of cerebral ischemia in a patient receiving oral isotretinoin for severe acne."3.74Cerebral ischemia probably related to isotretinoin. ( Laroche, ML; Macian-Montoro, F; Merle, L; Vallat, JM, 2007)
"The present study was carried out to investigate the effect of the combination of an endothelin antagonist TAK-044 and an antiinflammatory agent aspirin in middle cerebral artery (MCA) occlusion model of acute ischemic stroke in rats."3.74Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats. ( Briyal, S; Gulati, A; Gupta, YK, 2007)
"In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)."3.74[Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007)
"A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included."3.74Can aspirin resistance be clinically predicted in stroke patients? ( Bang, OY; Choi, YJ; Huh, K; Joo, IS; Lee, PH; Seok, JI; Yoon, JH, 2008)
"We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)."3.73Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005)
"We aimed to study the timing of aspirin prescription in ischaemic stroke comparing patients admitted to an acute stroke unit (ASU) directly or via a general medical ward."3.73Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units. ( MacLeod, MJ; Reid, J; Williams, D, 2005)
"To study the discontinuation of aspirin therapy as a risk factor for ischemic stroke (IS)."3.73Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. ( Bezerra, DC; Bogousslavsky, J; Maulaz, AB; Michel, P, 2005)
" The antiplatelet drugs acetylsalicylic acid (aspirin) and a thienopyridine derivative (ticlopidine) are commonly used to treat cerebral ischemia but exert different effects on high-shear-stress-induced platelet aggregation (H-SIPA) in the plasma."3.73Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. ( Fujimura, Y; Iida, J; Ishizashi, H; Kawaguchi, S; Matsumoto, M; Sakaki, T; Yagi, H, 2005)
"Our findings do not concur with the hypothesis that aspirin, dipyridamole, or the combination may be especially effective in preventing vascular events in patients with previous cerebral ischemia that was caused by LVD compared with SVD."3.73Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. ( Algra, A; Ariesen, MJ; Kappelle, LJ, 2006)
"We studied outpatients of 5 neurological ambulatory centers in an urban city, Valencia, all with a history of ischemic stroke who had received aspirin for at least 6 months."3.73Adherence to aspirin in secondary prevention of ischemic stroke. ( Ferrer, JM; Lago, A; Pareja, A; Ponz, A; Santos, MT; Tembl, JI; Vallés, J, 2006)
"The purpose of this study was to determine safety and tolerability of clopidogrel in children with arterial ischemic stroke (AIS)."3.73The risks and safety of clopidogrel in pediatric arterial ischemic stroke. ( Allen, A; deVeber, G; Hune, S; MacGregor, D; Rafay, MF; Soman, T, 2006)
"Millions of people around the world regularly consume aspirin, but its value in determining stroke severity is still not clear."3.73Does prior aspirin use reduce stroke mortality? ( Demirkaya, M; Karlikaya, G; Orken, C; Tireli, H; Varlbas, F, 2006)
" Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy."3.73Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. ( Galor, A; Hoffman, GS; Lee, MS; Smith, SD, 2006)
"In the recently published Warfarin Aspirin Recurrent Stroke Study (WARSS), a low-intensity anticoagulation regimen was used because of safety concerns."3.72Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. ( , 2003)
"The authors describe course and outcome of eight patients with ischemic stroke as the first thrombotic manifestation of antiphospholipid syndrome who received low-dose aspirin as prophylactic treatment."3.72Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. ( de Groot, PG; Derksen, RH; Kappelle, LJ, 2003)
"Of 596 ischemic strokes, 32 percent occurred during warfarin therapy, 27 percent during aspirin therapy, and 42 percent during neither type of therapy."3.72Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. ( Chang, Y; Go, AS; Henault, LE; Hylek, EM; Jensvold, NG; Selby, JV; Singer, DE, 2003)
"To investigate the protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion rats."3.72[Protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion in rats]. ( Chen, CH; Qiu, LY; Yu, J; Zhou, Y, 2003)
"Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial."3.72Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2004)
"The results with GP in acute ischemic stroke are promising and further studies should be initiated using especially tirofiban, but with monitoring by cerebral diffusion-weighted MRI before and after treatment."3.72[Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice]. ( Haerten, K; Krabbe, C; Raiber, M, 2004)
"From a consecutive series of AF patients with first-ever ischemic stroke, we evaluated prospectively those with moderate to severe disability (grade 4-5 on the modified Rankin Scale) who were treated during a 5-year follow-up period with either warfarin or aspirin."3.72Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. ( Manios, E; Moulopoulos, SD; Spengos, K; Toumanidis, S; Tsivgoulis, G; Vemmos, KN; Zakopoulos, N, 2004)
" The findings also suggest that older patients and those who have used aspirin before stroke are at higher risk of a severe HT on rtPA."3.71Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). ( Bluhmki, E; Larrue, V; Müller, A; von Kummer R, R, 2001)
"The potential neuroprotective effects of the novel nitro-derivate of aspirin (NCX4016) on permanent focal cerebral ischemia in spontaneously hypertensive rats (SHRs) was investigated."3.71Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat. ( Ambrosini, MV; Del Soldato, P; Fredduzzi, S; Mariucci, G; Tantucci, M, 2001)
"Patients with both patent foramen ovale and atrial septal aneurysm who have had a stroke constitute a subgroup at substantial risk for recurrent stroke, and preventive strategies other than aspirin should be considered."3.71Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. ( Arquizan, C; Cabanes, L; Coste, J; Derumeaux, G; Lamy, C; Mas, JL; Zuber, M, 2001)
"A previous study indicated that diaspirin-crosslinked hemoglobin (DCLHb) decreases cerebral ischemia after subarachnoid hemorrhage."3.70Subarachnoid molecular hemoglobin after subarachnoid hemorrhage in rats: effect on the area of hypoperfusion. ( Cole, DJ; Cross, LM; Drummond, JC; McKay, LD; Patel, PM, 1998)
"Recently developed interventional radiologic techniques, such as embolization with platinum coils, may induce thrombus formation within an aneurysm."3.70Detection of microemboli distal to cerebral aneurysms before and after therapeutic embolization. ( Berlit, P; Henkes, H; Klötzsch, C; Kühne, D; Nahser, HC, 1998)
"Anesthetized swine were randomized to receive SPR, diaspirin cross-linked hemoglobin, or DR after cryogenic brain injury and uncontrolled hemorrhagic shock and studied for 70 minutes after the combined insults."3.70Comparison of standard and alternative prehospital resuscitation in uncontrolled hemorrhagic shock and head injury. ( Bourguignon, P; Buckingham, S; Nichols, P; Novak, L; Osler, T; Sartorelli, K; Shackford, SR, 1999)
"Ischemic event rates were estimated for 12,931 aspirin users drawn from the Saskatchewan Health population between 1990 and 1995 who had an index diagnosis of myocardial infarction, ischemic stroke, or peripheral arterial disease."3.70Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi ( Caro, JJ; Migliaccio-Walle, K, 1999)
"Large intervention studies suggest that aspirin may reduce mortality when given to patients who present with strokes or transient ischemic attacks."3.70Does prior use of aspirin affect outcome in ischemic stroke? ( Kalra, L; Perez, I; Smithard, DG; Sulch, D, 2000)
"This follow-up study was designed to evaluate whether the use of aspirin either before or after aneurysm rupture affects the occurrence of delayed cerebral ischemia."3.69Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Juvela, S, 1995)
"To assess the risk of bleeding complications in patients treated with combination aspirin and heparin for cerebral ischemia."3.69Safety of combination aspirin and anticoagulation in acute ischemic stroke. ( Fagan, SC; Kertland, HR; Tietjen, GE, 1994)
"During a 1-year period, we prospectively studied the mechanism and severity of stroke in 47 patients sustaining a cerebral infarction while taking aspirin."3.68Mechanism of stroke in patients taking aspirin. ( Chimowitz, MI; Furlan, AJ; Nayak, S; Sila, CA, 1990)
"The aggregability of platelets to arachidonic acid (AA) was investigated in 26 control subjects, 40 patients with essential hypertension, 20 patients with ischemic cerebrovascular diseases (CVD) not taking aspirin and 11 patients with CVD taking aspirin."3.66Platelet aggregation induced by arachidonic acid and thromboxane generation in patients with hypertension or cerebrovascular disease. ( Abe, H; Fujisawa, A; Kimura, K; Kusunoki, M; Matsumoto, M; Matsuyama, T; Uyama, O; Yoneda, S, 1981)
"Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none."3.30Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023)
"Cerebral small vessel disease is characterized by progressive cerebral white matter changes (WMCs)."3.11Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial. ( Cho, SJ; Choi, SH; Choi, YH; Han, HJ; Jeong, JH; Kim, BC; Kim, EJ; Kim, JH; Kim, S; Lee, JH; Lee, JM; Na, DL; Oh, MS; Park, G; Park, HY; Park, KC; Park, KH; Park, KW; Park, SA; Shim, Y; Yoon, B; Yoon, SJ; Youn, YC, 2022)
"Cancer is a frequent finding in ischaemic stroke patients."2.94Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. ( Berkowitz, SD; Chamorro, A; Demchuk, A; Hart, RG; Joensuu, H; Kasner, SE; Liu, YY; Marti-Fabregas, J; Martinez-Majander, N; Mundl, H; Ntaios, G; Perera, KS; Prats-Sanchez, L; Rudilosso, S; Saarinen, J; Tatlisumak, T; Themeles, E; Tiainen, M; Ylikotila, P, 2020)
"The concept of embolic stroke of undetermined source (ESUS) unifies a subgroup of cryptogenic strokes based on neuroimaging, a defined minimum set of diagnostic tests, and exclusion of certain causes."2.94Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. ( Ameriso, SF; Arauz, A; Berkowitz, SD; Chamorro, Á; Connolly, SJ; Hankey, GJ; Hart, RG; Kasner, SE; Korompoki, E; Lindgren, A; Muir, KW; Mundl, H; Ozturk, S; Pearce, LA; Perera, K; Rudilosso, S; Sharma, M; Shoamanesh, A; Shuaib, A; Tatlisumak, T; Toni, D; Veltkamp, R, 2020)
"OBJECTIVE Clinical vasospasm and delayed cerebral ischemia (DCI) are devastating complications of aneurysmal subarachnoid hemorrhage (aSAH)."2.87Dual antiplatelet therapy in aneurysmal subarachnoid hemorrhage: association with reduced risk of clinical vasospasm and delayed cerebral ischemia. ( Allan, L; Broderick, J; Brown, RD; Chalouhi, N; Chimowitz, M; Derdeyn, CP; Hasan, D; Jabbour, P; Leira, EC; Nagahama, Y; Nakagawa, D; Starke, RM; Torner, JC; Zanaty, M, 2018)
"aspirin monotherapy was carried out, to determine optimal peri-operative management with these antiplatelet agents."2.82Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis. ( Bissacco, D; Chechik, O; Chisci, E; Cusimano, MD; Ku, JC; Larrue, V; Macdonald, RL; Michelagnoli, S; Nasr, N; Pasarikovski, CR; Priola, SM; Rabinovich, Y; Settembrini, PG; Taslimi, S; Yang, VXD; Zuccato, J, 2022)
"Acute stroke is the leading cause of disability in the UK and a leading cause of mortality worldwide."2.82Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician. ( Appleton, JP; Bath, PM; Dawson, J; England, TJ; Eveson, D; Krishnan, K; Law, ZK; Mavilakandy, A; Minhas, JS; Mistri, A; Robinson, TG; Sprigg, N, 2022)
"The primary outcome is IS recurrence."2.80Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015)
"60."2.79Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. ( Alvarez-Sabín, J; Maisterra, O; Quintana, M; Santamarina, E, 2014)
"Despite improvements in treatment, stroke still carries a high death toll and disability in Asia."2.76The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011)
" These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke."2.76Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. ( Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011)
" It is impossible to exclude that long term administration of warfarin in strategy of sinus rhythm maintenance attenuated advantages of normal rhythm in relation of lowering of stroke risk in AFFIRM study and other similar works."2.73[Prevention of ischemic stroke in middle aged patients with atrial fibrillation. Effect of sinus rhythm maintenance, aspirin, warfarin, and simvastatin]. ( Kanorskiĭ, SG; Shevelev, VI; Zafiraki, VK; Zingilevskiĭ, KB, 2007)
"Patients with minor ischemic stroke or transient ischemic attack represent a high-risk population for recurrent stroke."2.72Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G, 2021)
"Location of stenosis, type of qualifying event, and prior use of antithrombotic medications were not associated with increased risk."2.72Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. ( Benesch, CG; Chaturvedi, S; Chimowitz, MI; Cloft, HJ; Frankel, MR; Hertzberg, VS; Howlett-Smith, H; Jovin, TG; Kasner, SE; Levine, SR; Lynn, MJ; Romano, JG; Sila, CA; Stern, BJ, 2006)
" There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO."2.71Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. ( DiTullio, MR; Homma, S; Mohr, JP; Sacco, RL; Sciacca, RR, 2004)
"Both high blood pressure and low blood pressure were independent prognostic factors for poor outcome, relationships that appear to be mediated in part by increased rates of early recurrence and death resulting from presumed cerebral edema in patients with high blood pressure and increased coronary heart disease events in those with low blood pressure."2.70Blood pressure and clinical outcomes in the International Stroke Trial. ( Bath, PM; Leonardi-Bee, J; Phillips, SJ; Sandercock, PA, 2002)
"Aspirin use at entry was also associated with a 4-fold (95% CI, 1."2.69Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group. ( Beauchamp, NJ; Hart, RG; Kronmal, RA; Manolio, TA; Newman, A; Talbert, RL, 1998)
"We studied 68 patients with 50% to 99% stenosis of one of the following arteries: intracranial vertebral (n = 31), basilar (n = 28), posterior cerebral (PCA) (n = 6), or posterior inferior cerebellar (PICA) (n = 3)."2.69Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. ( , 1998)
" Two patients in the 100 mg/kg group had adverse events that were possibly drug related: one suffered fatal brain and pulmonary edema, the other transient renal and pancreatic insufficiency."2.69Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. ( Carton, H; Hacke, W; Kaste, M; Koudstaal, PJ; Przybelski, RJ; Saxena, R; Stern, KN; Wijnhoud, AD, 1999)
"As part of a multicenter treatment trial of vascular dementia, this method was then used to analyze MR films in 13 patients with vascular dementia who all had an MR study at baseline and at 1 year."2.68Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis. ( Broderick, JP; Dhawan, AP; Gaskill, M; Khoury, J; Narayan, S, 1996)
"Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events."2.68A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996)
"Only aspirin has been evaluated in the setting of primary prevention and it seems to be ineffective in preventing cerebral infarction."2.68[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors]. ( Canaple, S; Rosa, A, 1996)
" This paper reviews the pattern of adverse reactions to AAS and their relationship to the dosage of ASS evaluated."2.68[Secondary prevention of ischemic strokes: effect of dosage of aspirin]. ( Alvarez-Sabín, J; Calvo, G; Morros, R, 1997)
"The subjects were 75 patients with cerebral ischemia and 26 control subjects."2.67Shear-induced platelet aggregation in cerebral ischemia. ( Fukuyama, M; Handa, M; Ikeda, Y; Itagaki, I; Maruyama, S; Uchiyama, S; Yamazaki, M, 1994)
"048), and the frequency of adverse events was not significantly different between the two treatment groups."2.67The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. ( Weisberg, LA, 1993)
"The number of fatal and non fatal cerebral infarction was 31 in the P group, 17 in the ASA group, and 18 in the ASA + D group."2.65[The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: Results]. ( Bousser, MG; Eschwege, E; Haguenau, M; Lefauconnier, JM; Thibult, N; Touboul, D; Touboul, PJ, 1983)
"Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke."2.61Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019)
"Stroke is one of the leading causes of death."2.55Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance. ( Chaurasia, P; Munshi, A; Singh, S; Vasudeva, K, 2017)
"Performance in patients with cerebral ischemia was poor."2.53Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. ( Algra, A; Greving, JP; Hilkens, NA, 2016)
" Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events."2.52Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015)
" In addition, the discussion here reviews select acute ischemic stroke intravenous thrombolytic studies, such as the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study and European Cooperative Acute Stroke Studies, select neuroprotectant and endovascular clot retrieval device studies, and large cooperative databases, such as the Virtual International Stroke Trials Archive and Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry, to explore relationships between baseline stroke severity and other possible factors associated with efficacy and safety outcomes."2.48How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials. ( Gorelick, PB, 2012)
"In acute intracerebral hemorrhage the beneficial effect of recombinant coagulation factor VII found in a small study could not be proved in a large phase III trial."2.45[Pharmacotherapy of stroke]. ( Bereczki, D, 2009)
"Most strokes are caused by a sudden blockage of an artery in the brain (called an ischaemic stroke) that is usually due to a blood clot."2.45Antiplatelet treatment in ischemic stroke treatment. ( Arnao, V; Di Raimondo, D; Di Sciacca, R; La Placa, S; Licata, G; Miceli, S; Milio, G; Pinto, A; Tuttolomondo, A, 2009)
"Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States."2.44Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008)
"Ischemic stroke is a common complication after CABG."2.44Prevention of ischemic stroke: surgery. ( Chaturvedi, S; Rajamani, K, 2007)
"Twenty-three children had varicella at age 1."2.43Post-varicella arteriopathy of childhood: natural history of vascular stenosis. ( Armstrong, D; deVeber, G; Domi, T; Lanthier, S, 2005)
"Approximately 7000 intracerebral hemorrhages (ICHs) annually in the US are caused by use of antithrombotic therapies."2.43Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. ( Hart, RG; Pearce, LA; Tonarelli, SB, 2005)
" The optimum doses of antiplatelet drugs depend upon several variables, such as genetic and environmental factors, so that clinical and laboratory response for dosage varies for each patient."2.43Antiplatelet therapy in ischemic stroke. ( Káposzta, Z; Pongrácz, E, 2005)
"About 80% of strokes have ischemic origin."2.43[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005)
"Ischemic stroke is a leading cause of death and disability in the Western world."2.43Therapy for early reperfusion after stroke. ( Juttler, E; Kohrmann, M; Schellinger, PD, 2006)
"Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal."2.42Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. ( Michiels, JJ, 2003)
"The risk of TIA or stroke recurrence reaches 30-45%."2.42[Stenosis of the carotid arteries]. ( Kaźmierski, MK, 2003)
"Ticlopidine is a reserve drug due to its unfavorable side effect profile (neutropenia, TTP)."2.42[The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review]. ( Jüttler, E; Meyding-Lamadé, UK; Schellinger, PD; Schwark, C, 2004)
"Paroxysmal AF is an important cause of brain embolism, that is often difficult to document."2.42Atrial fibrillation and cardioembolic stroke. ( Ferro, JM, 2004)
"Aspirin treatment does not preclude control of underlying and comorbid conditions such as diabetes mellitus, hypertension, and dyslipidemia."2.41Aspirin in the prophylaxis of coronary artery disease. ( Mehta, P, 2002)
"In comparison with transient ischemic attacks in patients with vascular risk factors, the usual neurologic presentation of ET consists of brief attacks of sudden cerebral or visual dysfunction, which can be either well localized or diffuse and entirely nonspecific."2.40Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. ( Koudstaal, A; Koudstaal, PJ, 1997)
"Four patients presented transient ischemic attacks, one amaurosis fugax, two suffered from a minor stroke, four had non-focalized ischemic cerebral symptoms and two were asymptomatic."2.40Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review. ( Limet, R; Sakalihasan, N; Van Damme, H, 1999)
" Furthermore, in assessing the potential benefits of long-term use of ASA for prophylactic purposes in these patients, one should also evaluate the side-effects and intolerance related to its chronic use, as well as its potential complications especially from a gastrointestinal perspective."2.39Aspirin in asymptomatic carotid disease. ( Côté, R, 1994)
" Among the anti-aggregant agents, only Aspirin at high dosage (1 to 1."2.37[The fate of patients with carotid stenosis. Comparative study, based on the literature, of their natural history and evolution under medical treatment or following endarterectomy]. ( Bachet, P; Ninet, J; Pasquier, J, 1985)
"The therapeutic outcomes for acute ischemic stroke (AIS) with early neurological deterioration (END) are adverse."1.91Efficacy and Prognosis of Adjuvant Argatroban Treatment in Acute Ischemic Stroke Patients with Early Neurological Deterioration. ( Wu, T; Xu, S; Xu, Z; Zhang, W; Zhang, Y, 2023)
"Aspirin nanoparticles were formulated in this study which may offer better therapeutic advantages over the conventional aspirin tablets in the prevention and management of acute myocardial infarction and ischaemic stroke."1.91Formulation of aspirin nanoparticles using solvent evaporation method and in vivo evaluation of its antithrombotic effect. ( Alhajj, L; Ovenseri Airemwen, C; Pozharani, LB, 2023)
"Acute cerebral ischemia was discovered to be the most common cerebrovascular disease associated with SARS-CoV-2."1.72Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies? ( Ates, O; Dogan, M; Ersoz, E; Hacioglu Kasim, FB; Karaarslan, N; Ozbek, H; Yilmaz, I, 2022)
"We report a case of ischaemic stroke in a 34-year-old male recreational bodybuilder following a 3-month period of anabolic androgenic steroid (AAS) use and 1-month period of 'post-cycle therapy' (tamoxifen and clomiphene citrate), the latter treatments aimed at restoring normal endogenous testosterone production after initial AAS use."1.62Anabolic steroid use and ischaemic stroke in a young fitness enthusiast. ( Choulerton, J; Guha, N; Squires, R, 2021)
"Platelet thrombosis is the main pathogeny resulting in the low curability of ischemic stroke, a leading cause of mortality and disability worldwide."1.56Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke. ( Chen, Z; He, Y; Huang, W; Ji, C; Lee, KH; Li, S; Li, Y; Ming, Y; Morris-Natschke, SL; Niu, H; Wei, Z; Xin, G; Xing, Z; Yang, X; Yu, K; Zhang, B; Zhang, J; Zhang, X, 2020)
"Neonatal ischemic stroke has a higher incidence than childhood stroke."1.56Preventive Effects of Neuroprotective Agents in a Neonatal Rat of Photothrombotic Stroke Model. ( Choi, SG; Kang, JW; Kim, DW; Kim, SK; Shin, HJ; Song, HJ; Yi, YY, 2020)
"TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis."1.51The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019)
"Aspirin use was independently associated with reduced DCI risk (P < ."1.51Post-treatment Antiplatelet Therapy Reduces Risk for Delayed Cerebral Ischemia due to Aneurysmal Subarachnoid Hemorrhage. ( Darkwah Oppong, M; Deuschl, C; Forsting, M; Gembruch, O; Jabbarli, R; Kaier, K; Kleinschnitz, C; Köhrmann, M; Mönninghoff, C; Pierscianek, D; Sure, U, 2019)
"Twenty-and-a-half syndrome is reported for the first time."1.51Twenty-and-a-half syndrome: a case report. ( Chouksey, D; Dani, R; Dube, M; Dubey, A, 2019)
"Post-LVAD strokes are an important cause of morbidity and reduced quality of life."1.48Cerebrovascular Accidents During Mechanical Circulatory Support: New Predictors of Ischemic and Hemorrhagic Strokes and Outcome. ( Ahmed, FS; Akbik, F; Feske, SK; Givertz, MM; Izzy, S; Renault, S; Rubin, DB; Smallwood, JA; Sylvester, KW; Vaitkevicius, H, 2018)
"A 37-year-old woman with idiopathic thrombocytopenic purpura (ITP) suffered from multiple trauma scheduled for open reduction and internal fixation for right tibial and left radius fracture five days after SAE."1.48Bilateral visual loss and cerebral infarction after spleen embolization in a trauma patient with idiopathic thrombocytopenic purpura: A case report. ( Chen, JY; Hung, KC; Lan, KM; Li, YY; Lin, WC; Sun, CK; Wang, WT, 2018)
"The participants were 5,696 adults with COPD with a first myocardial infarction (n = 2,850) or ischemic stroke (n = 3,010) and at least one acute exacerbation from the UK Clinical Practice Research Datalink with linked Hospital Episodes Statistics data."1.48Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. ( Connell, O; Douglas, I; Müllerová, H; Pearce, N; Quint, JK; Rothnie, KJ; Smeeth, L, 2018)
"The aspirin reaction unit was blindly measured at the following two times: after 3 hours of aspirin loading and on the fifth day of aspirin administration."1.48Clinical Significance of Acute and Serial Platelet Function Testing in Acute Ischemic Stroke. ( Cho, KH; Choi, KH; Kim, JT; Lee, JS; Park, MS; Saver, JL, 2018)
"Cerebral ischemia was induced for 2 h followed by reperfusion for 22 h."1.43Protective Effect of Guggulipid in High Fat Diet and Middle Cerebral Artery Occlusion (MCAO) Induced Ischemic Cerebral Injury in Rats. ( Ahmad, MA; Akhtar, M; Mujeeb, M; Najmi, AK, 2016)
"Rivaroxaban is an oral anticoagulant that acts as a direct, competitive factor Xa inhibitor."1.43Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report. ( Adamo, A; Bilora, F; Pomerri, F; Prandoni, P, 2016)
"HPR-aspirin was persistent 75days later in 36% patients."1.43High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016)
"Nineteen patients presented vascular recurrence after stroke, and 19 matched patients did not present vascular recurrence during the first year of follow-up."1.43PPM1A Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients. ( Bin Dukhyil, AA; Carrera, C; Cullell, N; Fernandez-Cadenas, I; Fontana, P; Gallego-Fabrega, C; Krupinski, J; Martí-Fàbregas, J; Montaner, J; Muiño, E; Pera, J; Pezzini, A; Reny, JL; Segura, T; Serrano-Heras, G; Slowik, A, 2016)
"Stroke is the second largest cause of death worldwide."1.42Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometry. ( Evans, PA; Hawkins, K; Lawrence, M; Morris, RH; Potter, JF; Sabra, A; Stanford, SN; Storton, S; Wani, M; Williams, PR, 2015)
"Patients with a history of cerebral hemorrhage were excluded."1.40Associations of durations of antiplatelet use and vascular risk factors with the presence of cerebral microbleeds. ( Hattori, N; Okuma, Y; Tanaka, R; Tanaka, Y; Ueno, Y; Urabe, T; Yamashiro, K, 2014)
"Oral anticoagulation is the recommended treatment for stroke prevention in patients with atrial fibrillation."1.40Atrial fibrillation patients do not benefit from acetylsalicylic acid. ( Friberg, L; Själander, A; Själander, S; Svensson, PJ, 2014)
"Routine follow-up has revealed no recurrence of symptoms."1.40The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis. ( BinBrek, AS; Mahmoud, WE; Murugesan, V; Rajani, AR, 2014)
"About 80% of strokes are ischaemic."1.39Antithrombotic drugs and ischaemic stroke. ( , 2013)
"The risk for preeclampsia increased in patients who were positive for multiple antiphospholipid antibodies (aPL) (odds ratio (OR) 3."1.38Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. ( Brinks, R; Fischer-Betz, R; Schneider, M; Specker, C, 2012)
"Focal cerebral ischemia was induced by MCA occlusion for 2 hours followed by reperfusion for 22 hours."1.37Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats. ( Ahmad, SJ; Akhtar, M; Islam, F; Khanam, R; Pillai, KK; Pratap, R, 2011)
"The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes."1.37Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011)
"Pretreatment with cilostazol (100 mg/kg) significantly reduced infarct size."1.36Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. ( Hashimoto, A; Ito, H; Matsumoto, Y; Miyakoda, G; Yao, H, 2010)
"We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)."1.36Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010)
"Women with CHD also had a higher rate of cerebral ischemia than did men (27."1.36Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. ( Gerhat, D; Handisurya, A; Hudson, S; Kamyar, MR; Kautzky-Willer, A; Lemmens-Gruber, R; Luger, A; Stemer, G, 2010)
" In these patients, we recommend use of the combination of aspirin and extended-release dipyridamole (25/200 mg bid) over aspirin (Grade 1A) and suggest clopidogrel over aspirin (Grade 2B), and recommend avoiding long-term use of the combination of aspirin and clopidogrel (Grade 1B)."1.35Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Albers, GW; Amarenco, P; Easton, JD; Sacco, RL; Teal, P, 2008)
"Aspirin (30 mg/kg) treatment also reduced platelet aggregation."1.35Aspirin attenuates cerebral ischemic injury in diabetic rats. ( Fu, FH; Han, B; Wang, T; Yu, X; Zhang, LM; Zhu, M, 2009)
"Moyamoya disease is a progressive, unilateral, or bilateral carotid artery stenosis of unknown etiology."1.35Moyamoya disease in an 8-year-old boy presenting with weakness. ( Johnson, LH; Tenney, J, 2009)
"Neu2000 protected against the effects of middle cerebral artery occlusion, even when delivered 8 h after reperfusion."1.34Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. ( Ahn, YM; Byun, HY; Cho, JY; Cho, SI; Chung, JM; Gwag, BJ; Im, DS; Kim, KW; Ko, SY; Kwon, HJ; Lee, HU; Lee, JY; Lee, MJ; Lee, YA; Lim, HR; Moon, HS; Noh, JH; Park, SM; Son, SJ; Won, SJ; Yoon, SH; Yun, BS, 2007)
"Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury."1.34TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. ( Al-Bahrani, A; Bakhiet, M; Shaath, H; Taha, S, 2007)
"Aspirin resistance was found in 32% of cases."1.33Prevalence of aspirin resistance measured by PFA-100. ( Castano, S; Coma-Canella, I; Velasco, A, 2005)
"Cerebral ischemia was mechanically induced by 2-hour occlusion of the left middle cerebral artery (MCA) using an intraluminal filament followed by 24-hour reperfusion."1.33Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. ( Hong, KW; Lee, JH; Lee, WS; Park, SY, 2005)
"(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke."1.33Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005)
" The aim of the monitoring of ASA therapy should be the identification of nonresponders to prevent a long-term intake of the drug without adequate benefit, to justify a dose escalation, or to initiate an alternative antiplatelet drug therapy."1.33Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. ( Feuring, M; Losel, R; Schultz, A; Wehling, M, 2005)
"The metabolic syndrome is present in about half of individuals with symptomatic intracranial atherosclerotic disease and is associated with a substantially higher risk of major vascular events."1.33Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. ( Chimowitz, M; Lynn, MJ; Ovbiagele, B; Saver, JL, 2006)
"Poststroke recurrence rate was low (7."1.32Ischaemic stroke in young people: a prospective and long-term follow-up study. ( Carerj, S; Di Perri, R; Epifanio, A; Gallitto, G; Gangemi, S; Granata, A; La Spina, P; Leggiadro, N; Manganaro, A; Musolino, R; Tripodi, F, 2003)
"Two of the intracerebral hemorrhages occurred in the site where asymptomatic MBs were found at baseline."1.32Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. ( Fan, YH; Lam, WW; Mok, VC; Wong, KS; Zhang, L, 2003)
"Hypertension was a more common risk factor in AS patients (69% AS patients vs."1.32Risk factors and in-hospital outcomes in stroke and myocardial infarction patients. ( Ivanusa, M; Ivanusa, Z, 2004)
"Strokes were subtyped according to inferred mechanism."1.32Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. ( Barzegar, S; Bauer, K; Costigan, T; Furie, KL; Kistler, JP; Mohr, JP; Rosenberg, R; Rosner, B; Sciacca, R; Thompson, JL; Thornell, B, 2004)
"An 18-year-old Saudi male with systemic lupus erythematosus (SLE) presented with mild right hemiparesis, followed by recurrent ischemic stroke."1.31Systemic lupus erythematosus associated with moyamoya syndrome. ( Al Rayes, HM; El Ramahi, KM, 2000)
"Because brain ischemia has recently been recognized to contribute to the pathogenesis of AD, we studied the effect of focal brain ischemia in 8- and 20-month-old mice overexpressing the 751-amino acid isoform of human APP."1.31Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. ( Bures, J; Goldsteins, G; Higgins, LS; Kauppinen, RA; Keinänen, R; Kettunen, MI; Koistinaho, J; Koistinaho, M; Liu, D; Ort, M; Salminen, A, 2002)
"History of untreated hypertension prior to the initial stroke (RR = 1."1.30Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study. ( Baranska-Gieruszczak, M; Czlonkowska, A; Hier, DB; Lechowicz, W; Ryglewicz, D, 1997)
"Aspirin-treated and non-aspirin-treated patients did not differ in stroke severity."1.30Does daily aspirin diminish severity of first-ever stroke? ( Bornstein, NM; Hass, Y; Karepov, V; Korczyn, AD, 1997)
" Of the 52 with partial inhibition at initial testing, 35 achieved complete inhibition either by ASA dosage escalation (in 325 mg/d increments) or fluctuation of response at the same dosage, but 8 of those 35 (22."1.29Development of aspirin resistance in persons with previous ischemic stroke. ( Bolin, KM; Brace, LD; Helgason, CM; Hoff, JA; Mangat, A; Tortorice, KL; Winkler, SR, 1994)
"The total brain ischemia has been implemented in accordance with an original technique for 17 to 35 min."1.28[Anti-ischemic protection of the brain using water-soluble form of aspirin-acelisin]. ( Bilenko, MV; Komarov, PG; Morganov, AA; Tel'pukhov, VI; Tikhomirova, AI, 1992)
"Eight patients, 3 with systemic lupus erythematosus (SLE) or "SLE-like" disease, 1 with sarcoidosis, and 4 with no connective tissue disease had transient ischemic attacks (TIA) or cerebral infarctions associated with high levels of anticardiolipin antibodies (ACA)."1.28Cerebral ischemia associated with anticardiolipin antibodies. ( Ernerudh, J; Lindström, F; Olsson, JE; Vrethem, M, 1992)
"62 patients with transient ischemic attack (TIA), 60 with reversible ischemic neurologic deficit (RIND) and 57 with stroke with minimum residuum (SMR) were followed, in a retrospective survey, from the first 7 days to the 3rd month of evolution."1.27Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum. ( Calandre, L; Molina, JA, 1985)
"Mitral valve prolapse is usually a benign condition, however, serious complications have been reported to be associated with it."1.27Mitral valve prolapse and thromboembolic disease in pregnancy: a case report. ( Bergh, PA; Breen, JL; Gregori, CA; Hollander, D, 1988)
"Vascular dementia is a common and potentially reversible type of dementing illness."1.27Validation of cognitive and functional assessment instruments in vascular dementia. ( Greenough, PG; Hershey, LA; Jaffe, DF; Yang, SL, 1987)

Research

Studies (798)

TimeframeStudies, this research(%)All Research%
pre-199060 (7.52)18.7374
1990's142 (17.79)18.2507
2000's232 (29.07)29.6817
2010's288 (36.09)24.3611
2020's76 (9.52)2.80

Authors

AuthorsStudies
Sun, Y1
Jiang, J1
Zhang, Z3
Yu, P1
Wang, L2
Xu, C1
Liu, W2
Wang, Y22
Wu, J2
Ling, J1
Wang, X4
Li, T1
Liu, J3
Lai, Y1
Ji, H2
Peng, S1
Tian, J1
Zhang, Y6
Xin, G1
Ming, Y1
Ji, C1
Wei, Z1
Li, S3
Morris-Natschke, SL1
Zhang, X3
Yu, K1
Li, Y3
Zhang, B4
Zhang, J1
Xing, Z1
He, Y3
Chen, Z5
Yang, X2
Niu, H1
Lee, KH1
Huang, W3
Anand, SS2
Hiatt, W1
Dyal, L1
Bauersachs, R1
Berkowitz, SD6
Branch, KRH1
Debus, S1
Fox, KAA1
Liang, Y1
Muehlhofer, E2
Nehler, M1
Haskell, LP2
Patel, M1
Szarek, M2
Yusuf, S8
Eikelboom, J3
Bonaca, MP2
Ryu, WS3
Schellingerhout, D1
Hong, KS9
Jeong, SW1
Kim, BJ7
Kim, JT7
Lee, KB5
Park, TH4
Park, SS2
Park, JM7
Kang, K4
Cho, YJ5
Park, HK1
Lee, BC5
Yu, KH6
Oh, MS5
Lee, SJ7
Kim, JG3
Cha, JK10
Kim, DH4
Lee, J12
Han, MK4
Park, MS6
Choi, KH6
Nahrendorf, M1
Bae, HJ6
Kim, DE5
Sundaravadivel, P1
Christopher, R1
Ramanujam, N1
Chandra, SR1
Kim, BC3
Youn, YC1
Jeong, JH1
Han, HJ1
Kim, JH1
Lee, JH6
Park, KH1
Park, KW4
Kim, EJ1
Shim, Y1
Lee, JM2
Choi, YH1
Park, G1
Kim, S2
Park, HY1
Yoon, B1
Yoon, SJ1
Cho, SJ1
Park, KC1
Na, DL1
Park, SA1
Choi, SH1
Xu, J1
Xu, X1
Wang, H2
He, L2
Liu, Q3
Du, Y1
Wang, J5
Yang, Y2
Huang, Z1
Minhas, JS3
Chithiramohan, T1
Barnes, SC1
Clough, RH1
Kadicheeni, M1
Beishon, LC1
Robinson, T1
van der Steen, W1
van de Graaf, RA1
Chalos, V2
Lingsma, HF1
van Doormaal, PJ1
Coutinho, JM1
Emmer, BJ1
de Ridder, I1
van Zwam, W1
van der Worp, HB2
van der Schaaf, I1
Gons, RAR1
Yo, LSF1
Boiten, J1
van den Wijngaard, I1
Hofmeijer, J1
Martens, J1
Schonewille, W1
Vos, JA1
Tuladhar, AM1
de Laat, KF1
van Hasselt, B1
Remmers, M1
Vos, D1
Rozeman, A1
Elgersma, O1
Uyttenboogaart, M2
Bokkers, RPH1
van Tuijl, J1
Boukrab, I1
van den Berg, R1
Beenen, LFM1
Roosendaal, SD1
Postma, AA1
Krietemeijer, M1
Lycklama, G1
Meijer, FJA1
Hammer, S1
van der Hoorn, A1
Yoo, AJ1
Gerrits, D1
Truijman, MTB1
Zinkstok, S1
Koudstaal, PJ10
Manschot, S1
Kerkhoff, H1
Nieboer, D1
Berkhemer, O1
Wolff, L1
van der Sluijs, PM1
van Voorst, H1
Tolhuisen, M1
Roos, YBWEM1
Majoie, CBLM1
Staals, J2
van Oostenbrugge, RJ1
Jenniskens, SFM1
van Dijk, LC1
den Hertog, HM1
van Es, ACGM1
van der Lugt, A2
Dippel, DWJ1
Roozenbeek, B2
Ku, JC1
Taslimi, S1
Zuccato, J1
Pasarikovski, CR1
Nasr, N1
Chechik, O1
Chisci, E1
Bissacco, D1
Larrue, V2
Rabinovich, Y1
Michelagnoli, S1
Settembrini, PG1
Priola, SM1
Cusimano, MD1
Yang, VXD1
Macdonald, RL1
Bor, WL1
de Veer, AJW1
Olie, RH1
Rikken, SAOF1
Chan Pin Yin, DRPP1
Herrman, JPR1
Vrolix, M1
Meuwissen, M1
Vandendriessche, T1
van Mieghem, C1
Magro, M1
Bennaghmouch, N1
Hermanides, R1
Adriaenssens, T1
Dewilde, WJM1
Ten Berg, JM1
Shah, J1
Liu, S2
Yu, W1
Pan, Y7
Meng, X8
Chen, W4
Jing, J7
Lin, J8
Jiang, Y2
Johnston, SC11
Bath, PM20
Dong, Q4
Xu, AD1
Li, H10
Feler, J1
Chuck, C1
Anderson, M1
Poggi, J1
Sweeney, J1
Moldovan, K1
Jayaraman, MV1
McTaggart, R1
Torabi, R1
Zhang, K1
Liu, T1
Niu, X1
Clarke, A1
Reddin, C1
Murphy, R1
O'Donnell, MJ2
Ajabnoor, AM1
Zghebi, SS1
Parisi, R1
Ashcroft, DM1
Rutter, MK1
Doran, T1
Carr, MJ1
Mamas, MA2
Kontopantelis, E1
Zheng, F1
Stavrinou, P1
Hu, W1
Ates, O1
Yilmaz, I1
Karaarslan, N1
Ersoz, E1
Hacioglu Kasim, FB1
Dogan, M1
Ozbek, H1
Lim, ST2
Murphy, SJX2
Murphy, SM2
Coughlan, T3
O'Neill, D6
Tierney, S2
Egan, B2
Collins, DR2
McCarthy, AJ1
Lim, SY1
Smith, DR1
Cox, D3
McCabe, DJH2
Krishnan, K5
Law, ZK2
Robinson, TG5
Sprigg, N8
Mavilakandy, A2
England, TJ5
Eveson, D2
Mistri, A2
Dawson, J3
Appleton, JP5
Gao, Y1
Han, S1
Wang, C6
Wang, T2
Zhao, X8
Liu, L8
Amarenco, P5
Zhao, D1
Chen, X3
Wang, R1
Pang, H1
Duan, C1
Xiong, Y4
Gu, H1
Wang, S1
Yang, KX1
Hao, M1
Feng, X1
Medina-Rodríguez, M1
Moniche, F1
de Albóniga-Chindurza, A1
Ortega-Quintanilla, J1
Ainz-Gómez, L1
Pardo-Galiana, B1
Cabezas-Rodríguez, JA1
Aguilar-Pérez, M1
Zamora, A1
Delgado-Acosta, F1
Jiménez-Gómez, E1
Bravo Rey, I1
Oteros Fernández, R1
Freijo Guerrero, MDM1
González Díaz, E1
Escudero-Martínez, I1
Morales Caba, L1
Vielba-Gomez, I1
Mosteiro, S1
Castellanos Rodrigo, MDM1
Amaya Pascasio, L1
Hidalgo, C1
Fernandez Prudencio, L1
Ramirez Moreno, JM1
Díaz Pérez, J1
Sanz-Fernandez, G1
Baena-Palomino, P1
Gamero-García, MÁ1
Jiménez Jorge, S1
Rosso Fernández, C1
Montaner, J3
González García, A1
Zapata-Arriaza, E1
Clares de Andrade, JB1
Mohr, JP10
Lima, FO1
de Carvalho, JJF1
Maia Barros, LC1
Pontes-Neto, OM2
de Abreu, GQ1
Silva, GS1
Kim, JS2
Kang, Y1
Sohn, SH1
Hwang, HY1
Xu, S1
Zhang, W2
Xu, Z2
Wu, T2
Yuan, B2
Xu, A3
Xie, X4
Jin, A1
Suo, Y1
Yang, H1
Feng, Y1
Zhou, Y2
Li, X1
Liu, B1
Zhu, H2
Zhao, J1
Huang, X3
Li, Z4
Zhang, ZM1
Lin, ZH1
Zhu, GL1
Klail, T1
Sedova, P1
Vinklarek, JF1
Kovacova, I1
Bar, M1
Cihlar, F1
Cernik, D1
Kočí, L1
Jura, R1
Herzig, R1
Husty, J1
Kocher, M1
Kovar, M1
Nevšímalová, M1
Raupach, J1
Rocek, M1
Sanak, D1
Sevcik, P1
Skoloudik, D1
Sramek, M1
Vanicek, J1
Vaško, P1
Vaclavik, D1
Tomek, A1
Mikulik, R3
Zi, W2
Song, J1
Kong, W1
Huang, J3
Guo, C1
He, W2
Yu, Y1
Geng, W1
Tan, X1
Tian, Y2
Liu, Z1
Cao, M1
Cheng, D1
Li, B1
Wang, P1
Yu, Z2
Liang, H1
Yang, S2
Tang, M1
Tang, Y1
Wu, Y3
Yao, L1
Shi, Z1
He, P1
Zhao, H2
Luo, J1
Wan, Y1
Shi, Q1
Wang, M2
Huang, F1
Mu, J1
Zheng, J1
Xie, S2
Cai, T1
Peng, Y1
Xie, W1
Qiu, Z2
Liu, C1
Yue, C1
Li, L1
Yang, D4
Miao, J1
Yang, J3
Hu, J1
Nogueira, RG1
Wang, D4
Saver, JL9
Li, F3
Yang, Q1
Chen, C5
Ma, F1
Wen, X1
Liu, X5
Tang, Q1
Woodhouse, LJ4
Christensen, H5
Dineen, RA3
James, M3
Montgomery, AA2
Ranta, A3
Bykov, VV1
Bykova, AV1
Motov, VS1
Larchenko, VV1
Chernysheva, GA1
Smol'yakova, VI1
Aliev, OI1
Khazanov, VA1
Vengerovskii, AI1
Udut, VV1
Alhajj, L1
Ovenseri Airemwen, C1
Pozharani, LB1
Hankey, GJ11
Vidyanti, AN1
Chan, L1
Lin, CL1
Muo, CH1
Hsu, CY2
Chen, YC5
Wu, D2
Hu, CJ2
Majidi, S2
Luby, M1
Lynch, JK1
Hsia, AW1
Benson, RT1
Kalaria, CP1
Nadareishvili, Z2
Latour, LL1
Leigh, R1
Kinsella, JA2
Feeley, TM1
Walsh, RA1
Harbison, JA1
Madhavan, P1
O'Neill, SM1
Colgan, MP1
Moran, N1
Hamilton, G1
Meaney, JF1
Kim, SM1
Jung, JM3
Lee, JS9
Kwon, SU6
Kimpton, J1
Khong, T1
Park, JH3
Kim, YJ2
Wong, LKS2
Yu, S3
Hwang, YH2
Rha, JH3
Heo, SH4
Ahn, SH2
Seo, WK2
Kwon, JH3
Sohn, SI4
Navarro, JC2
Kim, HY2
Kim, EG2
Nam, HS1
Kang, DW4
Paciaroni, M1
Ince, B1
Hu, B1
Jeng, JS1
Kutluk, K1
Lou, M2
Parfenov, V1
Wong, KSL1
Zamani, B1
Paek, D1
Min Han, J1
Del Aguila, M1
Girotra, S1
Zhao, G1
Lin, F1
Wang, Z3
Shao, X1
Gong, Y1
Zhang, S1
Cui, Y1
Lei, H1
Cheng, Z1
Guo, D1
Zhang, Q3
Kumar, A1
Shariff, M1
Doshi, R1
Rosińska, J1
Maciejewska, J1
Narożny, R1
Kozubski, W1
Łukasik, M1
Martinez-Majander, N1
Ntaios, G4
Liu, YY1
Ylikotila, P1
Joensuu, H1
Saarinen, J1
Perera, KS2
Marti-Fabregas, J2
Chamorro, A5
Rudilosso, S2
Prats-Sanchez, L1
Mundl, H4
Themeles, E2
Tiainen, M1
Demchuk, A1
Kasner, SE5
Hart, RG18
Tatlisumak, T3
Hočevar, A1
Ješe, R1
Tomšič, M1
Rotar, Ž1
Pande, SD1
Win, MM1
Khine, AA1
Zaw, EM1
Manoharraj, N1
Lolong, L1
Tin, AS1
Shoji, S1
Sawano, M1
Sandhu, AT1
Heidenreich, PA1
Shiraishi, Y1
Ikemura, N1
Ueno, K1
Suzuki, M1
Numasawa, Y1
Fukuda, K1
Kohsaka, S1
Elshafei, MN1
Imam, Y1
Mohamed, MFH1
AlSaud, AE1
Ahmed, MS1
Obeidat, K1
Saeid, R1
Ali, M1
Abdallah, IM1
Parray, AS1
Danjuma, MI1
Yi, YY1
Shin, HJ1
Choi, SG1
Kang, JW1
Song, HJ1
Kim, SK2
Kim, DW1
Albay, CEQ1
Leyson, FGD1
Cheng, FC1
Shao, T1
Cheng, Y2
Jin, J2
Huang, L1
Luo, C1
Han, Z4
Ge, W1
Xu, Y2
Veltkamp, R2
Pearce, LA5
Korompoki, E1
Sharma, M3
Toni, D7
Ameriso, SF4
Lindgren, A3
Arauz, A3
Ozturk, S2
Muir, KW4
Perera, K1
Shuaib, A3
Shoamanesh, A3
Connolly, SJ6
Wu, B1
Shi, L1
A van de Graaf, R1
C G M van Es, A1
M den Hertog, H1
van Dijk, L1
F M Jenniskens, S1
J van Oostenbrugge, R1
H van Zwam, W1
B W E M Roos, Y1
B L M Majoie, C1
F Lingsma, H1
W J Dippel, D1
Lanthier, L1
Huard, G1
Plourde, ME1
Cauchon, M1
Chen, Y4
Li, J1
Ou, Z1
Liang, Z1
Deng, W1
Wu, Z2
Jiang, H1
Ouyang, F1
Xing, S1
Zeng, J2
Hamilton, F1
Arnold, D1
Henley, W1
Payne, RA1
Huang, K1
Cheng, CL2
Yang, YK1
Zhou, H1
Shan, B1
Fu, J1
Feng, Q1
Shen, R1
Jin, X1
Kaushik, A1
Deora, S1
Choudhary, R1
Kargiotis, O1
Tsivgoulis, G2
Hill, MD1
Wong, YS1
Tsai, CF1
Hsu, YH1
Ong, CT1
Fu, B1
Li, P1
Xu, D1
Hou, K1
Gou, X1
Lv, N1
Fang, W1
de Castro-Afonso, LH1
Nakiri, GS1
Abud, TG1
Monsignore, LM1
de Freitas, RK1
Abud, DG1
Choulerton, J1
Guha, N1
Squires, R1
Kim, SJ1
Kwon, OD1
Choi, HC1
Lee, EJ3
Cho, B1
Alušík, Š1
Paluch, Z1
Zitikyte, G1
Roy, DC1
Dhaliwal, S1
Lun, R1
Hutton, B1
Shorr, R1
Dowlatshahi, D1
Yaghi, S1
de Havenon, A1
Rostanski, S1
Kvernland, A1
Mac Grory, B1
Furie, KL4
Kim, AS3
Easton, JD9
Henninger, N1
Johnston, C1
Wang, A2
Olesen, KKW1
Heide-Jørgensen, U1
Thim, T1
Thomsen, RW1
Bøtker, HE1
Sørensen, HT2
Maeng, M1
El Otmani, H1
Berrada, M1
Abdulhakeem, Z1
Bellakhdar, S1
El Moutawakil, B2
Abdoh Rafai, M1
Sanderson, NC1
Parker, WAE1
Storey, RF1
Han, M1
Kuang, J1
Tu, J1
Starcevich, K1
Gao, P1
Peng, C1
Yin, S1
Chen, J2
Jia, W1
Yi, Y1
Krantz, MJ1
Debus, SE1
Hsia, J1
Patel, MR1
Nehler, MR1
Hess, CN1
Capell, WH1
Bracken, T1
Mátyás, L1
Krievins, DK1
Nault, P1
Stefanov, S1
Hiatt, WR1
Bauersachs, RM1
Christophe, BR1
Mehta, SH1
Garton, AL1
Sisti, J1
Connolly, ES2
Wa, D1
Zhu, P1
Long, Z1
Fiolaki, A1
Katsanos, AH1
Kyritsis, AP1
Papadaki, S1
Kosmidou, M1
Moschonas, IC1
Tselepis, AD2
Giannopoulos, S1
Cai, H1
Cai, B2
Sun, L2
Zhang, H1
Zhou, S1
Cao, L2
Guo, H1
Sun, W4
Yan, B1
Davis, SM1
Leon Guerrero, CR1
Gandhy, S1
Burger, KM1
Sigounas, D1
Rosafio, F1
Lelli, N1
Mimmi, S1
Vandelli, L1
Bigliardi, G1
Dell'Acqua, ML1
Picchetto, L1
Pentore, R1
Ferraro, D1
Trenti, T1
Nichelli, P1
Zini, A1
Rao, Z1
Zheng, H1
Wang, F1
Dong, K2
Cao, Y1
Milionis, H2
Papavasileiou, V1
Spengos, K2
Manios, E2
Elisaf, M1
Vemmos, K1
Larsen, SB1
Grove, EL2
Neergaard-Petersen, S1
Würtz, M2
Hvas, AM1
Kristensen, SD1
Han, YF1
Dai, QL1
Chen, XL1
Xiong, YY1
Yin, Q2
Xu, GL1
Zhu, WS1
Zhang, RL1
Ma, MM1
Liu, WH1
Liu, XF1
Zhang, N1
Zhou, L1
Choi, MH1
Lee, SE1
Shin, DH1
Hong, JM1
Chen, S1
Wei, D1
Vasudeva, K1
Chaurasia, P1
Singh, S1
Munshi, A3
Nagahama, Y1
Allan, L1
Nakagawa, D1
Zanaty, M1
Starke, RM1
Chalouhi, N2
Jabbour, P1
Brown, RD1
Derdeyn, CP2
Leira, EC2
Broderick, J2
Chimowitz, M2
Torner, JC1
Hasan, D1
Beridze, M2
Duley, L2
Flaherty, K2
Havard, D1
Heptinstall, S3
Markus, HS3
Pocock, SJ1
Randall, M1
Scutt, P2
Venables, GS2
Navi, BB1
Marshall, RS1
Bobrow, D1
Singer, S1
Stone, JB1
DeSancho, MT1
DeAngelis, LM1
Cappellari, M1
Turcato, G1
Forlivesi, S1
Zivelonghi, C1
Bovi, P1
Bonetti, B1
Antigüedad-Muñoz, J1
de la Riva, P1
Arenaza Choperena, G1
Muñoz Lopetegi, A1
Andrés Marín, N1
Fernández-Eulate, G1
Moreno Valladares, M1
Martínez Zabaleta, M1
Kumar, S1
de Lusignan, S1
McGovern, A1
Correa, A1
Hriskova, M1
Gatenby, P1
Jones, S1
Goldsmith, D1
Camm, AJ1
Labovitz, DL1
Dhamoon, MS1
Rahmani, MR1
Shamsizadeh, A1
Moghadam-Ahmadi, A1
Kaeidi, A1
Allahtavakoli, M1
Schmidt, M1
Horváth-Puhó, E1
Henderson, VW1
Christiansen, CF1
Izzy, S1
Rubin, DB1
Ahmed, FS1
Akbik, F1
Renault, S1
Sylvester, KW1
Vaitkevicius, H1
Smallwood, JA1
Givertz, MM1
Feske, SK1
Wang, WT1
Li, YY1
Lin, WC1
Chen, JY1
Lan, KM1
Sun, CK1
Hung, KC1
Liu, CY1
Chen, HC1
Rothnie, KJ1
Connell, O1
Müllerová, H1
Smeeth, L1
Pearce, N1
Douglas, I1
Quint, JK1
Li, W2
Dai, Z1
Liu, R1
Hao, Y1
Han, Y1
Xu, G2
Farrant, M2
Barsan, W3
Conwit, RA1
Elm, JJ2
Lindblad, AS2
Palesch, YY2
Bangdiwala, SI2
Swaminathan, B1
Lavados, P1
Davalos, A6
Shamalov, N1
Cunha, L3
Lang, W1
Czlonkowska, A3
Eckstein, J1
Gagliardi, RJ3
Bereczki, D3
Uchiyama, S10
Yoon, BW3
Brouns, R1
Endres, M3
Bornstein, N2
De Vries Basson, MM1
Pare, G1
Pater, C1
Kirsch, B1
Sheridan, P2
Peters, G2
Weitz, JI1
Peacock, WF1
Benavente, OR1
Joyner, C1
Yi, X6
Chai, Z2
Zhou, Q4
Huang, R1
Cho, KH5
Schmaier, AA1
Bhatt, DL7
Fyfe, I1
Kalantzi, KI1
Ntalas, IV1
Chantzichristos, VG1
Tsoumani, ME1
Adamopoulos, D1
Asimakopoulos, C1
Bourdakis, A1
Darmanis, P1
Dimitriadou, A1
Gkiokas, S1
Ipeirotis, K1
Kitikidou, K1
Klonaris, I1
Kostaki, A1
Logothetis, D1
Mainas, K1
Mais, T1
Maragiannis, A1
Martiadou, K1
Mavronasos, K1
Michelongonas, I1
Mitropoulos, D1
Papadimitriou, G1
Papadopoulos, A1
Papaioakeim, M1
Sofillas, K1
Stabola, S1
Stefanakis, E1
Stergiou, D1
Thoma, M1
Zenetos, A1
Zisekas, S1
Goudevenos, JA1
Panagiotakos, DB1
Giustino, G1
Redfors, B1
Kirtane, AJ1
Mehran, R1
Dangas, GD1
Witzenbichler, B1
Neumann, FJ1
Weisz, G1
Généreux, P1
Maehara, A1
McAndrew, T1
Farhan, S1
Rinaldi, MJ1
Metzger, DC1
Henry, TD1
Cox, DA1
Duffy, PL1
Mazzaferri, EL1
Brodie, BR1
Stuckey, TD1
Gurbel, P1
Ben-Yehuda, O1
Stone, GW1
Leys, D8
Moulin, S1
Khatri, P1
Kleindorfer, DO1
Devlin, T1
Sawyer, RN2
Starr, M1
Mejilla, J1
Chatterjee, A1
Jauch, EC1
Levine, SR2
Romano, JG3
Vagal, A1
Purdon, B1
Devenport, J1
Pavlov, A1
Yeatts, SD1
Wang, CW1
Su, LL1
Hua, QJ1
Fan, YN1
Xi, TT1
Liu, YX1
Ji, SB1
Chen, L1
Cao, S1
Barlas, RS1
Loke, YK1
Bettencourt-Silva, JH1
Ford, I2
Clark, AB1
Bowles, KM1
Metcalf, AK1
Potter, JF2
Myint, PK1
Liu, AF1
Zhou, J2
Wang, K2
Li, C2
Qiu, H1
Jiang, WJ1
Regenhardt, RW1
Biseko, MR1
Shayo, AF1
Mmbando, TN1
Grundy, SJ1
Saadi, A1
Wibecan, L1
Kharal, GA1
Parker, R1
Klein, JP1
Mateen, FJ1
Okeng'o, K1
Saber, H1
Kherallah, RY1
Hadied, MO1
Kazemlou, S1
Chamiraju, P1
Narayanan, S1
Dalugama, C1
Gawarammana, IB1
Sanchez-Lopez, J1
Fernandez-Travieso, JC1
Illnait-Ferrer, J1
Fernandez-Dorta, L1
Mendoza-Castano, S1
Mas-Ferreiro, R1
Mesa-Angarica, M1
Reyes-Suarez, P1
Jia, L1
Li, R1
Yin, X1
Luo, H1
Kheiri, B1
Osman, M1
Abdalla, A1
Haykal, T1
Swaid, B1
Ahmed, S2
Chahine, A1
Hassan, M1
Bachuwa, G1
Al Qasmi, M1
Ornello, R1
Carolei, A2
Darkwah Oppong, M1
Gembruch, O1
Pierscianek, D1
Köhrmann, M2
Kleinschnitz, C1
Deuschl, C1
Mönninghoff, C1
Kaier, K1
Forsting, M3
Sure, U1
Jabbarli, R1
Aguilar-Salinas, P1
Agnoletto, GJ1
Brasiliense, LBC1
Santos, R1
Granja, MF1
Gonsales, D1
Aghaebrahim, A1
Sauvageau, E1
Hanel, RA1
Hao, Q2
Tampi, M1
O'Donnell, M3
Foroutan, F1
Siemieniuk, RA1
Guyatt, G2
Prasad, K1
Siemieniuk, R1
Lytvyn, L1
Heen, AF1
Agoritsas, T1
Vandvik, PO1
Gorthi, SP1
Fisch, L1
Jusufovic, M1
Muller, J1
Booth, B1
Horton, E1
Fraiz, A1
Siemieniuk, J1
Fobuzi, AC1
Katragunta, N1
Rochwerg, B1
Boucher, AA2
Taylor, JM2
Luchtman-Jones, L1
Dube, M1
Dani, R1
Dubey, A1
Chouksey, D1
Lu, BC1
Shi, XJ1
Liang, L2
Dong, N1
Liu, ZZ1
Jing, Y1
Yue, X1
Rahman, H1
Khan, SU1
Nasir, F1
Hammad, T1
Meyer, MA1
Kaluski, E1
Kim, D1
Nah, HW2
Choi, JC4
Kim, WJ2
Shin, DI2
Hong, JH1
Gorelick, PB4
Laskowitz, DT1
Miao, Z1
Uchino, K1
Tillman, H1
Sur, NB1
Di Tullio, MR6
Gutierrez, CM1
Dong, C1
Koch, S2
Gardener, H1
García-Rivera, EJ1
Zevallos, JC1
Burgin, WS1
Rose, DZ2
Goldberger, JJ1
Sacco, RL13
Rundek, T1
Gurunathan, A1
Ricci, KW1
Vadivelu, S1
Quinn, CT1
Toyoda, K3
Yamaguchi, T3
Kimura, K4
Hoshino, H2
Sakai, N1
Okada, Y2
Tanaka, K1
Origasa, H2
Naritomi, H2
Houkin, K1
Yamaguchi, K1
Isobe, M1
Minematsu, K4
Chen, XP1
Wei, DC1
Chen, SQ1
He, WZ1
Veltkamp, RC1
Coutts, SB1
Harima, K1
Honda, S1
Mikami, K1
Kitajima, M1
Urushizaka, M1
Tomisawa, T1
Hagii, J1
Metoki, H1
Yasujima, M1
Osanai, T1
Patrono, C3
Baigent, C1
Podlasek, A1
Al Sultan, AA1
Assis, Z1
Kashani, N1
Goyal, M1
Almekhlafi, MA1
Dharmasaroja, PA1
Muengtaweepongsa, S1
Sae-Lim, S1
Jussen, D1
Horn, P1
Vajkoczy, P1
Yamashiro, K1
Tanaka, R1
Okuma, Y1
Ueno, Y1
Tanaka, Y2
Hattori, N1
Urabe, T1
Sorkin, GC1
Dumont, TM1
Wach, MM1
Eller, JL1
Mokin, M1
Natarajan, SK1
Baxter, MS1
Snyder, KV1
Levy, EI1
Hopkins, LN1
Siddiqui, AH1
Shepankevich, LA1
Vostrikova, EB1
Pilipenko, PI1
Beynon, C1
Sakowitz, OW1
Unterberg, AW1
D'Amelio, M1
Terruso, V1
Famoso, G1
Di Benedetto, N1
Realmuto, S1
Valentino, F1
Ragonese, P1
Savettieri, G1
Aridon, P1
Sambu, N1
Radhakrishnan, A1
Englyst, N1
Weir, N1
Curzen, N1
Homma, S6
Thompson, JL6
Sanford, AR3
Mann, DL4
Levin, B4
Pullicino, PM4
Freudenberger, RS4
Teerlink, JR4
Graham, S4
Massie, BM2
Labovitz, AJ4
Gabriel, AP2
Lip, GY10
Estol, CJ3
Lok, DJ4
Ponikowski, P4
Anker, SD4
Qian, M2
Haddad, H1
Diek, M1
Meyer, DM1
Compton, P1
Eastwood, JA1
Gylys, K1
Zivin, JA1
Sathishkumar, D1
George, R1
Irodi, A1
Thomas, M1
Jastrzębska, M1
Chełstowski, K1
Wódecka, A1
Siennicka, A1
Clark, J1
Nowacki, P1
Chabriat, H1
Maeder, P1
Gass, A1
Michel, P3
Bracoud, L1
Hennerici, M1
Lee, M3
Rao, NM2
Wu, YL2
Ovbiagele, B5
Själander, S1
Själander, A1
Svensson, PJ1
Friberg, L1
Castilla-Guerra, L2
Navas-Alcántara, MS2
Fernández-Moreno, MC1
Nakagawa, I1
Wada, T1
Park, HS1
Nishimura, F1
Yamada, S1
Nakagawa, H1
Kichikawa, K1
Nakase, H1
Ferreiro, JL1
Ueno, M1
Bauer, D1
Angiolillo, DJ1
Nosul, M1
Kolb, GF1
Lau, YC1
Qian, Y1
Bi, Q1
Arslan, Y1
Yoldaş, TK1
Zorlu, Y1
Nomani, F1
Kamal, AK4
Kwon, HM1
Lee, YS2
Fernandez-Moreno, Mdel C1
Jimenez-Gonzalo, F1
Alvarez-Sabín, J4
Quintana, M2
Santamarina, E1
Maisterra, O1
Chen, CY1
Lee, KT1
Lee, CT1
Lai, WT1
Huang, YB1
Ciccone, A2
Motto, C2
Abraha, I1
Cozzolino, F1
Santilli, I1
Loidi Pascual, L1
Valcayo Peñalba, A1
Yerani Ruiz de Azúa Ciria, A1
Yanguas Bayona, I1
Chi, W1
Sandercock, PA7
Counsell, C3
Tseng, MC1
Cecconi, E1
Davis, S1
Jones, EF1
Cohen, AA1
Heiss, WD2
Kaste, M5
Laouénan, C1
Young, D1
Macleod, M1
Donnan, GA3
Meng, H1
Xu, L2
Kong, D1
Chen, P1
Gong, X1
Bai, J1
Zou, F1
Yang, Z1
Eikelboom, JW7
Shestakovska, O5
Connolly, S2
Bai, W1
Duan, Z1
Cai, Q1
Liu, D2
Ma, M1
Ahmad, MA2
Najmi, AK2
Mujeeb, M2
Akhtar, M3
Davidai, G1
Cotton, D4
Gorelick, P3
Lipton, RB1
Sacco, R2
Diener, HC11
Berkowitz, AL1
Westover, MB1
Bianchi, MT1
Chou, SH1
Paraskevas, KI1
Veith, FJ1
Vanassche, T1
Lauw, MN1
Healey, JS1
Alings, M1
Avezum, A1
Díaz, R1
Hohnloser, SH1
Lewis, BS1
Joly, B1
Menard, AL1
Ozkul-Wermester, O1
Triquenot-Bagan, A1
Guegan-Massardier, E1
Borg, JY1
Le Cam-Duchez, V1
Rajani, AR1
Mahmoud, WE1
Murugesan, V1
BinBrek, AS1
Lee, HC1
Lee, JD2
Chang, KC1
Wu, CY1
Lee, TH3
Wang, HH1
Stanford, SN1
Sabra, A1
Lawrence, M1
Morris, RH1
Storton, S1
Wani, M1
Hawkins, K1
Williams, PR1
Evans, PA1
Chýlová, M1
Moťovská, Z1
Osmančík, P1
Procházka, B1
Kalvach, P1
Robson, K1
Dineen, R1
Pocock, S2
Agayeva, N2
Gungor, L1
Topcuoglu, MA2
Arsava, EM2
Choi, MJ1
Nam, TS2
Lee, SH3
Kim, MK2
Ye, S1
Buchsbaum, R2
Freitas-Silva, M1
Gonçalves, L1
Medeiros, R1
Nunes, JP1
Thompson, DD1
Murray, GD1
Candelise, L2
Whiteley, WN1
Liu, F1
Tantry, US1
Gurbel, PA1
Lee, JY2
Blann, AD1
Skjøth, F1
Rasmussen, LH1
Larsen, TB1
Lahham, S1
Nelson, D1
Su, Y1
Cheng, X1
Shams ara, A1
Sheibani, V1
Esmaeilpour, K1
Eslaminejad, T1
Nematollahi-Mahani, SN1
Choi, SM1
Tziomalos, K2
Giampatzis, V2
Bouziana, SD2
Spanou, M2
Kostaki, S2
Papadopoulou, M2
Dourliou, V1
Sofogianni, A1
Savopoulos, C2
Hatzitolios, AI2
Fabiaña, N1
Ramaswami, AP1
Ang, ES1
De Silva, DA1
Smith, ER1
Barinov, EF1
Mamedaliyeva, S1
Tverdokhleb, TA1
Christiansen, CB1
Pallisgaard, J1
Gerds, TA1
Olesen, JB1
Jørgensen, ME1
Numé, AK1
Carlson, N1
Kristensen, SL1
Gislason, G1
Torp-Pedersen, C2
Hilkens, NA1
Algra, A18
Greving, JP1
Sternberg, Z2
Chichelli, T2
Sternberg, D1
Sawyer, R1
Ching, M2
Janicke, D2
Ambrus, JL1
Yu, J2
Munschauer, F1
Ko, YC1
Yeo, MJ1
Ko, Y1
Angelopoulou, SM1
Tsopozidi, M1
Murphy, SJ1
Coughlan, CA1
Tobin, O1
Kinsella, J1
Lonergan, R1
Gutkin, M1
McCabe, DJ3
Jung, S2
Kim, C1
Jang, MU1
Davis, K1
Dietrich, E1
Ishizuka, N1
Shimada, K1
Teramoto, T1
Yamazaki, T1
Oikawa, S1
Sugawara, M1
Ando, K1
Murata, M1
Yokoyama, K1
Matsumoto, M3
Ikeda, Y3
Rothwell, PM2
Norrving, B1
Mehta, Z1
Bilora, F1
Adamo, A1
Pomerri, F1
Prandoni, P1
Liu, P1
Fu, C1
Domanski, MJ1
Dillinger, JG1
Saeed, A1
Spagnoli, V1
Sollier, CB1
Sideris, G1
Silberman, SM1
Voicu, S1
Drouet, L2
Henry, P1
Gallego-Fabrega, C1
Carrera, C1
Reny, JL1
Fontana, P1
Slowik, A1
Pera, J1
Pezzini, A2
Serrano-Heras, G1
Segura, T1
Bin Dukhyil, AA1
Muiño, E1
Cullell, N1
Krupinski, J2
Fernandez-Cadenas, I1
Su, TH1
Chan, YL1
Lin, LC1
Wen, YW1
Guo, X1
Yu, L1
Chen, M1
Peng, X1
Guo, R1
Chang, DI1
Kim, GM1
Park, KY1
Sohn, CH1
Deng, QQ1
Tang, J1
Markus, H1
Huang, YN1
Ratanakorn, D1
Wong, KS4
Fu, JH1
Nelson, S1
Cloonan, L1
Kanakis, AS1
Fitzpatrick, KM1
Shideler, KI1
Perilla, AS1
Rost, NS1
Peng, LL1
Zhao, YQ1
Zhou, ZY1
Zhao, M1
Chen, XM1
Chen, LY1
Cai, YF2
Li, JL1
Huang, M1
Ho, HH1
Mok, KH1
Owais, T1
Rouman, M1
Breuer, M1
Hüter, L1
Fuchs, J1
Lauer, B1
Kuntze, T1
Pasala, T1
Hoo, JS1
Lockhart, MK1
Waheed, R1
Sengodan, P1
Alexander, J1
Gandhi, S1
Darteyre, S1
Renaud, C1
Fluss, J1
Laporte, S1
Bertoletti, L1
Chabrier, S1
Song, H1
Hou, C1
Cao, Q1
Feng, W1
Ji, X1
Sanchez, J1
Illnait, J1
Mas, R2
Mendoza, S1
Fernandez, L1
Mesa, M1
Vega, H1
Fernandez, J1
Reyes, P1
Ruiz, D1
Chen, YT1
Chen, HT1
Chao, PW1
Kuo, SC1
Ou, SM1
Shih, CJ1
Kim, SW1
Choi, KJ1
Park, JY1
Yoon, SH2
Lee, JK1
Li, XG1
Ma, N1
Sun, SS1
Wang, YJ1
Miao, ZR1
Zhao, ZG1
Secemsky, EA1
Yeh, RW1
Kereiakes, DJ1
Cutlip, DE1
Cohen, DJ1
Steg, PG1
Cannon, CP1
Apruzzese, PK1
D'Agostino, RB1
Massaro, JM1
Mauri, L1
Belvís, R1
Pagonabarraga, J1
Santamaría, A1
Kulisevsky, J1
Li, ZG2
Yu, ZC1
Wang, DZ1
Ju, WP1
Zhan, X1
Wu, QZ2
Wu, XJ1
Cong, HM1
Man, HH1
Sztriha, LK2
Vécsei, L2
Albers, GW5
Teal, P3
Karepov, V2
Tolpina, G1
Kuliczkowski, W1
Serebruany, V2
Michaud, K1
Hallenbeck, JM1
Wolfe, F1
Ounpuu, S1
Lawton, WA1
Palesch, Y2
Martin, RH3
Bath, P2
Chan, BP1
Chen, ST1
Dahlöf, B1
De Keyser, J3
Estol, C2
Gu, V1
Hermansson, K2
Hilbrich, L1
Lu, C2
Machnig, T1
Pais, P1
Roberts, R2
Skvortsova, V1
Vandermaelen, C1
Voigt, T1
Weber, M1
Vande Griend, JP1
Saseen, JJ1
Suri, MF2
Hussein, HM1
Abdelmoula, MM1
Divani, AA1
Qureshi, AI4
Sare, GM1
Gray, LJ3
Moulin, T1
Woimant, F1
England, T1
Geeganage, C1
De Deyn, PP3
Ringelstein, EB4
Lemaitre, RN1
Rice, K1
Marciante, K1
Bis, JC1
Lumley, TS1
Wiggins, KL1
Smith, NL1
Heckbert, SR1
Psaty, BM1
Jeon, HW1
Kang, MJ1
Fu, FH1
Han, B1
Zhu, M2
Yu, X1
Zhang, LM1
Hanhart, J1
Koskas, P1
Obadia, M1
Le Mer, Y1
Sahel, JA1
Paques, M1
Minnerup, J1
Schäbitz, WR2
Berger, CT1
Wolbers, M1
Meyer, P1
Daikeler, T1
Hess, C1
Sousa, AS1
Xavier, SS1
Freitas, GR2
Hasslocher-Moreno, A1
Chourkani, N1
Sibai, M1
Moutaouakil, F1
Rafai, M1
Bourezgui, M1
Slassi, I1
van den Bergh, WM1
Rinkel, GJ1
Zytkiewicz, M1
Giełwanowska, L1
Wojtasińska, E1
Psuja, P1
Zawilska, K1
Park, MK1
Smith, PC1
Wanserski, G1
Neher, JO1
Björklund, L1
Wallander, MA1
Johansson, S1
Lesén, E1
Hegge, KA1
Faxon, DP1
Freedman, JE1
Pu, F1
Motohashi, K1
Kaneko, T1
Manome, N1
Irie, K1
Takata, J1
Egashira, N1
Oishi, R1
Okamoto, T1
Sei, Y1
Yokozawa, T1
Mishima, K1
Iwasaki, K1
Fujiwara, M1
Chang, YJ1
Ryu, SJ2
Chen, JR1
Hu, HH3
Yip, PK1
Chiu, TF1
Halkes, PH2
van Gijn, J6
Kappelle, LJ3
Georgiadis, D1
Arnold, M2
von Buedingen, HC1
Valko, P1
Sarikaya, H1
Rousson, V1
Mattle, HP2
Bousser, MG8
Baumgartner, RW2
Balucani, C1
Cordonnier, C1
Telman, G1
Kouperberg, E1
Sprecher, E1
Yarnitsky, D1
Biller, J3
Famakin, BM1
Chimowitz, MI3
Lynn, MJ3
Stern, BJ3
George, MG1
Tenney, J1
Johnson, LH1
Hermann, A1
Dzialowski, I1
Koch, R1
Gahn, G1
De Schryver, EL3
Beckman, JA1
Penalba, A1
García-Bonilla, L1
Po, HL2
Lin, YJ1
Hseuh, IH1
Slaviero, F1
Annes, RD1
Frighetto, L1
Schirmer, LM1
Vanzin, JR1
Fröhlich, AC1
Ferraz, J1
Azambuja, ND1
Bal Dit Sollier, C1
Crassard, I1
Simoneau, G1
Bergmann, JF1
Gomez, CR1
Ito, H1
Hashimoto, A1
Matsumoto, Y1
Yao, H1
Miyakoda, G1
Pinto, A1
Di Raimondo, D1
Tuttolomondo, A1
Di Sciacca, R1
Arnao, V1
La Placa, S1
Milio, G1
Miceli, S1
Licata, G1
Zinkstok, SM2
Vermeulen, M2
Stam, J2
de Haan, RJ2
Roos, YB2
Ha, SW1
Guo, JJ1
Xu, E2
Lin, QY1
Zeng, GL1
Xie, HF1
Meyer, D1
Lee, BH1
Park, JS2
Kwak, JJ1
Hwang, ES1
Choi, DH1
Kim, YH1
Pak, HN1
Diedler, J1
Ahmed, N2
Sykora, M1
Overgaard, K2
Luijckx, GJ2
Soinne, L1
Ford, GA2
Lees, KR3
Wahlgren, N2
Ringleb, P1
Torgano, G1
Zecca, B1
Monzani, V1
Maestroni, A1
Rossi, P1
Cazzaniga, M1
Manganaro, D1
Boiti, C1
Zilioli, E1
Borutti, G1
Falaschi, F1
Mandelli, C1
Laufs, U1
Hoppe, UC1
Rosenkranz, S1
Kirchhof, P1
Böhm, M1
Grond, M2
Hacke, W8
Meinertz, T1
Röther, J1
Dichgans, M2
Burke, JP1
Sander, S1
Shah, H1
Zarotsky, V1
Henk, H1
Pratap, R1
Pillai, KK1
Khanam, R1
Islam, F1
Ahmad, SJ1
Pan, SL1
Lien, IN4
Chen, TH1
Quinn, T1
Rafferty, M1
Higgins, P1
Ray, G1
Walters, MR1
Benbassat, J1
Baumal, R1
Herishanu, Y1
Menon, BK1
Frankel, MR2
Labresh, KA1
Ellrodt, G1
Hernandez, AF1
Fonarow, GC1
Schwamm, LH2
Smith, EE1
Inzitari, D1
Piccardi, B1
Sarti, C1
Lu, N1
Liu, G1
Lee, SP2
Suh, JW2
Lee, HY2
Kang, HJ2
Koo, BK2
Chae, IH2
Choi, DJ2
Rha, SW2
Bae, JW2
Cho, MC2
Kwon, TG2
Bae, JH2
Kim, HS2
Hansen, ML1
Sørensen, R1
Clausen, MT1
Fog-Petersen, ML1
Raunsø, J1
Gadsbøll, N1
Gislason, GH1
Folke, F1
Andersen, SS1
Schramm, TK1
Abildstrøm, SZ1
Poulsen, HE1
Køber, L1
Colli, A2
D'Amico, R2
Mestres, CA1
Pomar, JL1
Cámara, ML1
Ruyra, X1
Mulet, J1
Pan, J1
Xia, Q1
Luo, B1
Gizewski, ER2
Weber, R2
Bischoff, A1
Venker, C1
Stracke, P1
Berlit, P2
Diehl, RR1
Kurre, W1
Sorgenfrei, U1
Krämer, M1
Chapot, R1
Zhou, M1
Zhang, D1
Yang, M1
Zhou, D1
Shimokhina, NIu1
Petrova, MM1
Savchenko, AA1
Sakata, T1
Kario, K1
Bugnicourt, JM1
Roussel, B1
Garcia, PY1
Canaple, S2
Lamy, C2
Godefroy, O1
O'Carroll, R1
Whittaker, J1
Hamilton, B1
Johnston, M1
Sudlow, C2
Dennis, M1
Kautzky-Willer, A1
Kamyar, MR1
Gerhat, D1
Handisurya, A1
Stemer, G1
Hudson, S1
Luger, A1
Lemmens-Gruber, R1
Mas, JL3
Brennan, D1
Mak, KH1
Fox, KA1
Topol, EJ4
Fedorov, A1
Chibisova, Y1
Szymaszek, A1
Alexandrov, M1
Gall, C1
Sabel, BA1
Cho, YS1
Youn, TJ1
Naqvi, I1
Husain, MR1
Khealani, BA1
Sani, Y1
Pokov, I1
Schevchuck, A1
Fong, A1
Thevathasan, L1
Hanley, D1
Kao, YH1
Lin, SJ1
Lee, CH1
Lai, ML2
Khan, M1
Urano, Y1
Horie, Y1
Halawani, SH1
Williams, DJ1
Adefurin, A1
Webster, J1
Greaves, M1
Tate, J1
Bushnell, C1
Adelman, EE1
Lisabeth, L1
Brown, DL1
Lynch, DR1
Ueno, H1
Koyama, H1
Mima, Y1
Fukumoto, S1
Tanaka, S1
Shoji, T2
Emoto, M1
Nishizawa, Y1
Inaba, M1
Pujol Lereis, VA1
Ameriso, S1
Povedano, GP1
Feher, A1
Pusch, G1
Harang, G1
Gasztonyi, B1
Papp, E1
Werling, D1
Menyhart, M1
Komaromy, H1
Szapary, L2
Feher, G2
Oyama, N1
Yagita, Y1
Kawamura, M1
Sugiyama, Y1
Terasaki, Y1
Omura-Matsuoka, E1
Sasaki, T1
Kitagawa, K2
Mono, ML1
Geister, L1
Galimanis, A1
Praz, F1
Fischer, U1
Wolff, S1
Findling, O1
Windecker, S1
Wahl, A1
Meier, B1
Nedeltchev, K1
Duelsner, A1
Gatzke, N1
Glaser, J1
Hillmeister, P1
Li, M1
Lehmann, K1
Urban, D1
Meyborg, H1
Stawowy, P1
Busjahn, A1
Nagorka, S1
Persson, AB1
Buschmann, IR1
Georgiadis, AL1
Cordina, SM1
Vazquez, G1
Tariq, N1
Lakshminarayan, K1
Adams, HP5
Greenhalgh, J1
Bagust, A1
Boland, A1
Martin Saborido, C1
Oyee, J1
Blundell, M1
Dundar, Y1
Dickson, R1
Proudlove, C1
Fisher, M2
Nakamura, T1
Tsuruta, S1
Pelegrín, L1
Mesquida, M1
Rey, A2
Sánchez-Dalmau, B1
Frohman, L1
Bang, OY2
Wang, QS1
Chen, XY1
Han, JH1
Soo, Y1
Leung, TW2
Mok, V1
Vinisko, R1
Meves, SH1
Overbeck, U1
Endres, HG1
Krogias, C1
Neubauer, H1
Sharma, V2
Kaul, S2
Al-Hazzani, A2
Prabha, TS1
Rao, PP1
Dadheech, S1
Jyothy, A2
Fiorella, D1
Fujita, K1
Komatsu, Y1
Sato, N1
Higuchi, O1
Kujiraoka, Y1
Kamezaki, T1
Suzuki, K3
Matsumura, A1
Radovic, V1
Mehta, B1
Farooq, O1
Munschauer, FE1
Weimar, C1
Wanke, I1
Möller-Hartmann, C1
Blatchford, J1
Demchuk, AM1
Warach, S1
Diehl, A1
Acelajado, MC1
Oparil, S1
Del Zotto, E1
Ritelli, M1
Drera, B1
Gamba, M1
Giossi, A1
Volonghi, I1
Costa, P1
Barlati, S1
Gasparotti, R1
Padovani, A1
Colombi, M1
Geeganage, CM1
Dengler, R2
Bath, MW1
Wiesemann, S1
Passlick, B1
Johkura, K1
Yoshida, TN1
Kudo, Y1
Nakae, Y1
Momoo, T1
Kuroiwa, Y1
Nolte, CH1
Yaemsiri, S1
Sen, S1
Tinker, L1
Rosamond, W1
Wassertheil-Smoller, S1
He, K1
Mazya, M1
Egido, JA1
Agarwal, S1
Hachamovitch, R1
Menon, V1
Soo, YO1
Siu, DY1
Abrigo, J1
Ng, N1
Ahuja, AT1
Wong, LK1
Bazan, NG1
Eady, TN1
Khoutorova, L1
Atkins, KD1
Hong, S1
Lu, Y1
Zhang, C1
Jun, B1
Obenaus, A1
Fredman, G1
Winkler, JW1
Petasis, NA1
Serhan, CN1
Belayev, L1
Ammon, SE1
Mejia, V1
del Valle, ML1
Sheu, JS1
Liu, HC1
Yuan, RY2
Yu, JM1
Sheu, JJ1
Hung, CH1
Fischer-Betz, R1
Specker, C1
Brinks, R1
Schneider, M1
Chen, ZC1
Sun, JZ1
Shi, ZH1
Richard, S1
Toussaint-Hacquard, M1
Fay, R1
Lacour, JC1
Ducrocq, X1
Lecompte, T1
Futrell, N1
Alshatwi, AA1
Reyes-Iglesias, Y1
Yavagal, DR1
Arnarsdottir, L1
Hjalmarsson, C1
Bokemark, L1
Andersson, B1
Worthmann, H1
Schumacher, H1
Schwartz, A1
Eisert, WG1
Lichtinghagen, R1
Weissenborn, K1
Rossen, JD1
Wassef, SN1
Thomas, J1
Abel, TJ1
Jabbour, PM1
Kung, DK1
Hasan, DM1
Tobin, WO1
Collins, R2
Murphy, RP1
Bausili, M1
Abreu, S1
Unzueta, MC1
García Álvarez, M1
Crespí, J1
Moral, MV1
Simard, JM1
Geng, Z1
Silver, FL1
Sheth, KN1
Kimberly, WT1
Colucci, M1
Gerzanich, V1
Coppens, M1
Dorian, P1
Flaker, GC1
Kaatz, S1
Budaj, A1
Husted, S1
Vellimana, AK1
Kadkhodayan, Y1
Rich, KM1
Cross, DT1
Moran, CJ1
Zazulia, AR1
Chicoine, MR1
Dacey, RG1
Zipfel, GJ1
El-Mitwalli, A1
Azzam, H1
Abu-Hegazy, M1
Gomaa, M1
Wasel, Y1
Wadiwala, MF1
Martins, SC1
Pieri, A1
Moro, CH1
Jesus, PA1
Longo, A1
Evaristo, EF1
Carvalho, JJ1
Fernandes, JG1
Oliveira-Filho, J1
Griessenauer, CJ1
Fleming, JB1
Richards, BF1
Cava, LP1
Curé, JK1
Younan, DS1
Zhao, L3
Alexandrov, AV1
Barlinn, K1
Taylor, T1
Harrigan, MR1
Thomson, RM1
Anderson, DC2
Nilanont, Y1
Nidhinandana, S2
Suwanwela, NC1
Hanchaiphiboolkul, S1
Pimpak, T1
Tatsanavivat, P1
Saposnik, G1
Poungvarin, N2
Song, TJ1
Suh, SH1
Min, PK1
Kim, DJ1
Kim, BM1
Heo, JH1
Kim, YD1
Lee, KY3
Flaker, G1
Hart, R1
Lanas, F1
Xavier, D1
Cervera, A3
Castillo, J2
Aponte, JJ1
Planas, AM1
deVeber, G3
Chan, A1
Mehta, P1
Gabis, LV1
Yangala, R1
Lenn, NJ1
Bĕlohlávek, J1
Aschermann, M1
Musolino, R1
La Spina, P1
Granata, A1
Gallitto, G1
Leggiadro, N1
Carerj, S1
Manganaro, A1
Tripodi, F1
Epifanio, A1
Gangemi, S1
Di Perri, R1
Lorenzo Fernández, P1
Grau, AJ2
Reiners, S1
Lichy, C2
Buggle, F2
Ruf, A1
Kurth, T1
Kase, CS1
Berger, K2
Schaeffner, ES1
Buring, JE2
Gaziano, JM1
Jeong, MH1
Lee, KM1
Bae, HR2
Lim, YJ1
Cheon, SM1
Hennerici, MG1
Berge, E2
Sandercock, P5
Michiels, JJ1
Katsarou, E1
Attilakos, A1
Fessatou, S1
Tsapra, H1
Tzavara, V1
Dracou, C1
Derksen, RH1
de Groot, PG1
Schmülling, S1
Rudolf, J1
Strotmann-Tack, T1
Schneweis, S1
Sobesky, J1
Thiel, A1
Fan, YH1
Zhang, L1
Lam, WW1
Mok, VC1
Hylek, EM1
Go, AS1
Chang, Y1
Jensvold, NG1
Henault, LE1
Selby, JV1
Singer, DE1
Uddin, G1
Hussain, M1
Wang, CX1
Todd, KG1
Kaźmierski, MK1
Griffin, G1
Sarma, GR1
Roy, AK1
Qiu, LY1
Chen, CH1
Yamazaki, M2
Sulter, G1
Elting, JW1
Maurits, N1
Luyckx, GJ1
Ringleb, PA3
Hirsch, AT2
Berger, C2
Xia, F2
Schwab, S2
Grau, A1
Ariesen, MJ2
van Walraven, C2
Jo, WS1
Shin, HC1
Ho, JM1
Kim, JW1
Haerten, K1
Krabbe, C1
Raiber, M1
Boddy, AW1
Dukovic, DA1
Brandt, T1
Nesher, G1
Berkun, Y1
Mates, M1
Baras, M1
Nesher, R1
Rubinow, A1
Sonnenblick, M1
Sato, H1
Koretsune, Y1
Fukunami, M1
Kodama, K1
Yamada, Y1
Fujii, K1
Hori, M1
Schellinger, PD4
Jüttler, E2
Meyding-Lamadé, UK1
Schwark, C2
Negri, M1
Martignoni, A1
Baccheschi, J1
Santilli, G1
Marchesi, E1
Ferro, JM1
DiTullio, MR1
Sciacca, RR1
Ivanusa, M1
Ivanusa, Z1
Pongrácz, E2
Gherli, T1
Fragnito, C1
Nicolini, F1
Borrello, B1
Saccani, S1
Beghi, C1
Lewis, SC2
Warlow, CP1
Harrison, P1
Sidhu, PS1
Brown, MM1
Machin, SJ1
Rosenberg, R1
Bauer, K1
Rosner, B1
Sciacca, R1
Barzegar, S1
Thornell, B1
Costigan, T1
Kistler, JP2
Serebruany, VL2
Malinin, AI2
Sane, DC1
Jilma, B1
Takserman, A1
Atar, D1
Hennekens, CH4
Gage, BF1
Pearce, L1
Boode, BS1
Petersen, P2
Bachman, DS1
Lucivero, V1
Mezzapesa, DM1
Petruzzellis, M1
Carella, A1
Lamberti, P1
Federico, F1
Leonardi-Bee, J4
Guiraud-Chaumeil, B1
Sivenius, J3
Yatsu, F1
Dewey, ME1
Yao, CS1
Tang, CS1
Meng, XL1
Ren, B1
Huang, SC1
Sun, YH1
Bao, HQ1
Moussouttas, M2
Papamitsakis, N1
Eriksson, P1
Lanthier, S1
Armstrong, D1
Domi, T1
Fletcher, S1
Weaver, C1
May, J1
Fox, S1
Willmot, M1
Heptinstal, S1
Schwaninger, M2
Koistinaho, M2
Koistinaho, J2
Coma-Canella, I1
Velasco, A1
Castano, S1
Di Napoli, M1
Cappelli, R1
Ceccarelli, E1
Di Gianfilippo, G1
Donati, C1
Emsley, HC1
Forconi, S1
Hopkins, SJ1
Masotti, L1
Paciucci, A1
Papa, F1
Roncacci, S1
Sander, D1
Sander, K1
Smith, CJ1
Stefanini, A1
Weber, D1
McNaughton, H1
Barber, PA1
Gommans, J1
Nowitz, M1
Vemmos, KN1
Toumanidis, S1
Zakopoulos, N1
Moulopoulos, SD1
Busse, O1
Obach, V2
Reverter, JC1
Torres, F1
Ziegler, S1
Schillinger, M1
Funk, M1
Felber, K1
Exner, M1
Mlekusch, W1
Sabeti, S1
Amighi, J1
Minar, E1
Brunner, M1
Müller, M1
Mannhalter, C1
Tonarelli, SB1
Reid, J1
MacLeod, MJ1
Williams, D1
Park, SY1
Lee, WS1
Hong, KW1
Weisman, SM1
Káposzta, Z1
Espinoza, LR1
Maulaz, AB1
Bezerra, DC1
Bogousslavsky, J1
Norris, JW1
Feuring, M1
Schultz, A1
Losel, R1
Wehling, M1
Ziai, W1
Pokov, AN1
Alberts, MJ2
Hanley, DF1
Germanakis, I1
Sfyridaki, C1
Papadopoulou, E1
Raissaki, M1
Rammos, S1
Sarris, G1
Kalmanti, M1
Kamouchi, M1
Fujimoto, S1
Ibayashi, S1
Inoue, T1
Zee, RY1
Diehl, KA1
Ridker, PM2
Kawaguchi, S1
Ishizashi, H1
Yagi, H1
Iida, J1
Sakaki, T1
Fujimura, Y1
Gray, L1
Weaver, CS1
Howlett-Smith, H1
Hertzberg, VS1
Chaturvedi, S3
Benesch, CG1
Sila, CA2
Jovin, TG1
Cloft, HJ1
Pijak, MR1
Lago, A3
Tembl, JI1
Pareja, A1
Ponz, A1
Ferrer, JM1
Vallés, J3
Santos, MT3
Soman, T1
Rafay, MF1
Hune, S1
Allen, A1
MacGregor, D1
González-Correa, JA1
Arrebola, MM1
Cansino, AL1
Muñoz-Marín, J1
Guerrero, A1
Sánchez de la Cuesta, F1
De la Cruz, JP1
Kirmani, JF1
Safdar, A1
Sayed, MA1
Pande, RU1
Ferguson, R1
Hershey, LA2
Qazi, KJ1
Jonas, S1
Grieco, G1
Hoyos, L1
Espinoza, C1
Cantú, C1
Barinagarrementeria, F1
Román, G1
Aznar, J2
Sanchez, E2
Cosin, J2
Moscardó, A1
Piñón, M1
Broekman, MJ3
Marcus, AJ3
Ricci, S1
Lewis, S1
Debette, S1
Wallaschofski, H1
Lohmann, T1
Hild, E1
Kobsar, A1
Siegemund, A1
Spilcke-Liss, E1
Hentschel, B1
Stumpf, C1
Daniel, WG1
Garlichs, CD1
Eigenthaler, M1
Chairangsarit, P1
Sithinamsuwan, P1
Niyasom, S1
Udommongkol, C1
Suwantamee, J1
Flaherty, ML1
Kissela, B1
Broderick, JP3
Késmárky, G1
Koltai, K1
Horváth, B1
Tóth, K1
Onizuka, M1
Kazekawa, K1
Nagata, S1
Tsutsumi, M1
Aikawa, H1
Tomokiyo, M1
Iko, M1
Kodama, T1
Nii, K1
Matsubara, S1
Tanaka, A1
Karlikaya, G1
Varlbas, F1
Demirkaya, M1
Orken, C1
Tireli, H1
Lee, MS1
Smith, SD1
Galor, A1
Hoffman, GS1
Haberl, R1
Dalal, PM1
Mishra, NK1
Bhattacharjee, M1
Bhat, P1
Gwag, BJ1
Lee, YA1
Ko, SY1
Lee, MJ1
Im, DS1
Yun, BS1
Lim, HR1
Park, SM1
Byun, HY1
Son, SJ1
Kwon, HJ1
Cho, JY1
Won, SJ1
Kim, KW1
Ahn, YM1
Moon, HS1
Lee, HU1
Noh, JH1
Chung, JM1
Cho, SI1
Derendorf, H1
Whitehead, SN1
Bayona, NA1
Cheng, G1
Allen, GV1
Hachinski, VC1
Cechetto, DF1
Einhäupl, K1
Al-Bahrani, A1
Taha, S1
Shaath, H1
Bakhiet, M1
Chan, MT1
Choi, KC1
Wong, GK1
Poon, WS1
Chan, S1
Ros, S1
You, KY1
Nhem, S1
Salle, JY1
Dudognon, P1
Daviet, JC1
Kanorskiĭ, SG1
Shevelev, VI1
Zafiraki, VK1
Zingilevskiĭ, KB1
Ng, PW1
Tsoi, TH1
Li, HL1
Fong, WC1
Yeung, J1
Wong, CK1
Yip, KK1
Gao, H1
Wong, HB1
Laroche, ML1
Macian-Montoro, F1
Merle, L1
Vallat, JM1
Hohlfeld, T1
Weber, AA1
Junghans, U1
Schumacher, M1
Boucher, M1
Schrör, K1
Siebler, M1
Liu, CL1
Liao, SJ1
Zeng, JS1
Lin, JW1
Li, CX1
Xie, LC1
Shi, XG1
Huang, RX1
Briyal, S1
Gulati, A1
Gupta, YK1
Rajamani, K1
Okajima, K1
Abe, Y1
Salameh, MJ1
Jin, Z1
Boysen, G4
Freilinger, T1
Riedel, E1
Holtmannspötter, M1
Peters, N1
Poulsen, TS1
Husted, SE1
Sas, K1
Seres, E1
Boda, K1
Lenti, L1
Csifcsak, G1
Kovacs, N1
Seok, JI1
Joo, IS1
Yoon, JH1
Choi, YJ1
Lee, PH1
Huh, K1
Stauder, A1
Sommer, C1
Smout, J1
Cleanthis, M1
Stansby, G1
Fu, Y1
Guo, JW1
You, JS1
Wang, LX1
Liang, WX1
Huang, Y2
Huang, PX1
Schwammenthal, Y1
Tsabari, R1
Shenkman, B1
Schwartz, R1
Matetzky, S1
Lubetsky, A1
Orion, D1
Israeli-Korn, S1
Chapman, J1
Savion, N1
Varon, D1
Tanne, D1
Reaume, KT1
Regal, RE1
Dorsch, MP1
Adams, RJ1
Albers, G1
Benavente, O1
Furie, K1
Goldstein, LB3
Halperin, J1
Harbaugh, R1
Katzan, I1
Kelly-Hayes, M1
Kenton, EJ1
Marks, M1
Helgason, CM2
Grossi, E1
Pandey, D1
Valika, A1
Cursio, J1
Brace, LD2
Nielsen, AA1
Veien, KT1
Jørgensen, LG1
Buck, TC1
Brandslund, I1
Christensen, C1
Skliut, M1
Jamieson, DG1
Hong, Z1
Ding, M1
Gao, X1
Fan, D1
Wong, K1
Xiao, J1
Yao, C1
Omura, Y1
Agostoni, A1
Hinton, RC1
Harris, R1
Eschwege, E3
Haguenau, M3
Lefauconnier, JM3
Thibult, N2
Touboul, D3
Touboul, PJ3
Ordinas, A1
Sherman, DG1
Arai, H1
Miyakawa, T1
Ozaki, K1
Sakuragawa, N1
Gupta, MC1
Dhamija, JP1
Mathur, DS1
Sharma, BM1
Mizuno, Y1
Niijima, S1
Yoshida, M1
Adachi, S1
Haga, T1
Saudeau, D1
Autret, A2
Fukatsu, A1
Itoh, E1
Straub, PW1
Hansen, PE1
Hansen, JH1
Stenbjerg, S1
Marshall, M1
Todnem, K1
Vik-Mo, H1
Kusunoki, M2
Nagatsuka, K1
Isaka, Y1
Uyama, O2
Yoneda, S2
Abe, H2
Zabel-Langhennig, R1
Ruttmann, B1
Schiele, I1
Schäfer, W1
Aisch, W1
Byer, JA1
Cauchie, C1
Hamberg, M1
Svensson, J1
Blombäck, M2
Mettinger, KL2
Fujisawa, A1
Matsuyama, T1
Croveri, G1
Côté, R2
Battista, RN1
Abrahamowicz, M1
Langlois, Y1
Bourque, F1
Mackey, A1
Bonito, AJ2
Matchar, DB2
Duncan, PW2
DeFriese, GH1
Oddone, EZ1
Paul, JE1
Akin, DR1
Samsa, GP2
Casto, L1
Camerlingo, M1
Finazzi, G1
Censori, B1
Barbui, T1
Mamoli, A1
Juvela, S1
Korte, W1
Otremba, H1
Lutz, S1
Flury, R1
Schmid, L1
Weissert, M1
Gans, M1
Anderson, D1
Cole, DJ5
Drummond, JC5
Patel, PM2
Marcantonio, S1
Verry, M1
Panak, E1
Cazenave, JP1
Bolin, KM1
Hoff, JA1
Winkler, SR1
Mangat, A1
Tortorice, KL1
Schell, RM3
Tison, F1
Duché, B1
Loiseau, P1
Fagan, SC1
Kertland, HR1
Tietjen, GE1
Maruyama, S3
Handa, M1
Fukuyama, M1
Itagaki, I1
Verhoef, P1
Malinow, MR1
Kok, FJ1
Willett, WC1
Stampfer, MJ2
Solomon, DH1
Rosendaal, FR2
Ansell, J1
Recht, L1
Gaur, SP1
Garg, RK1
Kar, AM1
Srimal, RC1
Halperin, JL2
Rothlauf, EB1
Arruzazabala, ML1
Molina, V1
Carbajal, D1
Valdés, S1
Bornstein, NM2
Karepov, VG1
Aronovich, BD1
Gorbulev, AY1
Treves, TA1
Korczyn, AD2
Levy, DE2
Brott, TG1
Haley, EC1
Marler, JR1
Sheppard, GL1
Weisberg, LA1
Miller, VT1
Rothrock, JF1
Feinberg, WM1
Reynolds, L1
Bruno, A2
Malaterre, HR1
Daver, L1
Djiane, P1
Narayan, S1
Gaskill, M1
Dhawan, AP1
Khoury, J1
Barer, D1
Marini, C1
Motolese, M1
Rothwell, P1
Frey, JL1
Bloom, JM1
Roth, GJ1
Yamamoto, N1
Yokota, K1
Yamashita, A1
Oda, M1
Oláh, L1
Misz, M1
Fekete, I1
Bordánné, JE1
Takács, EI1
Díez-Tejedor, E1
Alonso de Leciñana, M1
Díaz-Marín, C1
Matías-Guiu, J3
Aguilar, M1
Bonaventura, I1
Martínez, I1
Quintana, S1
Bendixen, BH2
Violi, F1
Toplak, H1
Bahadori, B1
Wascher, TC1
Davie, AP1
Love, MP1
Herroelen, L1
De Klippel, N1
Cushman, M1
Tracy, RP1
Rosa, A1
Calvo, G1
Morros, R1
Stiegler, H1
Bittar, N1
Young, L1
Hattemer, CR1
Gandhi, AJ1
Kemp, SM1
Hall, EA1
Morton, DJ1
Yim, J1
Vlasses, PH1
Vennervàld, K1
Lee, TK6
Chan, KW1
Huang, ZS2
Ng, SK1
Lin, RT1
Chang, TW2
Yan, SH1
Deng, JC1
Liu, LH1
Lie, SK1
Sung, SM1
Ryglewicz, D1
Baranska-Gieruszczak, M1
Lechowicz, W1
Hier, DB1
Koudstaal, A1
Członkowska, A1
Szpak, GM1
Arlien-Søborg, P1
Hass, Y1
Orberk, E1
Killeen, I1
Osa, A1
Masuhr, F1
Busch, M1
Einhäupl, KM1
Codina, A2
Zarranz Imirizaldu, JJ1
Hamann, GF1
Noth, J1
Kosten, TR1
Gorter, JW1
Pellegrino, TR1
Ferguson, JJ1
Gonzalez, ER1
Kannel, WB1
Olin, JW1
Raps, EC1
Kronmal, RA1
Manolio, TA1
Talbert, RL1
Beauchamp, NJ1
Newman, A1
Fernández, PL1
McKay, LD1
Cross, LM1
Klötzsch, C1
Nahser, HC1
Henkes, H1
Kühne, D1
Büttner, Th1
Müller, Th1
Hellwig, K1
Meves, S1
Kuhn, W1
Aritzu, E1
Piana, A1
Saxena, R2
Wijnhoud, AD2
Man in 't Veld, AJ1
van den Meiracker, AH1
Boomsma, F1
Przybelski, RJ3
Lindley, RI2
He, J1
Whelton, PK1
Vu, B1
Klag, MJ1
Lee, IM1
Manson, JE1
Forbes, C1
Laakso, M1
Lowenthal, A1
Smets, P1
Riekkinen, P2
Hartmann, A1
Warlow, C3
Scott, G1
Scott, HM1
Bednar, MM3
Gross, CE3
Sanges, G1
Sampaolo, S1
Di Iorio, G1
Khayyam, N1
Thavendiranathan, P1
Carmichael, FJ1
Kus, B1
Jay, V1
Burnham, WM1
Akyuz, A1
Bolayir, E1
Dener, S1
Topalkara, K1
Topaktas, S1
Carton, H1
Stern, KN1
McBride, R1
Rothbart, RM1
Asinger, RW1
van Kooten, F1
Ciabattoni, G1
Grobbee, DE1
Kluft, C1
Gubitz, GJ1
Zusman, RM1
Chesebro, JH1
Comerota, A1
Hartmann, JR1
Massin, EK1
Raps, E1
Wolf, PA1
Van Damme, H1
Sakalihasan, N1
Limet, R1
Novak, L1
Shackford, SR1
Bourguignon, P1
Nichols, P1
Buckingham, S1
Osler, T1
Sartorelli, K1
Holm, J1
Hillarp, A1
Erhardt, L1
Berntorp, E1
Delanty, N1
Jolobe, OM1
Caro, JJ1
Migliaccio-Walle, K1
Kalra, L1
Perez, I1
Smithard, DG1
Sulch, D1
Hemphill, JC1
Abdelnoor, M1
Nakstad, PH1
Sandset, PM1
Mosso, M1
Chen, ZM1
Pan, HC1
Liu, LS1
Xie, JX1
Peto, R1
Sudlow, CL1
Dunbabin, DW1
Vila, N1
Revilla, M1
Ascaso, C1
Bergmann, SR1
El Ramahi, KM1
Al Rayes, HM1
Olson, J1
von Kummer R, R1
Müller, A1
Bluhmki, E1
Restrepo, L1
Fisch, G1
Farquhar, D1
Fredduzzi, S1
Mariucci, G1
Tantucci, M1
Del Soldato, P1
Ambrosini, MV1
Kumihashi, K1
Uchida, K1
Miyazaki, H1
Kobayashi, J1
Tsushima, T1
Machida, T1
Jackson, G1
Kalashnikova, LA1
Nasonov, EL1
Aleksandrova, EN1
Kosheleva, NM1
Reshetniak, TM1
Salozhin, KV1
De Cristóbal, J2
Moro, MA2
Leza, JC2
Camarero, J1
Colado, MI1
Lorenzo, P2
Lizasoain, I2
Howard, DB1
Russell, SR1
Ellenberger, C1
McConnell, JP1
Cheryk, LA1
Durocher, A1
Bang, NU1
Fleck, JD1
Williams, L1
Meschia, JF1
Sträter, R1
Kurnik, K1
Heller, C1
Schobess, R1
Luigs, P1
Nowak-Göttl, U1
Masson, C1
Arquizan, C1
Zuber, M1
Cabanes, L1
Derumeaux, G1
Coste, J1
Cárdenas, A1
Fernández-Tomé, P1
Lazar, RM1
Pettigrew, LC1
Jackson, CM1
Pullicino, P1
Powers, WJ1
Kettunen, MI1
Goldsteins, G1
Keinänen, R1
Salminen, A1
Ort, M1
Bures, J1
Kauppinen, RA1
Higgins, LS1
Gibson, JB1
Maxwell, RA1
Schweitzer, JB1
Fabian, TC1
Proctor, KG1
Hsi, DH1
Alaimo, DJ1
Pinsky, DJ1
Peschon, JJ1
Stocking, KL1
Fujita, T1
Ramasamy, R1
Kiss, S1
Choudhri, TF1
McTaggart, RA1
Liao, H1
Drosopoulos, JH1
Price, VL1
Maliszewski, CR1
Phillips, SJ1
Breddin, K1
Bogoiavlenskaia, NM1
Armitage, P1
Bradley, K1
Tel'pukhov, VI2
Bilenko, MV2
Khokhlov, AV1
Komarov, PG2
Maggioni, AP1
Franzosi, MG1
Santoro, E1
White, H1
Van de Werf, F1
Tognoni, G1
Tikhomirova, AI1
Morganov, AA1
Joseph, R3
Han, E2
Tsering, C1
Grunfeld, S2
Welch, KM2
Vrethem, M1
Ernerudh, J1
Lindström, F1
Olsson, JE1
Fogelholm, R2
Koop, H1
Leblhuber, F1
Költringer, P1
Reisecker, F1
Farrell, B1
Godwin, J1
Richards, S1
de Falco, FA1
Montariello, A1
Mastroroberto, G1
Visconti, OS1
Tchen, PH1
Chen, CJ1
Wu, SC1
Heye, N1
Campos, A1
Kannuki, S1
Cervós-Navarro, J1
Robertson, W1
Raymond, GL1
Crompton, JL1
Furlan, AJ1
Nayak, S1
Calandre, L2
Molina, JA1
Milandre, L1
Bonnefoi, B1
Aillaud, MF1
Sone, R1
Nagayama, T2
Shibagaki, Y1
Kobayashi, I2
Kusakabe, K1
Chrobocek, J1
Kuo, TL3
Liu, MC2
Slivka, A1
Lapinski, RH1
Adams, D1
Misselwitz, F1
Norden, C1
Heine, H1
Tsutsumi, Y1
Ketsa-Ard, K1
Caneschi, S2
Bonaventi, C2
Finzi, F2
Tito, P1
Bergh, PA1
Hollander, D1
Gregori, CA1
Breen, JL1
D'Andrea, G1
Oster, SB1
Lechner, H1
Schmidt, R1
Siemes, H1
Casaer, P1
Picó, M1
Monasterio, J1
Vilaseca, J1
Hsieh, BS1
Jaffe, DF1
Greenough, PG1
Yang, SL1
Gomara, S1
Ozaita, G1
Bermejo, F1
Ang, A1
Tans, JT1
Tulleken, CA1
Mehdorn, HM1
Long, JB1
Lynch, TG1
Karanfilian, RG1
Hobson, RW1
Ninet, J1
Bachet, P1
Pasquier, J1
Boss, AH1
Olseen, JS1
Rubin, JR1
Goldstone, J1

Clinical Trials (88)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]Phase 327,395 participants (Actual)Interventional2013-02-28Completed
A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease[NCT01932203]Phase 4255 participants (Actual)Interventional2013-07-17Active, not recruiting
INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE[NCT03871517]Phase 45,438 participants (Actual)Interventional2019-06-03Completed
A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and[NCT01013532]Phase 41,600 participants (Anticipated)Interventional2009-06-30Active, not recruiting
Low-dose Aspirin Therapy in Patients With Non-Cardioembolic Ischemic Stroke and Microbleeds[NCT04504864]Phase 4400 participants (Anticipated)Interventional2020-10-01Recruiting
Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial[NCT05553613]Phase 3900 participants (Actual)Interventional2022-10-01Completed
Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial[NCT06120725]Phase 3580 participants (Actual)Interventional2021-09-01Completed
Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS),[NCT02313909]Phase 37,213 participants (Actual)Interventional2014-12-23Terminated (stopped due to Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed)
An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke. Non-randomized Interventional Controlled Clinical Trial.[NCT04330872]Phase 442 participants (Actual)Interventional2019-08-26Completed
A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Tra[NCT03354429]Phase 311,016 participants (Actual)Interventional2018-01-22Completed
Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II[NCT04078737]Phase 36,412 participants (Actual)Interventional2019-09-23Completed
Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589]Phase 35,100 participants (Actual)Interventional2009-12-31Completed
The Effect of Cilostazol Compared to Aspirin on Endothelial Function Measured by Flow Mediated Dilatation in Acute Cerebral Ischemia Patients[NCT03116269]Phase 480 participants (Actual)Interventional2012-03-01Completed
Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion: A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial[NCT05902000]222 participants (Anticipated)Interventional2023-06-14Recruiting
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029]Phase 34,881 participants (Actual)Interventional2010-05-28Terminated (stopped due to The trial was halted by the DSMB.)
Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984]Phase 260 participants (Anticipated)Interventional2021-08-01Recruiting
Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911]Phase 2424 participants (Anticipated)Interventional2021-03-23Recruiting
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600]Phase 4400 participants (Anticipated)Interventional2023-12-31Not yet recruiting
Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862]350 participants (Anticipated)Interventional2023-04-24Recruiting
A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081]1,067 participants (Anticipated)Observational [Patient Registry]2021-02-03Recruiting
The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke[NCT05636748]120 participants (Anticipated)Observational2023-02-28Recruiting
Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497]Phase 41,220 participants (Actual)Interventional2015-09-30Completed
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794]8,575 participants (Actual)Observational2008-01-31Completed
A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)[NCT02072226]Phase 3313 participants (Actual)Interventional2014-05-31Terminated (stopped due to The study was terminated due to slow enrollment.)
Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889]Phase 3516 participants (Anticipated)Interventional2023-11-09Recruiting
Disparities in Stroke Outcomes and Care Delivery in Patients With Atrial Fibrillation: FLorida Puerto Rico Atrial Fibrillation Stroke Study (FLiPER-AF)[NCT03627806]104,308 participants (Actual)Observational [Patient Registry]2010-01-01Completed
Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370]Phase 41,884 participants (Actual)Interventional2013-12-13Completed
Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895]Phase 3204 participants (Anticipated)Interventional2021-04-01Not yet recruiting
Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy[NCT05553717]66 participants (Anticipated)Interventional2022-10-31Not yet recruiting
Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial[NCT00041938]Phase 32,305 participants (Actual)Interventional2002-10-31Completed
Transient Electrocardiogram Assessment in Stroke Evaluation[NCT03301662]100 participants (Anticipated)Observational2017-10-09Not yet recruiting
Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery[NCT00235248]Phase 3350 participants (Actual)Interventional2002-02-28Completed
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP[NCT00225849]Phase 410,000 participants Interventional2005-03-31Recruiting
A Prospective Multicenter Clinical Study of Aspirin for Prophylaxis in Patients With Hereditary or Acquired Thrombotic Thrombocytopenic Purpura[NCT05568147]Phase 2/Phase 3100 participants (Anticipated)Interventional2022-10-01Not yet recruiting
COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial[NCT00814268]Phase 4358 participants (Actual)Interventional2008-12-31Completed
Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875]63 participants (Actual)Observational2017-12-12Completed
The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance[NCT01925872]2,000 participants (Anticipated)Observational2013-05-31Enrolling by invitation
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938]Phase 425,682 participants (Actual)Interventional2009-10-31Completed
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062]Phase 420,332 participants (Actual)Interventional2003-08-31Completed
Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas[NCT05519046]60 participants (Anticipated)Interventional2022-05-06Recruiting
Implantation of CERENOVUS ENTERPRISE 2 Intracranial Stent in Patients With Severe Symptomatic Intracranial Atherosclerotic Stenosis: A Multicenter, Prospective and Single-Arm Study in China[NCT05316311]194 participants (Anticipated)Interventional2022-05-24Recruiting
The Predictive Value of Retinal Vascular Signs for Patients With Intracranial Artery Stenosis: A Prospective, Continuity Study, Cross-sectional Study[NCT05270746]1,000 participants (Anticipated)Observational2022-02-27Not yet recruiting
Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828]Phase 4960 participants (Actual)Interventional2006-11-30Completed
CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295]1,000 participants (Anticipated)Observational [Patient Registry]2018-05-01Recruiting
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794]Phase 4222 participants (Actual)Interventional2015-01-31Completed
Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574]84 participants (Actual)Observational2019-02-26Completed
Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298]Phase 4178 participants (Actual)Interventional2012-03-31Completed
Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995]Phase 4140 participants (Actual)Interventional2012-02-01Completed
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969]Phase 42,200 participants (Actual)Interventional2016-04-30Completed
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid[NCT00311402]Phase 31,295 participants (Actual)Interventional2006-04-30Completed
"PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314]142 participants (Actual)Interventional2019-11-20Completed
Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.[NCT01843361]159 participants (Actual)Observational2010-07-31Completed
Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction[NCT03318744]3,400 participants (Anticipated)Interventional2018-01-31Not yet recruiting
A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268]Phase 4107 participants (Actual)Interventional2015-04-30Completed
Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120]Phase 2200 participants (Anticipated)Interventional2021-03-02Not yet recruiting
A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851]Phase 45,000 participants (Anticipated)Interventional2016-06-30Recruiting
Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial[NCT00496769]Phase 36,421 participants (Actual)Interventional2007-08-31Completed
Aspirin Discontinuation After Left Atrial Appendage Occlusion in Atrial Fibrillation[NCT03821883]1,120 participants (Anticipated)Interventional2020-06-01Recruiting
English: Current Perspective of the Status of Anticoagulation in Clinical Practice in Primare Care. Spanish: Perspectiva Actual de la sitUación de la anticoaguLación en la práctica clínica de Atención Primaria.[NCT02273609]1,524 participants (Actual)Observational2014-02-28Completed
A Prospective Randomized Controlled Study of Additonal Left Atrial Appendage Electrical Isolation in Catheter Ablation Combined With Left Atrial Appendage Occlusion of Persistent Atrial Fibrillation[NCT04897204]120 participants (Anticipated)Interventional2021-06-01Not yet recruiting
Rehabilitation of Patients With Atrial Fibrillation[NCT03035539]58 participants (Actual)Interventional2012-05-31Completed
Patent Foramen Ovale in Cryptogenic Stroke Study[NCT00697151]Phase 4630 participants (Actual)Interventional1993-06-30Completed
Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial[NCT05907694]714 participants (Anticipated)Interventional2023-12-01Active, not recruiting
"Transcranial Doppler Assessment of Cerebral Embolization During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement: Comparison of High-dose Aspirin Versus Warfarin Plus Low-dose Aspirin"[NCT00465218]56 participants (Actual)Observational2007-03-31Completed
Observatory of Anticoagulation After Bioprosthetic Aortic Valve Replacement[NCT01293188]434 participants (Actual)Observational2011-01-31Completed
Multicenter Ambispective Study of Clinical Outcomes of the CoreValve™Evolut R™ 34mm System: All Comers Post-market Registry[NCT03621709]100 participants (Anticipated)Observational2017-08-01Active, not recruiting
Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212]2,931 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Focal Cerebral Arteriopathy Steroid Trial[NCT06040255]Phase 480 participants (Anticipated)Interventional2023-10-01Not yet recruiting
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis[NCT00929383]82 participants (Actual)Observational2009-02-28Completed
Effects of Task-oriented Progressive Resistance Strength Training and Balance Exercises in Functional Performance on Lower Limb in Individuals With Stroke[NCT04820660]18 participants (Actual)Interventional2019-03-01Completed
Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial[NCT00202020]Phase 3720 participants Interventional2004-05-31Completed
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261]Phase 41,001 participants (Actual)Interventional2003-04-30Completed
Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913]Phase 3300 participants (Anticipated)Interventional2016-01-31Recruiting
Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982]1,500 participants (Actual)Observational2012-10-31Completed
A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705]2,927 participants (Actual)Observational2019-09-20Completed
Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414]Phase 255 participants (Actual)Interventional2015-02-28Completed
Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028]100 participants (Anticipated)Observational2021-03-10Not yet recruiting
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312]228 participants (Actual)Interventional2012-01-31Completed
Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744]101 participants (Actual)Interventional2012-07-31Completed
[NCT00000500]Phase 30 participants Interventional1981-09-30Completed
Gender-Specific Effects of Physiologic GH Administration on Cardiovascular Risk Factors in Women With Growth Hormone Deficiency[NCT00136032]63 participants (Actual)Interventional2002-01-31Completed
A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311]Phase 470 participants (Actual)Interventional2006-10-31Completed
A Randomized Trial of Plaque Identifying Toothpaste on Reduction of Plaque and Inflammation[NCT02666508]61 participants (Actual)Interventional2015-09-01Completed
Correlation Between Oral Health and Systemic Inflammation (COHESION)[NCT03641989]112 participants (Actual)Interventional2018-09-17Completed
A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337]Phase 437 participants (Actual)Interventional2006-10-31Completed
A Phase III, Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of OCTAPLEX, a Four-factor Prothrombin Complex Concentrate (4F-PCC), Compared to the 4F-PCC Beriplex® P/N (Kcentra), for the Reversal of Vitamin K Antagonist (VKA) [NCT02740335]Phase 3208 participants (Actual)Interventional2017-06-08Completed
Acute Ischaemic STROKE: From LABoratory to(2) the Patient's BED. Retrospective Study of Blood Biomarkers and Neuroimaging as Predictors of Cerebral Edema, Extension of Ischemic Injury and Functional Outcome[NCT05725694]200 participants (Anticipated)Observational2015-10-01Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All-cause Mortality

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg313
Rivaroxaban 5mg + Aspirin Placebo366
Rivaroxaban Placebo + Aspirin 100mg378

All-cause Mortality in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg282

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg389
Rivaroxaban 5mg + Aspirin Placebo453
Rivaroxaban Placebo + Aspirin 100mg516

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg329
Rivaroxaban 5mg + Aspirin Placebo397
Rivaroxaban Placebo + Aspirin 100mg450

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg379
Rivaroxaban 5mg + Aspirin Placebo448
Rivaroxaban Placebo + Aspirin 100mg496

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg353

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg288
Rivaroxaban 5mg + Aspirin Placebo255
Rivaroxaban Placebo + Aspirin 100mg170

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg138

Incidence Rate of a Major Bleeding Event According to the International Society on Thrombosis and Haemostasis (ISTH) Criteria (Adjudicated)

Major bleeding event (as per ISTH), defined as bleeding event that met at least one of following: fatal bleeding; symptomatic bleeding in a critical area or organ (intraarticular, intramuscular with compartment syndrome, intraocular, intraspinal, pericardial, or retroperitoneal); symptomatic intracranial haemorrhage; clinically overt bleeding associated with a recent decrease in the hemoglobin level of greater than or equal to (>=) 2 grams per decilitre (g/dL) (20 grams per liter [g/L]; 1.24 millimoles per liter [mmol/L]) compared to the most recent hemoglobin value available before the event; clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. The results were based on classification of events that have been positively adjudicated as major bleeding events. Incidence rate estimated as number of subjects with incident events divided by cumulative at-risk time, where subject is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD1.82
Acetylsalicylic Acid 100 mg OD0.67

Incidence Rate of All-Cause Mortality

All-cause mortality includes all deaths of participants due to any cause. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD1.88
Acetylsalicylic Acid 100 mg OD1.50

Incidence Rate of Any of the Following: Cardiovascular Death, Recurrent Stroke, Systemic Embolism and Myocardial Infarction

Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. Cardiovascular death includes death due to hemorrhage and death with undetermined/unknown cause. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. The diagnosis of myocardial infarction requires the combination of: 1)evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and 2)supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD6.20
Acetylsalicylic Acid 100 mg OD5.85

Incidence Rate of Clinically Relevant Non-Major Bleeding Events

Non-major clinically relevant bleeding was defined as non-major overt bleeding but required medical attention (example: hospitalization, medical treatment for bleeding), and/or was associated with the study drug interruption of more than 14 days. The results were based on the outcome events at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD3.52
Acetylsalicylic Acid 100 mg OD2.32

Incidence Rate of Intracranial Hemorrhage

Intracranial hemorrhage included all bleeding events that occurred in intracerebral, sub arachnoidal as well as subdural or epidural sites. The below table displays results for all randomized participants and the outcomes at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD0.70
Acetylsalicylic Acid 100 mg OD0.35

Incidence Rate of Life-Threatening Bleeding Events

Life-threatening bleeding was defined as a subset of major bleeding that met at least one of the following criteria: 1) fatal bleeding; 2) symptomatic intracranial haemorrhage; 3) reduction in hemoglobin of at least 5 g/dl (50 g/l; 3.10 mmol/L); 4) transfusion of at least 4 units of packed red cells or whole blood; 5) associated with hypotension requiring the use of intravenous inotropic agents; 6) necessitated surgical intervention. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD1.02
Acetylsalicylic Acid 100 mg OD0.43

Incidence Rate of the Composite Efficacy Outcome (Adjudicated)

Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

Interventionevent/100 participant-years (Number)
Rivaroxaban 15 mg OD5.14
Acetylsalicylic Acid 100 mg OD4.78

Incidence Rate of the Following: Stroke, Ischemic Stroke, Disabling Stroke, Cardiovascular (CV) Death, Myocardial Infarction

"Disabling stroke is defined as stroke with modified Rankin score (mRS) greater than or equal to (>=) 4 as assessed by investigator. mRS spans 0-6, running from perfect health to death. A score of 0-3 indicates functional status ranging from no symptoms to moderate disability (defined in the mRS as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from moderately severe disability (unable to walk or to attend to own bodily needs without assistance)through to death. CV death includes death due to hemorrhage and death with undetermined/unknown cause. Diagnosis of myocardial infarction requires combination of: 1) evidence of myocardial necrosis either changes in cardiac biomarkers or post-mortem pathological findings); 2) supporting information derived from clinical presentation, electrocardiographic changes, or results of myocardial or coronary artery imaging." (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)

,
Interventionevent/100 participant-years (Number)
StrokeIschemic strokeDisabling strokeCV death(includes death due to hemorrhage)Myocardial infarction
Acetylsalicylic Acid 100 mg OD4.714.560.840.660.67
Rivaroxaban 15 mg OD5.114.711.200.990.49

Bleeding Event That Fulfils Serious Adverse Event Criteria and is Categorised as GUSTO Moderate/Severe

Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Moderate/Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention. GUSTO Moderate bleeding is a bleeding requiring transfusion of whole blood or packed red blood cells without haemodynamic compromise (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR36
PLACEBO11

Bleeding Event That Fulfils Serious Adverse Event Criteria and is Categorised as GUSTO Severe

Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR28
PLACEBO7

Composite of Subsequent Stroke or Death

Participants with subsequent stroke or death (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR303
PLACEBO362

ICH or Fatal Bleeding Event

Participants with ICH or fatal bleeding event (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR22
PLACEBO6

Ischaemic Stroke

Number of participants with ischaemic stroke (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR276
PLACEBO345

Number of Participants With Modified Rankin Scale (mRS) Score >1 at Visit 3

The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.0 - No symptoms,1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. (NCT03354429)
Timeframe: Visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR1282
PLACEBO1284

Premature Permanent Discontinuation of IP Due to Bleeding

Participants with premature permanent discontinuation of IP due to bleeding (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)

InterventionParticipants (Count of Participants)
TICAGRELOR152
PLACEBO32

Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage

Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel141
Placebo167

Composite of Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes

Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel121
Placebo160

Death From Any Cause

Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel18
Placebo12

Death From Ischemic Vascular Causes

Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel6
Placebo4

Hemorrhagic Stroke

Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel5
Placebo3

Ischemic or Hemorrhagic Stroke

Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel116
Placebo156

Ischemic Stroke

Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel112
Placebo155

Major Hemorrhage

Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel23
Placebo10

Major Hemorrhage Other Than Intracranial Hemorrhage

Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel17
Placebo7

Minor Hemorrhage

Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel40
Placebo13

Myocardial Infarction

Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel10
Placebo7

Other Symptomatic Intracranial Hemorrhage

Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo0

Symptomatic Intracerebral Hemorrhage

Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days

InterventionParticipants (Count of Participants)
Clopidogrel2
Placebo2

Overall Mortality

Reported here is the percentage of participants who died due to any cause during the study. (NCT02072226)
Timeframe: From baseline to Day 90

Interventionpercentage of participants (Number)
Alteplase + Aspirin Placebo0.6
Alteplase Placebo + Aspirin0

Percentage of Participants Who Died Due to Stroke and Neurological Disorders

Reported here is the percentage of participants who died due to stroke and neurological disorders. (NCT02072226)
Timeframe: From baseline to Day 90

Interventionpercentage of participants (Number)
Alteplase + Aspirin Placebo0
Alteplase Placebo + Aspirin0

Percentage of Participants With a Modified Rankin Scale (mRS) Score of 0 or 1 at Day 90

mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death prior to Day 90. Reported is the percentage of participants with scores of 0 or 1 on the mRS. (NCT02072226)
Timeframe: Day 90

Interventionpercentage of participants (Number)
Alteplase + Aspirin Placebo78.2
Alteplase Placebo + Aspirin81.5

Percentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02072226)
Timeframe: From baseline up to Day 90: Non-serious adverse events were collected through the Day 30 visit. Serious adverse events were collected through the end of study at Day 90.

Interventionpercentage of participants (Number)
Alteplase + Aspirin Placebo77.3
Alteplase Placebo + Aspirin68.0

Percentage of Participants With Serious Adverse Events

A serious adverse event (SAE) was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here. (NCT02072226)
Timeframe: From baseline to Day 90

Interventionpercentage of participants (Number)
Alteplase + Aspirin Placebo26.0
Alteplase Placebo + Aspirin13.1

Percentage of Participants With Symptomatic Intracranial Hemorrhage (ICH )

ICH was considered symptomatic if it was not seen on computed tomography (CT) or magnetic resonance imaging (MRI) scan at baseline and any neurologic decline was attributed to it by the local investigator. To detect intracranial hemorrhage, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration. (NCT02072226)
Timeframe: Within 36 hours after study drug administration on Day 1

Interventionpercentage of participants (Number)
Alteplase + Aspirin Placebo3.2
Alteplase Placebo + Aspirin0

Distribution of Participants Across the Ordinal mRS

mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death before Day 90. Reported are the percentages of participants for all scores on the mRS. (NCT02072226)
Timeframe: Day 90

,
Interventionpercentage of participants (Number)
mRS at Day 90 - 0mRS at Day 90 - 1mRS at Day 90 - 2mRS at Day 90 - 3mRS at Day 90 - 4mRS at Day 90 - 5 or 6 (death)
Alteplase + Aspirin Placebo44.933.311.52.65.12.6
Alteplase Placebo + Aspirin50.331.211.53.22.51.3

Percentage of Participants With Any ICH

To detect ICH, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration. (NCT02072226)
Timeframe: Within 36 hours after study drug administration on Day 1

,
Interventionpercentage of participants (Number)
Any ICH within 36 hours reported by siteAny ICH within 36 hours reported by central reader
Alteplase + Aspirin Placebo7.17.1
Alteplase Placebo + Aspirin2.63.3

Percentage of Participants With Global Favorable Recovery on mRS, NIHSS, BI, and GOS

Global favorable recovery is an integrated assessment of participants who meet the following: mRS Score 0-1, National Institutes of Health Stroke Scale (NIHSS) Score 0-1, Barthel Index [BI] greater than or equal to 95, and Glasgow Outcome Scale [GOS] equal to 1. mRS Score 0-1: 0= No symptoms at all, 1= No significant disability despite symptoms, able to carry out all usual duties and activities. NIHSS Score 0-1: 0= No stroke symptoms and 1= Minor stroke symptoms. BI is a 10 question index with a total score range of 0-100 with 100 being the best outcome. GOS =1: Good recovery. Reported here are the percentages of participants who achieved a favorable score on each of these scales. (NCT02072226)
Timeframe: Day 90

,
Interventionpercentage of participants (Number)
mRS 0 - 1 at Day 90NIHSS 0 - 1 at Day 90BI >= 95 at Day 90GOS = 1 at Day 90
Alteplase + Aspirin Placebo78.285.079.381.5
Alteplase Placebo + Aspirin81.581.788.785.6

Event Rate Per 100 Patient Years for Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death

The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years

Interventionevents per 100 patient-years (Number)
Aspirin7.93
Warfarin7.47

Event Rate Per 100 Patient Years of Death Component of Secondary Composite Outcome

Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of secondary composite outcome, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin4.41
Warfarin4.43

Event Rate Per 100 Patient Years of Heart Failure Hospitalization Component of Secondary Composite Outcome.

Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of heart failure hospitalization component of secondary composite outcome, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin5.67
Warfarin6.79

Event Rate Per 100 Patient Years of Intracerebral Hemorrhage Component of Secondary Composite Outcome

Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of secondary composite outcome, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin0.06
Warfarin0.11

Event Rate Per 100 Patient Years of Ischemic Stroke Component of Secondary Composite Outcome

Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of secondary composite outcome, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin1.14
Warfarin0.57

Event Rate Per 100 Patient Years of Myocardial Infarction Component of Secondary Composite Outcome

Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of myocardial infarction component of secondary composite outcome, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin0.87
Warfarin0.80

Event Rate Per 100 Patient-years for Composite Endpoint of Hospitalization for Heart Failure, Myocardial Infarction, Ischemic Stroke, Intracerebral Hemorrhage, or Death.

"The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.~Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25." (NCT00041938)
Timeframe: From randomization to the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years.

Interventionevents per 100 patient-years (Number)
Aspirin12.15
Warfarin12.70

Event Rate Per 100 Patient-years for Death

Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of primary composite outcome, up to 6 years

Interventionevents per 100 patient-years (Number)
Aspirin6.52
Warfarin6.63

Event Rate Per 100 Patient-years for Intracerebral Hemorrhage

Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of primary composite outcome, up to 6 years

Interventionrate per 100 patient years (Number)
Aspirin0.05
Warfarin0.12

Event Rate Per 100 Patient-years for Ischemic Stroke

Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years

Interventionrate per 100 patient years (Number)
Aspirin1.36
Warfarin0.72

Rate Per 100 Patient Years of Major Hemorrhage

Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until end of scheduled follow-up, up to 6 years

Interventionevents per 100 patient years (Number)
Aspirin0.87
Warfarin1.78

Rate Per 100 Patient-years of Minor Hemorrhage.

Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the end of scheduled follow-up, up to 6 years

Interventionevents per 100 patient-years (Number)
Aspirin7.34
Warfarin11.6

Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES1.70
Propensity-matched BMS2.61

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.69
DES 12-month DAPT1.45

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.40
DES 12-month DAPT1.35

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.03
BMS 12-month DAPT0.90

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.09
BMS 12-month DAPT1.05

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.74
DES 12-month DAPT1.88

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.53
DES 12-month DAPT1.57

MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES11.37
Propensity-matched BMS13.24

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.04
BMS 12-month DAPT4.69

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.68
BMS 12-month DAPT5.48

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT5.62
DES 12-month DAPT6.49

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT4.34
DES 12-month DAPT5.92

Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole1333
Clopidogrel1333

Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan1367
Placebo1463

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Aspirin + Extended Release Dipyridamole916
Clopidogrel898

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

InterventionParticipants (Number)
Telmisartan880
Placebo934

Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)

(NCT00153062)
Timeframe: Randomization to final patient contact

InterventionParticipants (Number)
Telmisartan125
Placebo151

Area Under Curve of Serial Cardiac Biomarkers

An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours

,,
InterventionHours*ng/ml (Median)
Troponin Icreatine kinase-MB isoenzyme
Control C1 (High Platelet Reactivity - no Tirofiban)38.092.7
Control C2 (Low Platelet Reactivity - no Tirofiban)121.4185.6
Group A (High Platelet Reactivity - Tirofiban)197.2252.5

Percentage of Participants With Periprocedural Myonecrosis

"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours

,,
InterventionParticipants (Count of Participants)
Troponin Icreatine kinase-MB isoenzyme
Control C1 (High Platelet Reactivity - no Tirofiban)1510
Control C2 (Low Platelet Reactivity - no Tirofiban)2625
Group A (High Platelet Reactivity - Tirofiban)1611

Number of Patients With Acute Coronary Syndrome (ACS)

ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule9
Acetylsalicylic Acid (ASA) 81 mg Tablet16

Number of Patients With Brain (Cerebral) Haemorrhage

All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule12
Acetylsalicylic Acid (ASA) 81 mg Tablet7

Number of Patients With Composite Endpoint of Stroke or Major Bleeding

This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage, subarachnoid haemorrhage and major bleeding. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule71
Acetylsalicylic Acid (ASA) 81 mg Tablet55

Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal)

All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule45
Acetylsalicylic Acid (ASA) 81 mg Tablet32

Number of Patients With Intracranial Haemorrhage

All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule13
Acetylsalicylic Acid (ASA) 81 mg Tablet13

Number of Patients With Ischemic Vascular Event Composite Endpoint

This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule57
Acetylsalicylic Acid (ASA) 81 mg Tablet51

Number of Patients With Other Vascular Events

This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule11
Acetylsalicylic Acid (ASA) 81 mg Tablet6

Number of Patients With Stroke

This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage and subarachnoid haemorrhage. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule57
Acetylsalicylic Acid (ASA) 81 mg Tablet39

Number of Patients With Subarachnoid Haemorrhage

All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule0
Acetylsalicylic Acid (ASA) 81 mg Tablet1

Number of Patients With Transient Ischemic Attack (TIA)

All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks

Interventionpatients (Number)
Aggrenox Capsule3
Acetylsalicylic Acid (ASA) 81 mg Tablet3

Event Rate for the Composite of Stroke of Any Type, Systemic Embolism, Myocardial Infarction, or Vascular Death During the Double-blind Treatment Period

Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)

InterventionPercentage of events per year (Number)
Apixaban, 2.5 or 5 mg Twice Daily4.21
Acetylsalicylic Acid, 81-324 mg Once Daily6.35

Event Rate of Stroke/Systemic Embolism During the Intended-treatment Period

Event rate=percent of participants with an event divided by the total participants in the arm. Intended-treatment period=date of randomization to the efficacy cutoff date, which was to be the date on which at least 226 unrefuted original primary efficacy events occurred (date revised to May 28, 2010 following cessation of study for superior efficacy.) (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)

InterventionPercentage of events (Number)
Apixaban, 2.5 or 5 mg Twice Daily1.62
Acetylsalicylic Acid, 81-324 mg Once Daily3.63

Rate of Unrefuted Bleeding From First Dose of Double-blind Study Drug to First Occurence of Unrefuted Bleeding During the Double-blind Treatment Period

Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Day 1 to first bleeding event up to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)

InterventionPercentage of events per year (Number)
Apixaban, 2.5 or 5 mg Twice Daily10.85
Acetylsalicylic Acid, 81-324 mg Once Daily8.32

Event Rate of All-cause Death; Net Clinical Benefit-Composite of Stroke, Systemic Embolism, Myocardial Infarction, Vascular Death, and Major Bleeding; and Vascular Death

Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)

,
InterventionPercentage of events per year (Number)
All-cause death (n=111, 140)Net clinical benefit (n=163, 220)Vascular death (n=84, 96)
Acetylsalicylic Acid, 81-324 mg Once Daily4.427.133.03
Apixaban, 2.5 or 5 mg Twice Daily3.515.232.65

Event Rates for Major Bleeding, Major or Clinically Relevant Nonmajor (CNRM) Bleeding, and All Bleeding in the Double-blind Period

Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to the earlier of a patient's discontinuation of double-blind study drug or the attainment of at least 226 primary efficacy events up to May 28, 2010

,
InterventionPercentage of events per year (Number)
Major bleedingMajor or CRNM bleedingAll bleeding
Acetylsalicylic Acid, 81-324 mg Once Daily0.923.248.32
Apixaban, 2.5 or 5 mg Twice Daily1.414.4610.85

Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality

BL=baseline, LLN=lower limit of normal, ULN=upper limit of normal. Hemoglobin (g/dL), low: BL>2 or value ≤8; hematocrit(%), low: <0.75*BL; erythrocytes (*10^6 cells/μL), low: <0.75*BL; platelet count (*10^9 cells/L),low: <100*10^9 cells/L; leukocytes (*10^3 cells/μL), low if <0.8*BL and BLULN or <0.75*LLN when BL is missing or LLN ≤BL≤ ULN, high if >1.2*BL and BL>ULN or >ULN when BL and BL1.25*ULN when BL is missing or LLN≤BL≤ULN; neutrophils (absolute), low: <1.0*10^3 cells/μL; eosinophils (absolute), high: >0.750*10^3 cells/μL; basophils (absolute), high: >0.4*10^3 cells/μL; monocytes (absolute), high: 2*10^3 cells/μL; lymphocytes (absolute), low if <0.75*10^3 cells/μL, high if >7.50*10^3 cells/μL; ALP (U/L), high: 2*ULN; AST (U/L), high: 3*ULN; AST (U/L), high: 3*ULN; bilirubin, total (mg/dL), high: >2*ULN; bilirubin, direct (mg/dL), high: 1.5*ULN; BUN (mg/dL), high:>2*ULN; creatinine (mg/dL), high: >1.5*ULN. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug

,
InterventionParticipants (Number)
Hemoglobin, low (n=1956, 1893)Hemoglobin, high (n=1956, 1893)Hematocrit, low (n=1728, 1687)Hematocrit, high (n=1728, 1687)Erythrocytes, low (n=1728, 1687)Erythrocytes, high (n=1728, 1687)Platelet count, low (n=2148, 2098)Platelet count, high (n=2148, 2098)Leukocytes, low (n=1738, 1698)Leukocytes, high (n=1738, 1698)Neutrophils (absolute), low (n=2170, 2138)Neutrophils (absolute), high (n=2170, 2138)Eosinophils (absolute), low (n=2170, 2138)Eosinophils (absolute), high (n=2170, 2138)Basophils (absolute), low (n=2170, 2138)Basophils (absolute), high (n=2170, 2138)Monocytes (absolute), low (n=2170, 2138)Monocytes (absolute), high (n=2170, 2138)Lymphocytes (absolute), low (n=2170, 2138)Lymphocytes (absolute), high (n=2170, 2138)Alkaline phosphatase (ALP), low (n=2781, 2758)ALP, high (n=2781, 2758)Aspartate phosphatase (AST), low (n=2779, 2753)AST, high (n=2779, 2753)Alanine aminotransferase (ALT), low (n=2779, 2753)ALT, high (n=2779, 2753)Bilirubin (total), low (n=2781, 2758)Bilirubin (total), high (n=2781, 2758)Bilirubin (direct), low (n=2773, 2750)Bilirubin (direct), high (n=2773, 2750)Blood urea nitrogen (BUN), low (n=2201, 2172)BUN, high (n=2201, 2172)Creatinine, low (n=2209, 2178)Creatinine, high (n=2209, 2178)
Acetylsalicylic Acid, 81-324 mg Once Daily12009012010014181006800026250270330310430248050071
Apixaban, 2.5 or 5 mg Twice Daily13101301207012142004800005240340280230300241042067

Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality (Continued)

LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Sodium, serum (mEq/L):low if <0.95*BL and BLULN or <0.95*LLN when BL missing or LLN ≤BL≤ULN, high if >1.05*BL and BL>ULN or >ULN and BL1.05*ULN when BL missing or LLN≤BL≤ULN; potassium(mEq/L):low if <0.90*BL and BLULN or <0.90*LLN if BL missing or LLN≤BL≤ULN, high if >1.10*BL and BL>ULN or>ULN and BL1.10*ULN when BL missing or LLN≤BL≤ULN; chloride(mEq/L):low if <0.90*BL and BLULN or <0.90*LLN if BL missing or LLN≤BL ≤ULN, high if >1.10*BL and BL>ULN or >ULN and BL1.10* ULN if BL missing or LLN≤BL≤ULN; calcium(mg/dL):low if <0.75*BL and BLULN or <0.80*LLN if BL missing or LLN≤BL≤ULN, high if >1.25*BL and BL>ULN or >ULN if BL1.20*ULN if BL missing or LLN≤BL≤ULN ; bicarbonate(mEq/L):low if <0.75*BL when BLULN or <0.75*LLN if BL missing or LLN≤BL≤ULN, high if >1.25*BL when BL>ULN or >ULN (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug

,
InterventionParticipants (Number)
Sodium (serum), low (n=1768, 1740)Sodium (serum), high (n=1768, 1740)Potassium (serum), low (n=1763, 1737)Potassium (serum), high (n=1763, 1737)Chloride (serum), low (n=1768, 1740)Chloride (serum), high (n=1768, 1740)Calcium (total), low (n=106, 109)Calcium (total), high (n=106, 109)Bicarbonate, low (n=1664, 1619)Bicarbonate, high (n=1664, 1619)
Acetylsalicylic Acid, 81-324 mg Once Daily62828310000
Apixaban, 2.5 or 5 mg Twice Daily21620000000

Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Abnormality (Continued)

ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Creatine kinase (U/L), high:>5*ULN; protein, total(g/L):low if <0.90*BL when BLULN or <0.90*LLN when BL is missing or LLN≤BL≤ULN, high if >1.10*BL if BL>ULN or >ULN when BL1.10*ULN if BL missing or LLN≤BL≤ULN.Protein,total(g/L): low if <0.90*BL if BLULN or <0.90*LLN if BL missing or LLN≤BL≤ULN, high if >1.10*BL if BL>ULN or >ULN if BL1.10*ULN if BL or LLN≤BL≤ULN; glucose, serum fasting (mg/dL): low if <0.8*BL if BLULN or <0.8*LLN when BL missing or LLN≤BL≤ULN, high if >2*BL when BL>ULN or >ULN when BL1.5*ULN if BL missing or LLN≤BL≤ULN; uric acid (mg/dL), high: >2*BL and BL>ULN or>1.5*ULN when BL missing or BL≤ULN; glucose, urine, high; protein, urine, high; blood, urine, high; leukocyte esterase, urine, high; RBC count, urine (Hpf), high; WBC count, urine (Hpf), high: ≥2 if BL=missing,=0 or =0.5 or if ≥3 if BL=1, or if ≥4 and BL≥2. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug

,
InterventionParticipants (Number)
Creatine kinase, low (n=2780, 2758)Creatine kinase, high (n=2780, 2758)Protein (total), low (n=103, 109)Protein (total), high (n=103, 109)Uric acid, low (n=386, 390)Uric acid, high (n=386, 390)Glucose (urine), low (n=2, 3)Glucose (urine), high (n=2, 3)Protein (urine), low (n=3, 5)Protein (urine), high (n=3, 5)Blood (urine), low (n=3, 5)Blood (urine), high (n=3, 5)Leukocyte esterase (urine), low (n=3,5)Leukocyte esterase (urine), high (n=3,5)Red blood cells (RBC) (urine), low (n=2,2)RBC (urine), high (n=2,2)White blood cells (urine), low (n=2,2)WBC (urine), high (n=2,2)
Acetylsalicylic Acid, 81-324 mg Once Daily0250000010100000000
Apixaban, 2.5 or 5 mg Twice Daily0130001000101000100

Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs), Bleeding AEs, Discontinuations Due to AEs, and Death as Outcome

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug

,
InterventionParticipants (Number)
AEsSAEsBleeding AEsDiscontinuations due to AEDeaths
Acetylsalicylic Acid, 81-324 mg Once Daily1925804259362115
Apixaban, 2.5 or 5 mg Twice Daily183365728126691

Cumulative Morbidity and Mortality Rate (Ischemic Event, Parenchymal Brain Hemorrhage, Subarachnoid or Intraventricular Hemorrhage or Death)

"Any stroke or neurological death at NCT00929383)
Timeframe: 30 days

Interventionparticipants (Number)
Patients Treated With a Wingspan Stent12

Cumulative Stroke Rate at 12 Months

The cumulative stroke rate at 12 months (any stroke or neurological death /= 31 days is 15.9% or 13 events per 82 patients (NCT00929383)
Timeframe: 12 months

Interventionparticipants (Number)
Patients Treated With a Wingspan Stent13

Rate of Recurrent Ischemic Stroke in the Target Territory

The rate of recurrent ischemic stroke from 31 days to 12 months post procedure was 1.3% or 1 event per 77 patients analyzed. (NCT00929383)
Timeframe: 12 Months

Interventionparticipants (Number)
Patients Treated With a Wingspan Stent1

Rate of Restenosis

"The rate of restenosis at 12 months was defined as the degree of residual stenosis greater than 50% as determined by the study sites using the WASID method. There was a 10.4% rate of restenosis >50% or 8 patients out of 77 analyzed. The differences in this analysis population N=77 vs. ITT N= 82 populations results from exclusion of N=4 patients with no stent implanted and N=1 patient who died prior to any follow up measures of restenosis.~The WASID method is a standardized protocol for measuring intracranial arterial stenosis.~[1-(Dstenosis/Dnormal)] x100=% stenosis (where D=vessel diameter)" (NCT00929383)
Timeframe: 12 Months

Interventionparticipants (Number)
Patients Treated With a Wingspan Stent8

Successful Wingspan™ Stent Implantation (Access to the Lesion With the Stent, Accurate Deployment of the Stent Across the Target Lesion)

The number of Wingspan Stents successfully deployed across the target lesion. (NCT00929383)
Timeframe: Peri-procedural

Interventionpatients w stent implanted (Number)
Patients Treated With a Wingspan Stent78

Percentage Leukocyte-Platelet Aggregate

Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days

Intervention%aggregation (Mean)
Placebo Baseline14.06
Placebo Follow up13.84
Aspirin Baseline11.18
Aspirin Randomization12.11
Clopidogrel Baseline13.06
Clopidogrel Randomization12.29

Percentage Monocyte-Platelet Aggregates

Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days

Intervention%aggregation (Mean)
Placebo Baseline15.53
Placebo Follow up15.43
Aspirin Baseline13.15
Aspirin Follow up14.96
Clopidogrel Baseline16.03
Clopidogrel Follow up14.85

Percentage Monocyte-Platelet Aggregates

Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days

Intervention%aggregation (Mean)
Placebo Baseline69.45
Placebo Follow up80.33
Aspirin Baseline82.04
Aspirin Randomization62.00
Clopidogrel Baseline78.86
Clopidogrel Randomization39.88

Percentage Platelet Aggregation in PRP After Stimulation With ADP 5μM for 5 Min

(NCT02559414)
Timeframe: Baseline, 14 Days

Intervention%aggregation (Mean)
Placebo Baseline69.45
Placebo Follow up80.33
Aspirin Baseline82.04
Aspirin Randomization62.00
Clopidogrel Baseline78.86
Clopidogrel Randomization39.88

Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min

The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days

Intervention%aggregation (Mean)
Placebo Baseline72.35
Placebo Follow up79.11
Aspirin Baseline72.79
Aspirin Randomization26.77
Clopidogrel Baseline71.07
Clopidogrel Randomization65.00

Number of Participants With Healed Peptic Ulcer

Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months

Interventionparticipants (Number)
Histamine-2 Receptor Antagonist Group106
Placebo Group101

Number of Participants With Ulcer Recurrence

Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month

Interventionparticipants (Number)
Proton Pump Inhibitor Group1
Histamine-2 Receptor Antagonist Group7

Change in Nitric Oxide Formation From Baseline to 3 Months

Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)

Interventionng/mL (Mean)
Arm 1 of 5 Randomized Treatment Arms27.6
Arm 2 of 5 Randomized Treatment Arms27.0
Arm 3 of 5 Randomized Treatment Arms31.4
Arm 4 of 5 Randomized Treatment Arms25.7
Arm 5 of 5 Randomized Treatment Arms28.3

Change in Hs-CRP Serum Level

"Measure description mg/L refers to the change in hs-CRP per mg/L from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline." (NCT02666508)
Timeframe: Baseline to 30 - 60 days post baseline

Interventionlog(mg/L) (Geometric Mean)
Plaque Identifying Toothpaste0.04
Non-plaque Identifying Toothpaste0.22

Change in Inflammation - PSS Analysis

"Measure description mg/L refers to the change in hs-CRP per mg/L from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline. -PSS analysis" (NCT02666508)
Timeframe: Baseline to 30-60 days post

Interventionlog(mg/L) (Geometric Mean)
Plaque Identifying Toothpaste-0.40
Non-plaque Identifying Toothpaste0.14

Change in Oral Plaque

"Measure description percentage refers to the change in plaque percentage from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline." (NCT02666508)
Timeframe: Baseline to 30 - 60 days post baseline

Interventionlog(percentage) (Geometric Mean)
Plaque Identifying Toothpaste-1.05
Non-plaque Identifying Toothpaste-0.03

Change in Oral Plaque - PSS Analysis

"Measure description percentage refers to the change in plaque percentage from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline for the Pre-Specified Subgroup (PSS)." (NCT02666508)
Timeframe: Baseline to 30-60 days post

Interventionlog(percentage) (Geometric Mean)
Plaque Identifying Toothpaste-1.05
Non-plaque Identifying Toothpaste-0.10

Change in Nitric Oxide Formation From Baseline to 3 Months.

Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)

Interventionng/mL (Mean)
1 of 5 Randomized Treatment Arms10.0
2 of 5 Randomized Treatment Arms11.2
3 of 5 Randomized Treatment Arms10.0
4 of 5 Randomized Treatment Arms11.0
5 of 5 Randomized Treatment Arms9.6

Coagulation Factor II Levels

"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor II~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion

Interventionmg/dL (Mean)
Octaplex49.5
Beriplex P/N (Kcentra)51.0

Coagulation Factor IX Levels

"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor II Factor IX~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion

Interventionm/dL (Mean)
Octaplex33.0
Beriplex P/N (Kcentra)31.5

Coagulation Factor VII Levels

"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor VII~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion

Interventionmg/dL (Mean)
Octaplex35.0
Beriplex P/N (Kcentra)23.0

Coagulation Factor X Levels

"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor X~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion

Interventionmg/dL (Mean)
Octaplex50.0
Beriplex P/N (Kcentra)63.0

Dichotomous Hemostasis Success

To demostrate clinical non-inferiority of treatment with Octaplex to treatment with Beriplex P/N (Kcentra) with respect to hemostatic success. Effective hemostatis includes Excellent and Good ratings, while Ineffective hemostasis includes Moderate, None and missing ratings from Global hemostatic efficacy observed by IEAB (NCT02740335)
Timeframe: At the end of surgery

,
InterventionParticipants (Count of Participants)
EffectiveIneffective
Beriplex P/N (Kcentra)976
Octaplex996

Hemostatic Efficacy Rating by IEAB

Hemostatic Efficacy rated by the Independent Endpoint Adjudication Committee based on a 1 to 4 point hemostatic efficacy scale, taking into account blood loss and transfusion requirements in the context of the surgery. Hemostatic efficacy was assessed based on objective criteria in the categories 'excellent', 'good', 'moderate', or 'none'. Ratings of 'excellent' and 'good' were considered as 'effective' hemostasis, while ratings of 'moderate' and 'none' were considered as 'ineffective' hemostasis. (NCT02740335)
Timeframe: At the end of the surgery

,
InterventionParticipants (Count of Participants)
Excellent - 4Good - 3Moderate - 2None - 1EffectiveIneffective
Beriplex P/N (Kcentra)504760976
Octaplex415860996

Measuring of International Normalized Ratio (INR) to ≤ 1.5

Number of patients with an international normalized ratio (INR) value of less or equal to 1.5 at 30 min (± 15 min) after the end of infusion. (NCT02740335)
Timeframe: 30 minutes after the end of infusion

,
InterventionParticipants (Count of Participants)
<=1.5> 1.5Missing
Beriplex P/N (Kcentra)74290
Octaplex82230

Reviews

144 reviews available for aspirin and Brain Ischemia

ArticleYear
Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis.
    Medicine, 2021, Dec-17, Volume: 100, Issue:50

    Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu

2021
Oral antiplatelet therapy for acute ischaemic stroke.
    The Cochrane database of systematic reviews, 2022, 01-14, Volume: 1

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Randomized Contro

2022
Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2022, Volume: 63, Issue:4

    Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy, Carotid; Hematoma; Hemorrhage; Hemorrhagi

2022
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
    Stroke and vascular neurology, 2022, Volume: 7, Issue:5

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient;

2022
Comparison of Aspirin and P2Y
    Current reviews in clinical and experimental pharmacology, 2023, Volume: 18, Issue:3

    Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Secon

2023
Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta-analysis.
    European journal of neurology, 2022, Volume: 29, Issue:9

    Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Str

2022
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
    Clinical medicine (London, England), 2022, Volume: 22, Issue:5

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient;

2022
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
    Clinical medicine (London, England), 2022, Volume: 22, Issue:5

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient;

2022
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
    Clinical medicine (London, England), 2022, Volume: 22, Issue:5

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient;

2022
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
    Clinical medicine (London, England), 2022, Volume: 22, Issue:5

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient;

2022
Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis.
    Current pharmaceutical design, 2023, Volume: 29, Issue:25

    Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Infarction; Drugs, Chinese Herbal; Humans; Stroke;

2023
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
    Stroke, 2019, Volume: 50, Issue:12

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He

2019
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc

2019
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc

2019
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc

2019
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc

2019
Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis.
    BMC neurology, 2020, Jun-03, Volume: 20, Issue:1

    Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient;

2020
The 2020 breakthroughs in early secondary prevention: dual antiplatelet therapy versus single antiplatelet therapy.
    Current opinion in neurology, 2021, 02-01, Volume: 34, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Early Medical Intervention; Hemorrh

2021
Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis.
    PloS one, 2021, Volume: 16, Issue:4

    Topics: Aspirin; Bayes Theorem; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet T

2021
Ticagrelor: clinical development and future potential.
    Reviews in cardiovascular medicine, 2021, Jun-30, Volume: 22, Issue:2

    Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Stroke; Ticagrelor

2021
Current and future perspectives on the treatment of cerebral ischemia.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:6

    Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Stroke; Thrombolytic Therapy; Tissue Plasminog

2017
Comparative efficacy and safety of antiplatelet agents in cerebral ischemic disease: A network meta-analysis.
    Journal of cellular biochemistry, 2019, Volume: 120, Issue:6

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Network Meta-Analysis; Odds Ratio; Platelet Aggregatio

2019
High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis.
    Journal of the neurological sciences, 2017, May-15, Volume: 376

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation

2017
Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance.
    CNS & neurological disorders drug targets, 2017, Volume: 16, Issue:9

    Topics: Animals; Aspirin; Brain Ischemia; Drug Resistance; Fibrinolytic Agents; Genome-Wide Association Stud

2017
Antiplatelet therapy and the risk of ischemic and hemorrhagic complications associated with Pipeline embolization of cerebral aneurysms: a systematic review and pooled analysis.
    Journal of neurointerventional surgery, 2019, Volume: 11, Issue:4

    Topics: Adult; Aged; Aspirin; Blood Vessel Prosthesis; Brain Ischemia; Cerebral Hemorrhage; Embolization, Th

2019
Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.
    Journal of thrombosis and thrombolysis, 2019, Volume: 47, Issue:2

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemor

2019
Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
    BMJ (Clinical research ed.), 2018, Dec-18, Volume: 363

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack

2018
Aspirin in childhood acute ischemic stroke: The evidence for treatment and efficacy testing.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:6

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Practice Guidelin

2019
Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack.
    Stroke, 2019, Volume: 50, Issue:4

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Human

2019
Role of aspirin in primary prevention of cardiovascular disease.
    Nature reviews. Cardiology, 2019, Volume: 16, Issue:11

    Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag

2019
Role of aspirin in primary prevention of cardiovascular disease.
    Nature reviews. Cardiology, 2019, Volume: 16, Issue:11

    Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag

2019
Role of aspirin in primary prevention of cardiovascular disease.
    Nature reviews. Cardiology, 2019, Volume: 16, Issue:11

    Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag

2019
Role of aspirin in primary prevention of cardiovascular disease.
    Nature reviews. Cardiology, 2019, Volume: 16, Issue:11

    Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag

2019
Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis.
    Journal of neurointerventional surgery, 2020, Volume: 12, Issue:2

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Prasugr

2020
[New form of a acetylsalicylic acid in the secondary prevention of ischemic stroke].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2013, Volume: 113, Issue:4

    Topics: Animals; Aspirin; Brain Ischemia; Humans; Secondary Prevention

2013
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
    Annals of internal medicine, 2013, Oct-01, Volume: 159, Issue:7

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human

2013
Systematic study of cilostazol on secondary stroke prevention: a meta-analysis.
    European journal of medical research, 2013, Dec-06, Volume: 18

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Disease Progression; Humans; Incidenc

2013
Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    The Cochrane database of systematic reviews, 2014, Mar-08, Issue:3

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Brain Ischemia; Humans; Immunoglobulin Fab Fragments; In

2014
Oral antiplatelet therapy for acute ischaemic stroke.
    The Cochrane database of systematic reviews, 2014, Mar-26, Issue:3

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlle

2014
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
    Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:1

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M

2015
Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:7

    Topics: Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Hemorr

2015
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:8

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggre

2015
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Thrombosis and haemostasis, 2015, Volume: 114, Issue:2

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug

2015
Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications.
    CNS neuroscience & therapeutics, 2015, Volume: 21, Issue:11

    Topics: Antiplatyhelmintic Agents; Aspirin; Brain Ischemia; Clopidogrel; Evidence-Based Medicine; Humans; St

2015
Structural causes of ischemic and hemorrhagic stroke in children: moyamoya and arteriovenous malformations.
    Current opinion in pediatrics, 2015, Volume: 27, Issue:6

    Topics: Adolescent; Aspirin; Brain Ischemia; Cerebral Angiography; Cerebral Revascularization; Child; Child,

2015
Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
    Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:1

    Topics: Algorithms; Anticoagulants; Aspirin; Brain Ischemia; Calibration; Cerebral Hemorrhage; Dipyridamole;

2016
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.
    Lancet (London, England), 2016, Jul-23, Volume: 388, Issue:10042

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Random

2016
Stroke: How good is aspirin for patients with acute brain ischaemia?
    Nature reviews. Neurology, 2016, Volume: 12, Issue:8

    Topics: Acute Disease; Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Randomized Controll

2016
Clopidogrel in secondary ischemic stroke prevention.
    Recent patents on cardiovascular drug discovery, 2008, Volume: 3, Issue:2

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Evidence-

2008
Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Pharmacotherapy, 2008, Volume: 28, Issue:10

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat

2008
Multifunctional actions of approved and candidate stroke drugs.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009, Volume: 6, Issue:1

    Topics: Albumins; Animals; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Cytidine Diphospha

2009
What's new in stroke? The top 10 studies of 2006-2008. Part I.
    Polskie Archiwum Medycyny Wewnetrznej, 2008, Volume: 118, Issue:11

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici

2008
FPIN's clinical inquiries. Aspirin in patients with acute ischemic stroke.
    American family physician, 2009, Feb-01, Volume: 79, Issue:3

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Education, Medical; Evidence-Based Medicine; Fibr

2009
Aspirin in cardiology--benefits and risks.
    International journal of clinical practice, 2009, Volume: 63, Issue:3

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female; Gastrointestinal Diseases; Humans

2009
Antiplatelet agents for prevention of recurrent ischemic stroke.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2009, Volume: 62, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practic

2009
Antiplatelet drugs for ischemic stroke prevention.
    Cerebrovascular diseases (Basel, Switzerland), 2009, Volume: 27 Suppl 1

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination;

2009
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Journal of the neurological sciences, 2009, Sep-15, Volume: 284, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic;

2009
Secondary stroke prevention with antithrombotic drugs.
    Current vascular pharmacology, 2010, Volume: 8, Issue:1

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Cyclooxygenase Inhibitors; Dipyridamole; Drug

2010
Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jul-01, Volume: 74 Suppl 1

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy,

2009
[Pharmacotherapy of stroke].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2009, Volume: 11, Issue:1

    Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Hungary; N

2009
Antiplatelet treatment in ischemic stroke treatment.
    Current topics in medicinal chemistry, 2009, Volume: 9, Issue:14

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine

2009
Antiplatelets and stroke outcomes: state of the science.
    Critical care nursing clinics of North America, 2009, Volume: 21, Issue:4

    Topics: Arachidonic Acid; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Clopidogrel; Dipy

2009
A critical review of aspirin in the secondary prevention of noncardioembolic ischaemic stroke.
    International journal of stroke : official journal of the International Stroke Society, 2010, Volume: 5, Issue:4

    Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Endarterectomy, Carotid; Fibrinolytic Agents; Hu

2010
[Actual review of diagnostics and endovascular therapy of intracranial arterial stenoses].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2011, Volume: 183, Issue:2

    Topics: Angiography, Digital Subtraction; Angioplasty; Aspirin; Brain Infarction; Brain Ischemia; Cerebral A

2011
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
    The Cochrane database of systematic reviews, 2011, Jan-19, Issue:1

    Topics: Asian People; Aspirin; Brain Ischemia; Cause of Death; Cilostazol; Gastrointestinal Hemorrhage; Huma

2011
Pregnancy and stroke risk in women.
    Women's health (London, England), 2011, Volume: 7, Issue:3

    Topics: Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Hypertension, Pregnancy-Induced; Plate

2011
Gender differences in the primary prevention of stroke with aspirin.
    Women's health (London, England), 2011, Volume: 7, Issue:3

    Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Female; Fibrinolytic Agents; Humans; Male; Meta-An

2011
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:31

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac

2011
Endovascular treatment of intracranial stenosis.
    World neurosurgery, 2011, Volume: 76, Issue:6 Suppl

    Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Arteries; Constriction, Path

2011
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
    Stroke, 2012, Volume: 43, Issue:4

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab

2012
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
    Archives of internal medicine, 2012, Apr-23, Volume: 172, Issue:8

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Brain Ischemia; Clopidogrel;

2012
How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials.
    Annals of the New York Academy of Sciences, 2012, Volume: 1268

    Topics: Acute Disease; Anticoagulants; Aspirin; Brain Damage, Chronic; Brain Ischemia; Cerebral Hemorrhage;

2012
Does inhibiting Sur1 complement rt-PA in cerebral ischemia?
    Annals of the New York Academy of Sciences, 2012, Volume: 1268

    Topics: Animals; Antioxidants; Aspirin; ATP-Binding Cassette Transporters; Brain Ischemia; Cells, Cultured;

2012
Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?
    Current pharmaceutical design, 2013, Volume: 19, Issue:21

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Life S

2013
Aspirin and clopidogrel for prevention of ischemic stroke.
    Current neurology and neuroscience reports, 2013, Volume: 13, Issue:2

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platel

2013
Aspirin in the prophylaxis of coronary artery disease.
    Current opinion in cardiology, 2002, Volume: 17, Issue:5

    Topics: Aspirin; Brain Ischemia; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Humans; Myocardi

2002
[Antithrombotic therapy for ischemic cerebrovascular accident].
    Archives des maladies du coeur et des vaisseaux, 2002, Volume: 95 Spec No 7

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Fibrinolytic Agents; Humans; Recurrenc

2002
Anticoagulants versus antiplatelet agents for acute ischemic stroke.
    Stroke, 2003, Volume: 34, Issue:6

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Heparin; Humans; Odds Ratio; Platelet Aggregation Inhibitor

2003
Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
    Pathologie-biologie, 2003, Volume: 51, Issue:3

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Erythromelalgia; Hemorrhagic Disorders; Humans; Myocardial

2003
[Stenosis of the carotid arteries].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2003, Volume: 56, Issue:5-6

    Topics: Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy; Humans; Recurrence;

2003
Are anticoagulants better than antiplatelet agents for treatment of acute ischemic stroke?
    American family physician, 2003, Oct-01, Volume: 68, Issue:7

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Evidence-Based Medicine; Humans; Plate

2003
Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care.
    Cerebrovascular diseases (Basel, Switzerland), 2004, Volume: 17 Suppl 3

    Topics: Aspirin; Brain Ischemia; Disease Management; Humans; Patient Care; Platelet Aggregation Inhibitors;

2004
Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials.
    Stroke, 2004, Volume: 35, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arterial Occlusive Diseases; Aspirin; Atrial Fibrillation;

2004
[Anti-platelet agents in neurological practice].
    Revue neurologique, 2004, Volume: 160, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Neurology; Platelet Aggregation Inhibitors

2004
Risk factors for cranial ischemic complications in giant cell arteritis.
    Medicine, 2004, Volume: 83, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Female; G

2004
[The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
    Fortschritte der Neurologie-Psychiatrie, 2004, Volume: 72, Issue:5

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Dose-Response Relation

2004
Atrial fibrillation and cardioembolic stroke.
    Minerva cardioangiologica, 2004, Volume: 52, Issue:2

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Comorbidity;

2004
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
    Circulation, 2004, Oct-19, Volume: 110, Issue:16

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studie

2004
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
    Stroke, 2005, Volume: 36, Issue:1

    Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Humans; Is

2005
Combination antiplatelet agents in ischemic cerebrovascular disease.
    The Mount Sinai journal of medicine, New York, 2005, Volume: 72, Issue:1

    Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Combinati

2005
Post-varicella arteriopathy of childhood: natural history of vascular stenosis.
    Neurology, 2005, Feb-22, Volume: 64, Issue:4

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiog

2005
Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:3

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Health Care Costs; Humans

2005
Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
    Neurology, 2005, Apr-12, Volume: 64, Issue:7

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Humans; Ischemic At

2005
Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation.
    Brain research. Brain research reviews, 2005, Volume: 48, Issue:2

    Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspirin; Brain Ischemia; Humans; Inflamm

2005
Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
    Stroke, 2005, Volume: 36, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Prote

2005
Management problems of spontaneous ICH.
    Hospital medicine (London, England : 1998), 2005, Volume: 66, Issue:4

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Hospitalization; Humans; Magnetic Reso

2005
Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.
    Stroke, 2005, Volume: 36, Issue:7

    Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur

2005
Risk of hemorrhagic stroke with aspirin use: an update.
    Stroke, 2005, Volume: 36, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Angiography; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain

2005
Antiplatelet therapy in ischemic stroke.
    Expert review of neurotherapeutics, 2005, Volume: 5, Issue:4

    Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Stroke; Thrombolytic Therapy

2005
Antiplatelet agents in secondary prevention of stroke: a perspective.
    Stroke, 2005, Volume: 36, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Brain Ischemia; Clinical Trials

2005
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
    Orvosi hetilap, 2005, Oct-09, Volume: 146, Issue:41

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel;

2005
[Options in the management of persistent foramen ovale after an ischemic stroke].
    Deutsche medizinische Wochenschrift (1946), 2006, Volume: 131 Suppl 5

    Topics: Aspirin; Brain Ischemia; Heart Septal Defects, Atrial; Humans; Ischemic Attack, Transient; Platelet

2006
Antithrombotic agents in cerebral ischaemia.
    The Journal of the Association of Physicians of India, 2006, Volume: 54

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Risk Assessment; Risk Factors;

2006
Therapy for early reperfusion after stroke.
    Nature clinical practice. Cardiovascular medicine, 2006, Volume: 3, Issue:12

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Diffusion Magnetic Resonance I

2006
Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA.
    BMJ (Clinical research ed.), 2007, Apr-28, Volume: 334, Issue:7599

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient

2007
Prevention of ischemic stroke: surgery.
    Current drug targets, 2007, Volume: 8, Issue:7

    Topics: Aspirin; Brain Ischemia; Carotid Artery, External; Carotid Artery, Internal; Carotid Stenosis; Coron

2007
Clinical practice. Acute ischemic stroke.
    The New England journal of medicine, 2007, Aug-09, Volume: 357, Issue:6

    Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Contraindications; Diag

2007
The PRoFESS trial: future impact on secondary stroke prevention.
    Expert review of neurotherapeutics, 2007, Volume: 7, Issue:9

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid

2007
Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient?
    Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 24 Suppl 1

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stro

2007
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    The Annals of pharmacotherapy, 2008, Volume: 42, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron

2008
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
    Current cardiology reports, 2008, Volume: 10, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemi

2008
Cardiovascular diseases in the elderly.
    The Medical clinics of North America, 1983, Volume: 67, Issue:2

    Topics: Aged; Aging; Amyloidosis; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Brain Ischemia; Car

1983
[Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
    Annales de medecine interne, 1983, Volume: 134, Issue:2

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Clofib

1983
[Current clinical results of antiplatelet medication].
    Sangre, 1984, Volume: 29, Issue:4-C

    Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; Dipyridamole; D

1984
Aspirin in asymptomatic carotid disease.
    Health reports, 1994, Volume: 6, Issue:1

    Topics: Aspirin; Brain Ischemia; Carotid Artery Diseases; Carotid Stenosis; Cerebrovascular Disorders; Human

1994
Antiplatelet therapy in the prevention of ischaemic stroke.
    Nouvelle revue francaise d'hematologie, 1994, Volume: 36, Issue:3

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Platele

1994
[Vascular hemi-parkinson disease].
    Revue neurologique, 1993, Volume: 149, Issue:10

    Topics: Aged; Aspirin; Benserazide; Brain Ischemia; Drug Therapy, Combination; Female; Functional Laterality

1993
Antithrombotic therapies for stroke prevention.
    Current opinion in neurology, 1994, Volume: 7, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Fibrinolyti

1994
Stroke prevention in atrial fibrillation.
    The Mount Sinai journal of medicine, New York, 1993, Volume: 60, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Humans; Ran

1993
Asymptomatic carotid stenosis: surgery's the answer, but that's not the question.
    Annals of neurology, 1996, Volume: 39, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia;

1996
Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?
    Stroke, 1996, Volume: 27, Issue:4

    Topics: Aspirin; Brain Ischemia; Cerebrovascular Circulation; Cerebrovascular Disorders; Coronary Circulatio

1996
[Antithrombotic treatment in acute ischemia stroke].
    Neurologia (Barcelona, Spain), 1995, Volume: 10 Suppl 2

    Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Heparin; Humans; Platelet Aggregation Inhibi

1995
Ticlopidine or clopidogrel as alternatives to aspirin in prevention of ischemic stroke.
    European neurology, 1996, Volume: 36, Issue:5

    Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; Humans; Platelet Aggregation Inhibi

1996
[Treatment protocol of cerebral vascular accident].
    Revista de neurologia, 1997, Volume: 25, Issue:137

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clinical Protocols; Endarterectomy; Human

1997
Brain attack. Acute therapeutic intervention. Antithrombotic and antiplatelet-aggregating drugs.
    Neurosurgery clinics of North America, 1997, Volume: 8, Issue:2

    Topics: Antibodies, Monoclonal; Aspirin; Brain Ischemia; Clinical Trials as Topic; Fibrinolytic Agents; Hepa

1997
Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin.
    Seminars in thrombosis and hemostasis, 1997, Volume: 23, Issue:4

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Diagnosis, Differential; Erythromelalgia; Headache; Humans;

1997
Low- versus high-dose aspirin in prevention of ischemic stroke.
    Clinical neuropharmacology, 1993, Volume: 16, Issue:6

    Topics: Animals; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Human

1993
[Antithrombotic therapy after cerebral ischemia].
    Fortschritte der Neurologie-Psychiatrie, 1997, Volume: 65, Issue:9

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy,

1997
[Anti-aggregation therapy for prevention of cerebral ischemic stroke: a risk benefit analysis].
    Medicina clinica, 1997, Dec-06, Volume: 109, Issue:20

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Risk; Ti

1997
[Acute cerebral infarct: physiopathology and modern therapeutic concepts].
    Der Radiologe, 1997, Volume: 37, Issue:11

    Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Infarction; Cerebrovascular Circula

1997
Pharmacotherapy of cerebral ischemia in cocaine dependence.
    Drug and alcohol dependence, 1998, Jan-01, Volume: 49, Issue:2

    Topics: Aspirin; Brain; Brain Ischemia; Cerebrovascular Circulation; Cocaine; Cocaine-Related Disorders; Cog

1998
[Secondary prevention following cerebral ischemia: is monotherapy with acetylsalicylic acid still first choice?].
    Nederlands tijdschrift voor geneeskunde, 1998, Feb-07, Volume: 142, Issue:6

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel

1998
Anticoagulants and antiplatelet agents in acute ischemic stroke.
    Virginia medical quarterly : VMQ, 1998,Spring, Volume: 125, Issue:2

    Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials a

1998
Antithrombotic and thrombolytic therapy for ischemic stroke.
    Chest, 1998, Volume: 114, Issue:5 Suppl

    Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Contraindications; Fibrinolytic Agents; Hepa

1998
Drug therapy for acute ischaemic stroke: risks versus benefits.
    Drug safety, 1998, Volume: 19, Issue:5

    Topics: Aspirin; Brain Ischemia; Heparin; Humans; Neuroprotective Agents; Risk Assessment; Thrombolytic Ther

1998
Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials.
    JAMA, 1998, Dec-09, Volume: 280, Issue:22

    Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation In

1998
[Effects of the results of randomized trials on the tactics of management of patients with acute stroke].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1999, Volume: 99, Issue:2

    Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Fibrinolytic Agen

1999
Antiplatelet therapy in acute cerebral ischemia.
    Stroke, 1999, Volume: 30, Issue:4

    Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhi

1999
Antithrombotic and thrombolytic therapy for ischemic stroke.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:2

    Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Platelet Aggregati

1999
Aspirin and heparin in acute ischaemic stroke in older patients.
    Drugs & aging, 1999, Volume: 15, Issue:1

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular D

1999
Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.
    Clinical cardiology, 1999, Volume: 22, Issue:9

    Topics: Algorithms; Arteriosclerosis; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Critic

1999
Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review.
    Acta chirurgica Belgica, 1999, Volume: 99, Issue:4

    Topics: Aged; Aneurysm; Angioplasty, Balloon; Aspirin; Blindness; Brain Ischemia; Carotid Artery Diseases; C

1999
[Prevention of cerebral ischemia: anti-platelet agents].
    Revue neurologique, 1999, Volume: 155, Issue:9

    Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Intracranial Embolism; Plate

1999
Ischemic stroke. Clinical strategies based on mechanisms and risk factors.
    Geriatrics, 2000, Volume: 55, Issue:3

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Brai

2000
[Transient ischemic attacks and prolonged reversible ischemic neurologic deficit. Diagnosis, differential diagnosis and treatment].
    Praxis, 2000, Mar-23, Volume: 89, Issue:13

    Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Diagnosis, Differential; Dipyridamole; Endarterectomy,

2000
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
    Stroke, 2000, Volume: 31, Issue:6

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha

2000
Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
    Stroke, 2000, Volume: 31, Issue:7

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib

2000
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
    Bibliotheca haematologica, 1977, Volume: 44

    Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial

1977
[The use of drugs that affect thrombocytes in cerebral ischemia].
    Duodecim; laaketieteellinen aikakauskirja, 1990, Volume: 106, Issue:11

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Female; Humans; Male; Ticlopidine

1990
[Value and limits of antiplatelet agents in cerebral ischemic pathology].
    Schweizer Archiv fur Neurologie und Psychiatrie (Zurich, Switzerland : 1985), 1988, Volume: 139, Issue:5

    Topics: Aspirin; Brain Ischemia; Humans; Intracranial Embolism and Thrombosis; Platelet Aggregation Inhibito

1988
[Platelet antiaggregants in cerebral ischemic pathology].
    La Revue du praticien, 1989, Nov-01, Volume: 39, Issue:25

    Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Platelet Aggregation Inhibit

1989
Asymptomatic carotid disease.
    Surgery, gynecology & obstetrics, 1985, Volume: 160, Issue:1

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor

1985
[The fate of patients with carotid stenosis. Comparative study, based on the literature, of their natural history and evolution under medical treatment or following endarterectomy].
    Journal des maladies vasculaires, 1985, Volume: 10 Suppl A

    Topics: Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; Carotid Artery Diseases; Combined Modalit

1985

Trials

194 trials available for aspirin and Brain Ischemia

ArticleYear
Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial.
    Stroke, 2022, Volume: 53, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Small Vessel Diseases; Cilostazol; Double

2022
Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial.
    Lancet (London, England), 2022, 03-12, Volume: 399, Issue:10329

    Topics: Adult; Aspirin; Brain Ischemia; Heparin; Humans; Magnetic Resonance Imaging; Stroke; Treatment Outco

2022
Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial.
    Stroke and vascular neurology, 2022, Volume: 7, Issue:5

    Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Strok

2022
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclero
    Stroke and vascular neurology, 2023, Volume: 8, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Atorvastatin; Brain Ischemia; Clopidogrel;

2023
Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol.
    European stroke journal, 2023, Volume: 8, Issue:1

    Topics: Aspirin; Brain Ischemia; Clinical Trials, Phase IV as Topic; Humans; Ischemic Stroke; Multicenter St

2023
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
    The Lancet. Neurology, 2023, Volume: 22, Issue:6

    Topics: Aspirin; Brain Ischemia; Double-Blind Method; Female; Humans; Ischemic Stroke; Male; Middle Aged; St

2023
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.
    The New England journal of medicine, 2023, Jun-01, Volume: 388, Issue:22

    Topics: Aspirin; Brain Ischemia; Cerebral Arterial Diseases; Fibrinolytic Agents; Humans; Intracranial Hemor

2023
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
    Scientific reports, 2023, 07-20, Volume: 13, Issue:1

    Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female

2023
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
    Stroke, 2020, Volume: 51, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M

2020
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
    Stroke, 2020, Volume: 51, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M

2020
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
    Stroke, 2020, Volume: 51, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M

2020
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
    Stroke, 2020, Volume: 51, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M

2020
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial.
    European journal of neurology, 2020, Volume: 27, Issue:5

    Topics: Aspirin; Brain Ischemia; Double-Blind Method; Factor Xa Inhibitors; Humans; Intracranial Embolism; I

2020
An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS).
    Medicine, 2020, Volume: 99, Issue:20

    Topics: Adolescent; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Female; Gastrointestinal Hemorrha

2020
A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2020, Volume: 78

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Therapy, Combin

2020
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial.
    JAMA neurology, 2020, 10-01, Volume: 77, Issue:10

    Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Hu

2020
Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both, or neither (MR CLEAN-MED). Rationale and study design.
    Trials, 2020, Jul-14, Volume: 21, Issue:1

    Topics: Adult; Aspirin; Brain Ischemia; Endovascular Procedures; Heparin; Humans; Ischemic Stroke; Multicent

2020
Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial.
    Stroke, 2021, Volume: 52, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dual Anti-Platelet

2021
Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial.
    Stroke and vascular neurology, 2021, Volume: 6, Issue:2

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibi

2021
Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial.
    Contemporary clinical trials, 2021, Volume: 108

    Topics: Aftercare; Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Ischemic Stroke

2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
    European heart journal, 2021, 10-14, Volume: 42, Issue:39

    Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral A

2021
Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE.
    Neurology, 2017, May-16, Volume: 88, Issue:20

    Topics: Aspirin; Brain Ischemia; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Fibrino

2017
Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique.
    BMC neurology, 2017, Aug-29, Volume: 17, Issue:1

    Topics: Adult; Aged; Arginine; Aspirin; Brain Ischemia; C-Reactive Protein; Cilostazol; Dilatation; Double-B

2017
Dual antiplatelet therapy in aneurysmal subarachnoid hemorrhage: association with reduced risk of clinical vasospasm and delayed cerebral ischemia.
    Journal of neurosurgery, 2018, Volume: 129, Issue:3

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Embolization, Therapeutic;

2018
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
    Lancet (London, England), 2018, 03-03, Volume: 391, Issue:10123

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb

2018
Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial.
    JAMA neurology, 2018, 03-01, Volume: 75, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Enoxaparin; Female; Fibrinolyti

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
    The New England journal of medicine, 2018, Jul-19, Volume: 379, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
    The New England journal of medicine, 2018, Jun-07, Volume: 378, Issue:23

    Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli

2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
    The New England journal of medicine, 2018, Jun-07, Volume: 378, Issue:23

    Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli

2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
    The New England journal of medicine, 2018, Jun-07, Volume: 378, Issue:23

    Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli

2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
    The New England journal of medicine, 2018, Jun-07, Volume: 378, Issue:23

    Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli

2018
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
    The Lancet. Neurology, 2018, Volume: 17, Issue:6

    Topics: Aged; Antioxidants; Asian People; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrh

2018
Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
    Current vascular pharmacology, 2019, Volume: 17, Issue:6

    Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Greece; H

2019
Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    JAMA, 2018, 07-10, Volume: 320, Issue:2

    Topics: Administration, Intravenous; Administration, Oral; Aged; Aspirin; Bayes Theorem; Brain Ischemia; Dou

2018
Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    Journal of neurology, 2018, Volume: 265, Issue:10

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fem

2018
Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients.
    Revista de neurologia, 2018, Nov-01, Volume: 67, Issue:9

    Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Drug Therapy, Combination; Fatty Alcohols; Femal

2018
Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time.
    European journal of neurology, 2019, Volume: 26, Issue:9

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle

2019
Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.
    JAMA neurology, 2019, 07-01, Volume: 76, Issue:7

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female;

2019
Disparities and Temporal Trends in the Use of Anticoagulation in Patients With Ischemic Stroke and Atrial Fibrillation.
    Stroke, 2019, Volume: 50, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Flori

2019
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
    The Lancet. Neurology, 2019, Volume: 18, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic;

2019
Combination therapy with beraprost sodium and aspirin for acute ischemic stroke: a single-center retrospective study.
    The Journal of international medical research, 2019, Volume: 47, Issue:7

    Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Epoprostenol; Female; Follow-Up Studies; H

2019
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2019, Volume: 28, Issue:8

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind Method; Factor Xa Inhibitors; Female; Hu

2019
Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial.
    Circulation. Heart failure, 2013, Sep-01, Volume: 6, Issue:5

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind

2013
Results of the PERFORM magnetic resonance imaging study.
    Journal of neurology, 2013, Volume: 260, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Brain; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Magnet

2013
Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events).
    Journal of the American College of Cardiology, 2014, Mar-04, Volume: 63, Issue:8

    Topics: Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Female; Humans; Male; Risk Factors; Single-Bl

2014
[Acetylsalicylic acid non-responders after ischemic insult in geriatric patients].
    Zeitschrift fur Gerontologie und Geriatrie, 2014, Volume: 47, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibit

2014
Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke.
    Stroke, 2014, Volume: 45, Issue:3

    Topics: Aged; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Protein; Cilostazol; Disease Progression; Doub

2014
Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
    Cerebrovascular diseases (Basel, Switzerland), 2014, Volume: 37, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence;

2014
Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:6

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Enoxaparin; Female; Humans; Male;

2014
Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques.
    Stroke, 2014, Volume: 45, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Brain Ischemia;

2014
Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
    Stroke, 2014, Volume: 45, Issue:7

    Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; D

2014
Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin.
    Gene, 2014, Aug-10, Volume: 546, Issue:2

    Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cohort Studies; Cyclooxygenase 1; Female; Gene Frequency; Ge

2014
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.
    European heart journal, 2015, Feb-01, Volume: 36, Issue:5

    Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Embolism; Female; Fibrinoly

2015
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study.
    BMJ open, 2014, Dec-02, Volume: 4, Issue:12

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Stud

2014
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi

2015
Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:3

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Double-Blind Method; Female; Humans; Internation

2015
Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Drug Resistan

2015
Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.
    Circulation. Heart failure, 2015, Volume: 8, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Chi-Square Distribution; Double-

2015
Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:7

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Double-Blind Method; Female;

2015
Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.
    Stroke, 2016, Volume: 47, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Comorbidity; Diabetes Mellitus; Dyslipidemias; Fem

2016
Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone.
    Stroke, 2016, Volume: 47, Issue:9

    Topics: Aged; Aspirin; Atherosclerosis; Brain; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therap

2016
The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial.
    Journal of the neurological sciences, 2016, Aug-15, Volume: 367

    Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Arterial Diseases; Clopidogrel; Drug Therapy, Co

2016
Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA.
    Neurology, 2016, Oct-11, Volume: 87, Issue:15

    Topics: Aged; Aspirin; Blood Glucose; Brain Ischemia; Clopidogrel; Diabetes Complications; Double-Blind Meth

2016
Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
    International journal of stroke : official journal of the International Stroke Society, 2017, Volume: 12, Issue:5

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans;

2017
[Long-term effect of policosanol on the functional recovery of non-cardioembolic ischemic stroke patients: a one year study].
    Revista de neurologia, 2017, Feb-16, Volume: 64, Issue:4

    Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aspirin; Brain Damage, Chronic; Brain Ischemia; C

2017
Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA.
    Neurology, 2017, Mar-14, Volume: 88, Issue:11

    Topics: Aged; Aspirin; Brain; Brain Infarction; Brain Ischemia; Clopidogrel; Female; Humans; Image Processin

2017
Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 26, Issue:3

    Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Drug Resistance; Female; Humans; Hypertr

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia;

2008
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience.
    Medical science monitor : international medical journal of experimental and clinical research, 2008, Volume: 14, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle A

2008
The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST).
    Stroke, 2009, Volume: 40, Issue:1

    Topics: Acute Disease; Aspirin; Blood Pressure; Brain; Brain Ischemia; Causality; Cerebral Hemorrhage; Comor

2009
Magnesium and aspirin treatment in patients with subarachnoid haemorrhage. Comparison of effects after endovascular and neurosurgical aneurysm occlusion.
    Journal of neurology, 2009, Volume: 256, Issue:2

    Topics: Aspirin; Brain Ischemia; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Magnesium

2009
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
    Stroke, 2009, Volume: 40, Issue:6

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde

2009
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
    Stroke, 2009, Volume: 40, Issue:6

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde

2009
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
    Stroke, 2009, Volume: 40, Issue:6

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde

2009
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
    Stroke, 2009, Volume: 40, Issue:6

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde

2009
Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2009, Volume: 28, Issue:4

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Biomarkers; Brain Ischemia; Female; Huma

2009
Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2009, Volume: 28, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug

2009
Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial.
    Cerebrovascular diseases (Basel, Switzerland), 2010, Volume: 29, Issue:1

    Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Intracranial Hemorr

2010
Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.
    European journal of neurology, 2010, Volume: 17, Issue:3

    Topics: Aspirin; Bleeding Time; Brain Ischemia; Cilostazol; Double-Blind Method; Drug Resistance; Drug Thera

2010
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
    Neuroscience bulletin, 2009, Volume: 25, Issue:6

    Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr

2009
Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.
    Cerebrovascular diseases (Basel, Switzerland), 2010, Volume: 29, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Disability Evaluation; Do

2010
Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
    Stroke, 2010, Volume: 41, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Female; Fibrinolytic Agents; Humans; Kapla

2010
A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial.
    Trials, 2010, May-12, Volume: 11

    Topics: Aspirin; Brain Ischemia; Drug Administration Schedule; Drug Therapy, Combination; Fibrinolytic Agent

2010
[Changes of plasma fibrinogen level among acute ischemic stroke subtypes according to TOAST criteria and effects of Songling Xuemaikang].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2010, Volume: 35, Issue:10

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drugs, Chinese Herbal; Female; Fibrinogen; Humans;

2010
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
    Trials, 2010, Aug-24, Volume: 11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel

2010
Radix/rhizoma notoginseng extract (sanchitongtshu) for ischemic stroke: a randomized controlled study.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2011, Apr-15, Volume: 18, Issue:6

    Topics: Activities of Daily Living; Aged; Aspirin; Brain Ischemia; Cognition Disorders; Double-Blind Method;

2011
Predictors of adherence to secondary preventive medication in stroke patients.
    Annals of behavioral medicine : a publication of the Society of Behavioral Medicine, 2011, Volume: 41, Issue:3

    Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Attitude to Health; Brain Ische

2011
Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial.
    International journal of stroke : official journal of the International Stroke Society, 2011, Volume: 6, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Hu

2011
Non-invasive alternating current stimulation induces recovery from stroke.
    Restorative neurology and neuroscience, 2010, Volume: 28, Issue:6

    Topics: Aged; Aphasia; Aspirin; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Electric Stimulation

2010
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
    Journal of the American College of Cardiology, 2011, Jan-18, Volume: 57, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination;

2011
Quality of life after ischemic stroke varies in western countries: data from the tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Emotions; Europe; Female;

2012
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
    Cerebrovascular diseases (Basel, Switzerland), 2011, Volume: 31, Issue:6

    Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action

2011
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
    Cerebrovascular diseases (Basel, Switzerland), 2011, Volume: 31, Issue:6

    Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action

2011
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
    Cerebrovascular diseases (Basel, Switzerland), 2011, Volume: 31, Issue:6

    Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action

2011
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
    Cerebrovascular diseases (Basel, Switzerland), 2011, Volume: 31, Issue:6

    Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action

2011
Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial.
    Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:10

    Topics: Aged; Aspirin; Brain Ischemia; Cholesterol, LDL; Cilostazol; Diabetes Mellitus; Endothelium, Vascula

2011
Aspirin resistance in cerebrovascular patients.
    International journal of cardiology, 2011, Oct-06, Volume: 152, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged

2011
Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study.
    Journal of the neurological sciences, 2012, Feb-15, Volume: 313, Issue:1-2

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle A

2012
Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arterial Occlusive Diseases; As

2012
Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke.
    Neurologia medico-chirurgica, 2011, Volume: 51, Issue:12

    Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Drug Therapy, Combinati

2011
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C

2012
Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke.
    Clinical neurology and neurosurgery, 2012, Volume: 114, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Brain Stem; Cerebellum; Cerebrovascular Circulatio

2012
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
    Stroke, 2012, Volume: 43, Issue:6

    Topics: Age Factors; Aged; Aspirin; Body Weight; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; F

2012
Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention.
    Stroke, 2012, Volume: 43, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel;

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Warfarin and aspirin in patients with heart failure and sinus rhythm.
    The New England journal of medicine, 2012, May-17, Volume: 366, Issue:20

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol

2012
Association of COX-2 rs20417 with aspirin resistance.
    Journal of thrombosis and thrombolysis, 2013, Volume: 35, Issue:1

    Topics: Adult; Aged; Alleles; Aspirin; Brain Ischemia; Cyclooxygenase 2; Drug Resistance; Female; Follow-Up

2013
Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke.
    BMC neurology, 2012, Aug-06, Volume: 12

    Topics: Aged; Aspirin; Brain Ischemia; Comorbidity; Dipyridamole; Drug Therapy, Combination; Female; Humans;

2012
Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke.
    International journal of molecular sciences, 2012, Volume: 13, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Chemokine CCL2; Dipyridamole; D

2012
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
    European heart journal, 2013, Volume: 34, Issue:3

    Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogre

2013
Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K
    Stroke, 2012, Volume: 43, Issue:12

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Contraindic

2012
What is better antiplatelet agent to prevent recurrent stroke?
    JPMA. The Journal of the Pakistan Medical Association, 2012, Volume: 62, Issue:9

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid

2012
Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
    Circulation. Arrhythmia and electrophysiology, 2013, Volume: 6, Issue:1

    Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Fibrinolytic Agents; Health Status Indic

2013
Unfractionated heparin is associated with a lower rise of serum vascular cell adhesion molecule-1 in acute ischemic stroke patients.
    Neuroscience letters, 2002, Aug-16, Volume: 328, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Female; Forecasting; Heparin; Humans;

2002
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
    Stroke, 2003, Volume: 34, Issue:4

    Topics: Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Clopidogrel; Cross-Ove

2003
Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel.
    Journal of thrombosis and thrombolysis, 2002, Volume: 14, Issue:2

    Topics: Aged; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Clopidogrel; D

2002
Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2003, Volume: 16, Issue:3

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Administration

2003
Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure.
    Stroke, 2003, Volume: 34, Issue:10

    Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up

2003
Nadroparin plus aspirin versus aspirin alone in the treatment of acute ischemic stroke.
    Neurology India, 2003, Volume: 51, Issue:2

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Humans; Injections, Subc

2003
Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2004, Volume: 17, Issue:2-3

    Topics: Acetaminophen; Acute Disease; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroida

2004
Leukocyte count as an independent predictor of recurrent ischemic events.
    Stroke, 2004, Volume: 35, Issue:5

    Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk

2004
Aspirin attenuates the incidence of silent brain lesions in patients with nonvalvular atrial fibrillation.
    Circulation journal : official journal of the Japanese Circulation Society, 2004, Volume: 68, Issue:5

    Topics: Aged; Aspirin; Atrial Fibrillation; Brain; Brain Ischemia; Female; Humans; Incidence; Magnetic Reson

2004
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
    Stroke, 2004, Volume: 35, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M

2004
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
    Stroke, 2004, Volume: 35, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M

2004
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
    Stroke, 2004, Volume: 35, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M

2004
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
    Stroke, 2004, Volume: 35, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M

2004
Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke.
    Clinical hemorheology and microcirculation, 2004, Volume: 30, Issue:3-4

    Topics: Adenosine Diphosphate; Adult; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Collagen; Epinep

2004
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V

2004
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V

2004
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V

2004
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V

2004
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V

2004
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V

2004
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V

2004
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V

2004
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
    Circulation, 2004, Aug-03, Volume: 110, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V

2004
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
    European journal of pharmacology, 2004, Sep-24, Volume: 499, Issue:3

    Topics: Aged; Antigens, CD; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; CD40 Ligand; Di

2004
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke.
    Thrombosis and haemostasis, 2005, Volume: 93, Issue:3

    Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Cell Adhesion; Clopidog

2005
The rapid anticoagulation prevents ischemic damage study in acute stroke--final results from the writing committee.
    Cerebrovascular diseases (Basel, Switzerland), 2005, Volume: 19, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Clinical Trials as Topic; Endpoint Determinati

2005
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.
    Stroke, 2005, Volume: 36, Issue:10

    Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Blood Platelets; Bra

2005
Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study.
    Atherosclerosis, 2006, Volume: 187, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Brain Ischemia; C-Reactive Protein; Cardiova

2006
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke.
    Platelets, 2006, Volume: 17, Issue:2

    Topics: Adult; Arteriosclerosis; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; C-Reactive Protein; C

2006
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
    Circulation, 2006, Jan-31, Volume: 113, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic

2006
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
    Circulation, 2006, Jan-31, Volume: 113, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic

2006
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
    Circulation, 2006, Jan-31, Volume: 113, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic

2006
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
    Circulation, 2006, Jan-31, Volume: 113, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic

2006
Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88 Suppl 3

    Topics: Aged; Aspirin; Brain Ischemia; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination

2005
ESPRIT study design and outcomes--a critical appraisal.
    Current medical research and opinion, 2007, Volume: 23, Issue:2

    Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H

2007
[Prevention of ischemic stroke in middle aged patients with atrial fibrillation. Effect of sinus rhythm maintenance, aspirin, warfarin, and simvastatin].
    Kardiologiia, 2007, Volume: 47, Issue:1

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy, Combination; Echocardiog

2007
Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study.
    The Lancet. Neurology, 2007, Volume: 6, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; A

2007
Variable platelet response to aspirin in patients with ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 24, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Biological Availabi

2007
Impact of valvular thickness on stroke recurrence in medically treated patients with stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 24, Issue:4

    Topics: Adult; Aged; Aortic Valve; Aspirin; Brain Ischemia; Double-Blind Method; Echocardiography, Transesop

2007
Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
    Stroke, 2007, Volume: 38, Issue:11

    Topics: Activities of Daily Living; Age Factors; Aged; Aspirin; Brain Ischemia; Double-Blind Method; Female;

2007
[Randomized multicenter control clinical study on acute ischemic stroke treatment with traditional Chinese medicine].
    Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, 2007, Volume: 30, Issue:9

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Drugs, Chinese Herbal; Fibr

2007
Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 25, Issue:4

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Female; Fol

2008
Platelet aggregation and recruitment with aspirin-clopidogrel therapy.
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 25, Issue:5

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Humans; Platelet Ag

2008
Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.
    The Lancet. Neurology, 2008, Volume: 7, Issue:6

    Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cilostazol; Double-Blind Method; Female;

2008
[Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
    Annales de medecine interne, 1983, Volume: 134, Issue:2

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Clofib

1983
[The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: Results].
    Revue neurologique, 1983, Volume: 139, Issue:5

    Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Clinical Trials as Topic; Dipyridamole; Drug Therapy,

1983
[The platelet inhibitor problem].
    Schweizerische medizinische Wochenschrift, 1981, Apr-04, Volume: 111, Issue:14

    Topics: Aspirin; Blood Transfusion; Brain Ischemia; Clinical Trials as Topic; Female; Humans; Male; Myocardi

1981
["A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Part I: Protocol (author's transl)].
    Revue neurologique, 1981, Volume: 137, Issue:5

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans;

1981
[Controlled cooperative trial. Secondary prevention of atherosclerosis-related cerebral ischemic accidents by aspirin dipyridamole. 2: Description of subjects at the beginning of the trial].
    Revue neurologique, 1982, Volume: 138, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Cerebral Infarction; Clinical Trials as Topic; Dipyridamole; Drug The

1982
[5-year controlled therapy study on the prevention of diabetic angiopathy with the platelet-function inhibitor acetylsalicylic acid].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1982, Oct-01, Volume: 37, Issue:19

    Topics: Adult; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Coronary Disease; Diabetic Angiopathies

1982
Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group.
    Lancet (London, England), 1995, Dec-09, Volume: 346, Issue:8989

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Confidence Intervals; Drug Therapy, Combination; Femal

1995
[Embolic complications in atrial fibrillation. Data of the Studio Italiano Fibrillation Atriale (SIFA)].
    Il Giornale di chirurgia, 1995, Volume: 16, Issue:3

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders

1995
Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group.
    Annals of internal medicine, 1995, Nov-01, Volume: 123, Issue:9

    Topics: Aged; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Stenosis; Double-Blind Method; Female; Gast

1995
Shear-induced platelet aggregation in cerebral ischemia.
    Stroke, 1994, Volume: 25, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Brain Ischemia; Cerebral Infarction;

1994
A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.
    Stroke, 1994, Volume: 25, Issue:10

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Brain Ischemi

1994
Failure of aspirin treatment after stroke.
    Stroke, 1994, Volume: 25, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Female;

1994
The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study.
    Neurology, 1993, Volume: 43, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Double-Blind Method; Female; Follow-Up Stu

1993
Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 1996, Volume: 6, Issue:1

    Topics: Aspirin; Brain; Brain Ischemia; Dementia, Vascular; Double-Blind Method; Female; Humans; Magnetic Re

1996
Multicentre Acute Stroke Trial--Italy.
    Lancet (London, England), 1996, Feb-10, Volume: 347, Issue:8998

    Topics: Acute Disease; Aspirin; Brain Ischemia; Humans; Italy; Risk Factors; Streptokinase; Thrombolytic The

1996
Multicentre Acute Stroke Trial--Italy.
    Lancet (London, England), 1996, Feb-10, Volume: 347, Issue:8998

    Topics: Acute Disease; Aspirin; Brain Ischemia; Humans; Italy; Research Design; Risk Factors; Streptokinase;

1996
Multicentre Acute Stroke Trial--Italy.
    Lancet (London, England), 1996, Feb-10, Volume: 347, Issue:8998

    Topics: Acute Disease; Aspirin; Brain Ischemia; Humans; Italy; Research Design; Risk Factors; Streptokinase;

1996
Multicentre Acute Stroke Trial--Italy.
    Lancet (London, England), 1996, Feb-10, Volume: 347, Issue:8998

    Topics: Acute Disease; Aspirin; Brain Ischemia; Humans; Italy; Risk Factors; Streptokinase; Thrombolytic The

1996
Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia.
    Journal of neurology, neurosurgery, and psychiatry, 1996, Volume: 60, Issue:2

    Topics: Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Humans; Risk Factors

1996
[Low doses of acetylsalicylic acid effectively inhibits thrombocyte aggregation after ischemic stroke].
    Orvosi hetilap, 1996, Mar-03, Volume: 137, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Brain Ischemia; Cerebrovascular Disorders

1996
Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study.
    Journal of neurology, neurosurgery, and psychiatry, 1996, Volume: 60, Issue:4

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Feasibility

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    Lancet (London, England), 1996, Nov-16, Volume: 348, Issue:9038

    Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method;

1996
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
    The New England journal of medicine, 1997, Apr-03, Volume: 336, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C-

1997
[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
    Archives des maladies du coeur et des vaisseaux, 1996, Volume: 89, Issue:11 Suppl

    Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Dose-Response Re

1996
[Secondary prevention of ischemic strokes: effect of dosage of aspirin].
    Revista de neurologia, 1997, Volume: 25, Issue:140

    Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Dose-Response Relationship, Drug; Humans; Placebos; Pl

1997
Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan.
    Thrombosis research, 1997, Jul-15, Volume: 87, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggr

1997
[Antithrombotic treatment of acute ischemic apoplexy].
    Ugeskrift for laeger, 1997, Sep-01, Volume: 159, Issue:36

    Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Plat

1997
A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.
    Annals of neurology, 1997, Volume: 42, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Female; Hemorrhage; Humans; Male; Middle Aged; Platel

1997
[Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease].
    Revista de neurologia, 1997, Volume: 25, Issue:147

    Topics: Adult; Aspirin; Brain Ischemia; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Bl

1997
[Prevention of vascular complications following cerebral ischemia of arterial origin; the ESPRIT trial: mild anticoagulant therapy, combination treatment with acetylsalicylic acid plus dipyridamole or treatment with acetylsalicylic acid alone?].
    Nederlands tijdschrift voor geneeskunde, 1998, Feb-07, Volume: 142, Issue:6

    Topics: Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Aspirin; Brain Ischemia; Cerebrovascular Disor

1998
Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group.
    Stroke, 1998, Volume: 29, Issue:5

    Topics: Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebrovascular Disorde

1998
Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group.
    Stroke, 1998, Volume: 29, Issue:7

    Topics: Aged; Anticoagulants; Aspirin; Basilar Artery; Brain Ischemia; Cerebellum; Cerebral Arteries; Cerebr

1998
Risk of aspirin use plus thrombolysis after acute ischaemic stroke: a further MAST-I analysis. MAST-I Collaborative Group. Multicentre Acute Stroke Trial--Italy.
    Lancet (London, England), 1998, Sep-12, Volume: 352, Issue:9131

    Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Drug Therapy, Combination; Fibrinolytic

1998
Effect of diaspirin cross-linked hemoglobin on endothelin-1 and blood pressure in acute ischemic stroke in man.
    Journal of hypertension, 1998, Volume: 16, Issue:10

    Topics: Acute Disease; Aged; Aspirin; Blood Pressure; Blood Substitutes; Brain Ischemia; Dose-Response Relat

1998
Exercise and risk of stroke in male physicians.
    Stroke, 1999, Volume: 30, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Brain Ischemia; Cerebral Hemorrhage; Cerebro

1999
Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group.
    Acta neurologica Scandinavica, 1999, Volume: 99, Issue:1

    Topics: Administration, Oral; Adult; Age Factors; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders;

1999
[Effects of the results of randomized trials on the tactics of management of patients with acute stroke].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1999, Volume: 99, Issue:2

    Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Fibrinolytic Agen

1999
The effect of aspirin, ticlopidine and their low-dose combination on platelet aggregability in acute ischemic stroke: a short duration follow-up study.
    European journal of neurology, 1999, Volume: 6, Issue:1

    Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combin

1999
Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke.
    Stroke, 1999, Volume: 30, Issue:5

    Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Blood Pressure; Blood Substitutes; Brain Ischemia;

1999
Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.
    Stroke, 1999, Volume: 30, Issue:6

    Topics: Aged; Alcohol Drinking; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascula

1999
Increased thromboxane biosynthesis is associated with poststroke dementia.
    Stroke, 1999, Volume: 30, Issue:8

    Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Cerebral Hemorrhage; Chronic Disease; Co

1999
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
    Thrombosis research, 1999, Nov-01, Volume: 96, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca

1999
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
    Lancet (London, England), 2000, Apr-08, Volume: 355, Issue:9211

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation;

2000
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
    Stroke, 2000, Volume: 31, Issue:6

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha

2000
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
    American heart journal, 2000, Volume: 140, Issue:1

    Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem

2000
Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation.
    The American journal of medicine, 2000, Volume: 109, Issue:1

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy

2000
Comparison of the acute-phase response in patients with ischemic stroke treated with high-dose heparin or aspirin.
    Journal of the neurological sciences, 2000, Sep-01, Volume: 178, Issue:1

    Topics: Acute-Phase Reaction; Aged; Analysis of Variance; Aspirin; Brain Ischemia; Female; Fibrinolytic Agen

2000
Urinary 11-dehydro-thromboxane B(2) and coagulation activation markers measured within 24 h of human acute ischemic stroke.
    Neuroscience letters, 2001, Nov-02, Volume: 313, Issue:1-2

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Coagulation; Brain Ischemi

2001
Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study.
    Stroke, 2001, Volume: 32, Issue:11

    Topics: Adolescent; Aspirin; Brain Ischemia; Child; Child, Preschool; Fibrinolytic Agents; Follow-Up Studies

2001
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
    The New England journal of medicine, 2001, Nov-15, Volume: 345, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind Method; Female

2001
Blood pressure and clinical outcomes in the International Stroke Trial.
    Stroke, 2002, Volume: 33, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Pressure; Brain Ischemia; Cohort Studies; Fe

2002
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
    Bibliotheca haematologica, 1977, Volume: 44

    Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial

1977
Aspirin for cerebral transient ischemic attacks or minor ischemic strokes.
    The New England journal of medicine, 1992, May-07, Volume: 326, Issue:19

    Topics: Aspirin; Brain Ischemia; Double-Blind Method; Humans; Ischemic Attack, Transient; Myocardial Infarct

1992
Second European Stroke Prevention Study. ESPS-2 Working Group.
    Journal of neurology, 1992, Volume: 239, Issue:6

    Topics: Aspirin; Brain Ischemia; Computer Simulation; Dipyridamole; Double-Blind Method; Drug Administration

1992
Aspirin for cerebral transient ischemic attacks or minor ischemic strokes.
    The New England journal of medicine, 1992, May-07, Volume: 326, Issue:19

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient

1992
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
    The New England journal of medicine, 1992, Jul-02, Volume: 327, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Drug Therapy, Combina

1992
The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.
    Journal of neurology, neurosurgery, and psychiatry, 1991, Volume: 54, Issue:12

    Topics: Aged; Aspirin; Brain Ischemia; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male;

1991
[Clinical efficacy of picotamide].
    La Clinica terapeutica, 1991, Jul-15, Volume: 138, Issue:1

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Tr

1991
Secondary prevention of ischemic stroke with low dose acetylsalicylic acid.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 1990, Volume: 89, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Follow-Up Studies; Humans; Male; Middle Ag

1990
Effect of ticlopidine and aspirin on platelet ionized calcium in ischemic stroke.
    Stroke, 1991, Volume: 22, Issue:4

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Calcium; Collagen; Humans; In Vitro Techniques; Platelet A

1991
European Stroke Prevention Study. ESPS Group.
    Stroke, 1990, Volume: 21, Issue:8

    Topics: Age Factors; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical T

1990
Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks.
    Acta neurologica Scandinavica, 1987, Volume: 76, Issue:6

    Topics: Adult; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; D

1987
[The extra-intracranial bypass operation: results of an international randomized study].
    Nederlands tijdschrift voor geneeskunde, 1986, Apr-12, Volume: 130, Issue:15

    Topics: Aspirin; Brain Ischemia; Cerebral Angiography; Cerebral Revascularization; Humans; Ischemic Attack,

1986
Asymptomatic carotid disease.
    Surgery, gynecology & obstetrics, 1985, Volume: 160, Issue:1

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor

1985

Other Studies

465 other studies available for aspirin and Brain Ischemia

ArticleYear
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
    Bioorganic & medicinal chemistry, 2008, Oct-01, Volume: 16, Issue:19

    Topics: Animals; Antioxidants; Brain Ischemia; Fibrinolytic Agents; Nitrogen Oxides; Pyrazines; Rats; Stroke

2008
Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one.
    Journal of medicinal chemistry, 2012, Aug-23, Volume: 55, Issue:16

    Topics: Animals; Antioxidants; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Fibrinolytic Agents; Fr

2012
Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke.
    European journal of medicinal chemistry, 2020, Aug-15, Volume: 200

    Topics: Administration, Oral; Animals; Biguanides; Brain Ischemia; Dose-Response Relationship, Drug; Male; M

2020
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
    European journal of preventive cardiology, 2022, 05-05, Volume: 29, Issue:5

    Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Hemor

2022
Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes.
    Annals of neurology, 2021, Volume: 90, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Infarction; Female; Fibr

2021
Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy.
    Thrombosis research, 2021, Volume: 208

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; P-Selectin; Thromboxane B2

2021
Dual Antiplatelet Therapy Plus Argatroban Prevents Early Neurological Deterioration in Branch Atherosclerosis Disease.
    Stroke, 2022, Volume: 53, Issue:1

    Topics: Arginine; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Humans; Pipecolic Acids; Platelet A

2022
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2022, Jul-22, Volume: 18, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy, Combination; Fibrinolyti

2022
Dual antiplatelet use in the management of COVID-19 associated acute ischemic stroke reocclusion.
    Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2023, Volume: 29, Issue:5

    Topics: Aspirin; Brain Ischemia; COVID-19; Humans; Ischemic Stroke; Middle Aged; Retrospective Studies; SARS

2023
Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study.
    PLoS medicine, 2022, Volume: 19, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemi

2022
Non-vitamin K oral anticoagulant compared with aspirin may not significantly reduce the rate of ischaemic stroke in patients with mixed cardiovascular disease in sinus rhythm.
    European journal of preventive cardiology, 2022, 08-22, Volume: 29, Issue:11

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular D

2022
Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?
    Journal of infection in developing countries, 2022, 06-30, Volume: 16, Issue:6

    Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; COVID-19; Enoxaparin; Humans; Manni

2022
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.
    Journal of the neurological sciences, 2022, 10-15, Volume: 441

    Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Humans; Ischemic Atta

2022
Determining the chemical profile of Caragana jubata (Pall.) Poir. by UPLC-QTOF-MS analysis and evaluating its anti-ischemic stroke effects.
    Journal of ethnopharmacology, 2023, Jun-12, Volume: 309

    Topics: Animals; Aspirin; Brain Ischemia; Caragana; Infarction, Middle Cerebral Artery; Ischemic Stroke; Pla

2023
Intravenous thrombolysis versus antiplatelet therapy in minor stroke patients with large vessel occlusion.
    CNS neuroscience & therapeutics, 2023, Volume: 29, Issue:6

    Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Platelet Aggregation Inhi

2023
In-Hospital Aspirin Dose as a Risk Factor for Hemorrhagic Transformation in Patients Not Treated With Thrombolysis.
    The neurologist, 2023, Sep-01, Volume: 28, Issue:5

    Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Hospitals; Humans; Ischemic Stroke; Retrospective Stud

2023
Comparative effectiveness of clopidogrel versus aspirin as a maintenance monotherapy 1 year after coronary artery bypass grafting.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2023, 04-03, Volume: 63, Issue:4

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Pla

2023
Efficacy and Prognosis of Adjuvant Argatroban Treatment in Acute Ischemic Stroke Patients with Early Neurological Deterioration.
    Discovery medicine, 2023, 04-01, Volume: 35, Issue:175

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Prognosis; Stroke; Treatment Outcome

2023
Tirofiban in the treatment of cancer-associated ischemic stroke.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:8

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Neoplasms; Retrospective Studies; Stroke; Tirofiba

2023
Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy.
    Journal of vascular and interventional radiology : JVIR, 2023, Volume: 34, Issue:9

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Intracranial Hemorrhages; Ischemic Stroke; Mechanical

2023
Pharmacological Effects of a New Soluble Guanylate Cyclase Stimulator in Experimental Ischemic Stroke.
    Bulletin of experimental biology and medicine, 2023, Volume: 175, Issue:6

    Topics: Animals; Aspirin; Brain Ischemia; Cerebral Infarction; Ischemic Stroke; Platelet Aggregation; Platel

2023
Formulation of aspirin nanoparticles using solvent evaporation method and in vivo evaluation of its antithrombotic effect.
    Pakistan journal of pharmaceutical sciences, 2023, Volume: 36, Issue:5(Special)

    Topics: Animals; Antioxidants; Aspirin; Brain Ischemia; Drug Carriers; Fibrinolytic Agents; Nanoparticles; P

2023
Review: After stroke or TIA, adding clopidogrel to aspirin for ≤ 1 month reduces recurrence and MACE.
    Annals of internal medicine, 2019, 08-20, Volume: 171, Issue:4

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib

2019
Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study.
    PloS one, 2019, Volume: 14, Issue:8

    Topics: Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrhage; Clopidogrel; Female; Ga

2019
MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS.
    Neurology, 2019, 10-15, Volume: 93, Issue:16

    Topics: Aged; Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Magnet

2019
Relationship between 'on-treatment platelet reactivity', shear stress, and micro-embolic signals in asymptomatic and symptomatic carotid stenosis.
    Journal of neurology, 2020, Volume: 267, Issue:1

    Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Carotid Stenosis; Female; Humans; Intracranial Embol

2020
Intensive antiplatelet therapy with three agents does not reduce risk of another stroke.
    Drug and therapeutics bulletin, 2020, Volume: 58, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stroke

2020
Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke.
    European neurology, 2019, Volume: 82, Issue:4-6

    Topics: Administration, Intravenous; Aged; Aspirin; Brain Ischemia; Clopidogrel; Dual Anti-Platelet Therapy;

2019
Aspirin plus clopidogrel versus aspirin Mono-Therapy for ischemic stroke.
    Scandinavian cardiovascular journal : SCJ, 2020, Volume: 54, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine

2020
Association of platelet-derived microvesicles with high on-treatment platelet reactivity in convalescent ischemic stroke patients treated with acetylsalicylic acid
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2019, Aug-31, Volume: 72, Issue:8

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Cell-Derived Microparticles; Humans; Stroke

2019
Risk factors for severe cranial ischaemic complications in giant cell arteritis.
    Rheumatology (Oxford, England), 2020, 10-01, Volume: 59, Issue:10

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischem

2020
Haemorrhagic transformation following ischaemic stroke: A retrospective study.
    Scientific reports, 2020, 03-24, Volume: 10, Issue:1

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Hemorrhage; Humans; Intr

2020
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    JAMA network open, 2020, 04-01, Volume: 3, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clo

2020
Preventive Effects of Neuroprotective Agents in a Neonatal Rat of Photothrombotic Stroke Model.
    International journal of molecular sciences, 2020, May-24, Volume: 21, Issue:10

    Topics: Animals; Animals, Newborn; Aspirin; Brain Ischemia; Clopidogrel; Disease Models, Animal; Inflammatio

2020
Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease.
    European heart journal. Cardiovascular pharmacotherapy, 2021, 11-03, Volume: 7, Issue:6

    Topics: Aspirin; Brain Ischemia; Coronary Artery Disease; Diabetes Mellitus; Humans; Percutaneous Coronary I

2021
[In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardi
    La Revue de medecine interne, 2020, Volume: 41, Issue:8

    Topics: Amputation, Surgical; Aspirin; Brain Ischemia; Chocolate; Cysts; Humans; Ischemia; Ischemic Stroke;

2020
Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions.
    International journal of stroke : official journal of the International Stroke Society, 2021, Volume: 16, Issue:4

    Topics: Aspirin; Brain Ischemia; Cohort Studies; Drug Therapy, Combination; Glucosephosphate Dehydrogenase;

2021
Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database.
    The European respiratory journal, 2021, Volume: 57, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Pneumonia; Primary Health Ca

2021
Not all aspirin products have equivalent antiplatelet efficacy-Aspirin formulated with magnesium stearate is less effective in preventing ischemic stroke.
    Pharmacoepidemiology and drug safety, 2020, Volume: 29, Issue:12

    Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Humans; Ischemic Stroke; Male; Pla

2020
Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients.
    Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:1

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient;

2021
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
    The New England journal of medicine, 2020, 10-22, Volume: 383, Issue:17

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor

2020
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. Reply.
    The New England journal of medicine, 2020, 10-22, Volume: 383, Issue:17

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor

2020
In acute ischemic stroke or TIA, adding ticagrelor to aspirin reduced stroke or death and increased severe bleeding.
    Annals of internal medicine, 2020, 12-15, Volume: 173, Issue:12

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Ischemic Stroke; Stroke; Ticagrelor

2020
Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged

2020
2019 novel coronavirus disease with secondary ischemic stroke: two case reports.
    BMC neurology, 2021, Jan-05, Volume: 21, Issue:1

    Topics: Aspirin; Atorvastatin; Brain Ischemia; COVID-19; Fibrinolytic Agents; Humans; Ischemic Stroke; Male;

2021
Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF-κB/NLRP3 Pathway in Ischemic Stroke.
    Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2021, Volume: 16, Issue:4

    Topics: Animals; Aspirin; Brain Ischemia; Clopidogrel; Inflammasomes; Ischemic Stroke; Isoindoles; NF-kappa

2021
Aspirin monotherapy in the treatment of distal intracranial aneurysms with a surface modified flow diverter: a pilot study.
    Journal of neurointerventional surgery, 2021, Volume: 13, Issue:4

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Embolization, Therapeutic; Endovascular Procedures; Female; Hu

2021
Anabolic steroid use and ischaemic stroke in a young fitness enthusiast.
    BMJ case reports, 2021, Feb-04, Volume: 14, Issue:2

    Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agent

2021
Non-persistence with anti-platelet therapy and long-term mortality after ischemic stroke: A nationwide study.
    PloS one, 2021, Volume: 16, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; C

2021
Antiplatelet therapy in secondary prevention of non-embolic ischaemic stroke.
    Vnitrni lekarstvi, 2020,Winter, Volume: 66, Issue:8

    Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemic Stroke; Platelet Aggregation In

2020
Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry.
    European heart journal. Cardiovascular pharmacotherapy, 2022, 08-11, Volume: 8, Issue:5

    Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Coronary Artery Disease; Denmark;

2022
Aspirin withdrawal: A risk factor for ischemic stroke severity.
    Journal de medecine vasculaire, 2021, Volume: 46, Issue:4

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Risk Factors; Stroke

2021
Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: Interaction with smoking.
    Journal of the neurological sciences, 2017, May-15, Volume: 376

    Topics: Asian People; Aspirin; Brain Ischemia; China; Cyclooxygenase 1; Female; Fibrinolytic Agents; Follow-

2017
Numerous Fusiform and Saccular Cerebral Aneurysms in Central Nervous System Lupus Presenting with Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:7

    Topics: Adult; Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Angiography; Diffusion Magnetic Re

2017
Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Chi-Square Distribution; Clopidog

2017
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:10

    Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resi

2017
Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Diabetes Mel

2017
Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
    Journal of the American Heart Association, 2017, Aug-05, Volume: 6, Issue:8

    Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Female

2017
Emergent loading dose of antiplatelets for stenting after IV rt-PA in acute ischemic stroke: a feasibility study.
    The International journal of neuroscience, 2018, Volume: 128, Issue:4

    Topics: Administration, Intravenous; Aged; Aspirin; Brain Ischemia; Clopidogrel; Computed Tomography Angiogr

2018
Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke.
    Brain research bulletin, 2017, Volume: 134

    Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Logistic Models;

2017
Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Sep-12, Volume: 23

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Infarction; Drug Therapy, Combination; Ep

2017
STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke.
    Stroke, 2018, Volume: 49, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; Fibrinol

2018
Internal Carotid Artery Web as the Cause of Recurrent Cryptogenic Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:5

    Topics: Adult; Aspirin; Atorvastatin; Biopsy; Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases

2018
Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care.
    BMJ (Clinical research ed.), 2018, 02-14, Volume: 360

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; England; Fe

2018
Charting the Course: Risk Scores for Major Bleeding in Transient Ischemic Attack and Ischemic Stroke.
    Stroke, 2018, Volume: 49, Issue:3

    Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibi

2018
Monoacylglycerol lipase inhibitor, JZL-184, confers neuroprotection in the mice middle cerebral artery occlusion model of stroke.
    Life sciences, 2018, Apr-01, Volume: 198

    Topics: Animals; Aspirin; Behavior, Animal; Benzodioxoles; Brain; Brain Edema; Brain Ischemia; Disease Model

2018
Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study.
    European heart journal. Cardiovascular pharmacotherapy, 2018, 07-01, Volume: 4, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Denmark; Drug Th

2018
Cerebrovascular Accidents During Mechanical Circulatory Support: New Predictors of Ischemic and Hemorrhagic Strokes and Outcome.
    Stroke, 2018, Volume: 49, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female; Heart Failure; Heart-Ass

2018
Bilateral visual loss and cerebral infarction after spleen embolization in a trauma patient with idiopathic thrombocytopenic purpura: A case report.
    Medicine, 2018, Volume: 97, Issue:16

    Topics: Adult; Aspirin; Blindness, Cortical; Brain Ischemia; Embolization, Therapeutic; Female; Humans; Magn

2018
Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study.
    Cardiology journal, 2019, Volume: 26, Issue:6

    Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Comparative Effectiveness

2019
Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease.
    Annals of the American Thoracic Society, 2018, Volume: 15, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Disease Progression; Female; Humans; Male; Myocard

2018
Management of acute tandem occlusions: Stent-retriever thrombectomy with emergency stenting or angioplasty.
    The Journal of international medical research, 2018, Volume: 46, Issue:7

    Topics: Aged; Angioplasty; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cl

2018
Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; China; Clinical Decision-Making; Clopidogrel; Cyto

2018
Clinical Significance of Acute and Serial Platelet Function Testing in Acute Ischemic Stroke.
    Journal of the American Heart Association, 2018, 06-01, Volume: 7, Issue:11

    Topics: Acute Disease; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Humans; Male; Pl

2018
Are Patients Getting Their Aspirin's Worth in Ischemic Stroke?
    Journal of the American Heart Association, 2018, 06-01, Volume: 7, Issue:11

    Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Stroke

2018
Positive trials in ischaemic stroke reported at ESOC 2018.
    Nature reviews. Neurology, 2018, Volume: 14, Issue:7

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Stroke

2018
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.
    JACC. Cardiovascular interventions, 2018, 07-09, Volume: 11, Issue:13

    Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dr

2018
What now for embolic stroke of undetermined source?
    Nature reviews. Neurology, 2018, Volume: 14, Issue:9

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Clinical Trials as Topic; Humans; Intracranial Embolism; Ri

2018
Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients.
    Brain research bulletin, 2018, Volume: 142

    Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged

2018
Argatroban plus aspirin versus aspirin in acute ischemic stroke.
    Neurological research, 2018, Volume: 40, Issue:10

    Topics: Arginine; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fema

2018
Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke.
    The American journal of cardiology, 2018, 09-15, Volume: 122, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combinati

2018
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
    Journal of neurointerventional surgery, 2019, Volume: 11, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag

2019
Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania.
    International journal for quality in health care : journal of the International Society for Quality in Health Care, 2019, Jun-01, Volume: 31, Issue:5

    Topics: Aged; Antihypertensive Agents; Aspirin; Brain Ischemia; Cohort Studies; Deglutition Disorders; Disab

2019
Ischemic stroke following a wasp sting - a rare complication: a case report.
    Journal of medical case reports, 2018, Oct-14, Volume: 12, Issue:1

    Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvasta

2018
Antiplatelet Agents in Acute Stroke and TIA.
    The New England journal of medicine, 2018, Oct-25, Volume: 379, Issue:17

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke

2018
Antiplatelet Agents in Acute Stroke and TIA.
    The New England journal of medicine, 2018, Oct-25, Volume: 379, Issue:17

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke

2018
Antiplatelet Agents in Acute Stroke and TIA.
    The New England journal of medicine, 2018, Oct-25, Volume: 379, Issue:17

    Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke

2018
Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke.
    Journal of atherosclerosis and thrombosis, 2019, Jun-01, Volume: 26, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers; Brain Ischemia;

2019
Primary stroke centers: are they worthy of an upgrade?
    Internal and emergency medicine, 2019, Volume: 14, Issue:2

    Topics: Aspirin; Brain Ischemia; Cardiac Resynchronization Therapy; Humans; Stroke; Tissue Plasminogen Activ

2019
Post-treatment Antiplatelet Therapy Reduces Risk for Delayed Cerebral Ischemia due to Aneurysmal Subarachnoid Hemorrhage.
    Neurosurgery, 2019, 12-01, Volume: 85, Issue:6

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Cohort Studies; Female; Hum

2019
Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study.
    Journal of neurointerventional surgery, 2019, Volume: 11, Issue:4

    Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Comb

2019
Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline.
    BMJ (Clinical research ed.), 2018, Dec-18, Volume: 363

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib

2018
Twenty-and-a-half syndrome: a case report.
    Journal of medical case reports, 2019, Feb-15, Volume: 13, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvast

2019
Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2019, Volume: 28, Issue:5

    Topics: Aged; Asian People; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; China; Clopidogrel; Drug R

2019
Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke.
    The journal of nutrition, health & aging, 2019, Volume: 23, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Humans; Male; Middle Aged; Mortality; Outcom

2019
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
    Stroke, 2019, Volume: 50, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T

2019
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
    Stroke, 2019, Volume: 50, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T

2019
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
    Stroke, 2019, Volume: 50, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T

2019
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
    Stroke, 2019, Volume: 50, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T

2019
Guideline: Starting dual antiplatelet therapy ≤ 24 h after high-risk TIA or minor ischemic stroke is recommended.
    Annals of internal medicine, 2019, 04-16, Volume: 170, Issue:8

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient;

2019
Hemoglobin Southampton complicated by cerebral ischemia, moyamoya, and hydroxyurea-induced methemoglobinemia.
    American journal of hematology, 2019, Volume: 94, Issue:8

    Topics: Aspirin; Brain Ischemia; Child; Female; Hemoglobinopathies; Hemoglobins, Abnormal; Humans; Hydroxyur

2019
Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2019, Volume: 28, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Comorbidity; Cross-Se

2019
Aspirin nonresponders in patients with ischaemic stroke.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:4

    Topics: Aspirin; Brain Ischemia; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregat

2013
Aspirin resistance in patients with hemodynamic cerebral ischemia undergoing extracranial-intracranial bypass surgery.
    Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 35, Issue:4

    Topics: Adolescent; Adult; Angiography, Digital Subtraction; Aspirin; Blood Coagulation Disorders; Brain Isc

2013
Associations of durations of antiplatelet use and vascular risk factors with the presence of cerebral microbleeds.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Chi-Square Distribution; Como

2014
Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?
    Journal of neurointerventional surgery, 2014, Volume: 6, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Revascularizatio

2014
Multiple electrode aggregometry in antiplatelet-related intracerebral haemorrhage.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2013, Volume: 20, Issue:12

    Topics: Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Humans; Male; Pla

2013
Early and late mortality of spontaneous hemorrhagic transformation of ischemic stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Cohort Studies; Disease Progressio

2014
"Aspirin resistance" in ischemic stroke: insights using short thrombelastography.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:8

    Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Cytokines; Drug Resistance; Female; Hu

2013
Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
    Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:1

    Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Brain Ischemia; Cerebral Hemorrhage; Heart Failure;

2013
Antiplatelet loading improves behavioral outcome in a rabbit model of stroke.
    Stroke, 2013, Volume: 44, Issue:11

    Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Aspirin; Blood Platelets; Brain Ischemia; Collagen

2013
PHACES syndrome with moyamoya vasculopathy - a case report.
    Dermatology online journal, 2013, Aug-15, Volume: 19, Issue:8

    Topics: Anticonvulsants; Aortic Coarctation; Aspirin; Brain Ischemia; Child, Preschool; Eye Abnormalities; F

2013
Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:8

    Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Cholesterol, HDL; Clopido

2013
Atrial fibrillation patients do not benefit from acetylsalicylic acid.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Female; Gastr

2014
Aspirin resistant patients with recent ischemic stroke.
    Revista clinica espanola, 2014, Volume: 214, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Humans; Platelet Aggregation Inhibitors; Rec

2014
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
    Journal of vascular surgery, 2014, Volume: 59, Issue:3

    Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Mag

2014
Acetylsalicylic acid for stroke prevention in atrial fibrillation: a conspiracy that needs to end?
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:5

    Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibitors;

2014
Interaction between vWF levels and aspirin resistance in ischemic stroke patients.
    Translational stroke research, 2013, Volume: 4, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Female; Humans; Male;

2013
LOAD: a pilot study of the safety of loading of aspirin & clopidogrel in acute ischaemic stroke and transient ischaemic attack. Is the loading dose of aspirin and clopidogrel a good alternative for patients with acute ischaemic stroke and TIA? How this wi
    JPMA. The Journal of the Pakistan Medical Association, 2013, Volume: 63, Issue:10

    Topics: Aspirin; Brain Ischemia; Female; Humans; Ischemic Attack, Transient; Male; Ticlopidine

2013
Antithrombotic drugs and ischaemic stroke.
    Prescrire international, 2013, Volume: 22, Issue:143

    Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Stroke

2013
Switching from aspirin to clopidogrel in patients with aspirin resistance after an ischemic stroke. Is it a good solution?
    European journal of internal medicine, 2014, Volume: 25, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Drug Resistance; Drug Substitution; F

2014
Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis.
    International journal of stroke : official journal of the International Stroke Society, 2014, Volume: 9, Issue:5

    Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate

2014
[Bullous hemorrhagic dermatosis induced by heparin: description of 2 new cases].
    Medicina clinica, 2014, Dec-09, Volume: 143, Issue:11

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Drug Eruptions; Enoxaparin; Hemo

2014
Neuroprotective effect of guggulipid alone and in combination with aspirin on middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia in rats.
    Toxicology mechanisms and methods, 2014, Volume: 24, Issue:6

    Topics: Acetylcholinesterase; Animals; Aspirin; Brain Ischemia; Catalase; Commiphora; Cyclooxygenase Inhibit

2014
Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis.
    European journal of neurology, 2014, Volume: 21, Issue:10

    Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination;

2014
Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings.
    Neurology, 2014, Sep-09, Volume: 83, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cost-Benefit Analysis;

2014
Thrombolysis May Reduce the Incidence/Extent of Postprocedural Ischemic Strokes Associated With Carotid Artery Stenting: A Hypothesis.
    Angiology, 2015, Volume: 66, Issue:7

    Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Hydroxy

2015
Involvement of Arg306 mutation in factor V gene in two young men with ischemic stroke.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:8

    Topics: Anticholesteremic Agents; Arginine; Aspirin; Brain Ischemia; DNA Mutational Analysis; Factor V; Fibr

2014
The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis.
    BMJ case reports, 2014, Nov-24, Volume: 2014

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Coronary Thrombosis; Diagnosis, Differential; Electrocardio

2014
Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometry.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation; Brain Ischemia; Female; Fibrinolytic Agents; Hu

2015
The effect of different doses and different routes of acetylsalicylic acid administration on platelet aggregation in healthy volunteers and ischemic stroke patients.
    Translational stroke research, 2015, Volume: 6, Issue:2

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Administration Routes;

2015
Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:4

    Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Cohort Studies; Drug Resistance; Female; Humans; In

2015
Can the previous therapeutic control of the main risk factors of cerebrovascular disease influence the acetylsalicylic Acid-nonresponsive status in acute ischemic stroke patients? Results from a portuguese prospective cohort study.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Studies; Female;

2015
Pediatric Acute Ischemic Cerebral Vascular Accidents: A Case Report.
    Pediatric emergency care, 2017, Volume: 33, Issue:3

    Topics: Aspirin; Brain Ischemia; Child; Diffusion Magnetic Resonance Imaging; Female; Heparin; Humans; Strok

2017
Coadministration of the Human Umbilical Cord Matrix-Derived Mesenchymal Cells and Aspirin Alters Postischemic Brain Injury in Rats.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:9

    Topics: Adipogenesis; Analysis of Variance; Animals; Aspirin; Brain Injuries; Brain Ischemia; Cell Different

2015
Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin Over Time in Acute Ischemic Stroke.
    Stroke, 2015, Volume: 46, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Female; Follow-Up Studies; Humans

2015
Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation.
    Journal of thrombosis and thrombolysis, 2016, Volume: 41, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibril

2016
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel;

2015
[Interaction of the Humoral Agonist During the Platelets Activation in Patients with Chronic Cerebral Ischemia].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 2015, Issue:3

    Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Platelets; Brain; Brain Ischemia; Chronic Disease; Epin

2015
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
    BMC neurology, 2015, Nov-02, Volume: 15

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies;

2015
The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance in Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Magnetic Resonance Imaging; Male;

2016
Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; CD40 Ligand; Clopidogrel; Femal

2016
Different Antiplatelet Strategies in Patients With New Ischemic Stroke While Taking Aspirin.
    Stroke, 2016, Volume: 47, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Follow-Up Studi

2016
Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome.
    Annals of neurology, 2016, Volume: 79, Issue:4

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Intracranial Hemorrhages; Male; Mi

2016
Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity.
    Cerebrovascular diseases (Basel, Switzerland), 2016, Volume: 41, Issue:5-6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Disability E

2016
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
    Journal of the neurological sciences, 2016, Feb-15, Volume: 361

    Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr

2016
Aspirin resistance is associated with increased stroke severity and infarct volume.
    Neurology, 2016, May-10, Volume: 86, Issue:19

    Topics: Aged; Aspirin; Brain; Brain Ischemia; Diffusion Magnetic Resonance Imaging; Drug Resistance; Female;

2016
Extended use of clopidogrel and aspirin after ischemic stroke.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, May-15, Volume: 73, Issue:10

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Humans; Platelet Aggregation Inh

2016
Protective Effect of Guggulipid in High Fat Diet and Middle Cerebral Artery Occlusion (MCAO) Induced Ischemic Cerebral Injury in Rats.
    Drug research, 2016, Volume: 66, Issue:8

    Topics: Animals; Aspirin; Atorvastatin; Brain; Brain Ischemia; Catalase; Commiphora; Diet, High-Fat; Drug Th

2016
Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report.
    Minerva cardioangiologica, 2016, Volume: 64, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Humans; Rivaroxaban; Str

2016
Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population.
    Journal of neurology, 2016, Volume: 263, Issue:8

    Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; M

2016
Dual Antiplatelet Therapy in the Prevention of Recurrent Ischemic Events.
    Journal of the American College of Cardiology, 2016, 06-14, Volume: 67, Issue:23

    Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemia; Platelet Aggregation Inhibitor

2016
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
    Thrombosis research, 2016, Volume: 144

    Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopido

2016
PPM1A Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients.
    Stroke, 2016, Volume: 47, Issue:7

    Topics: Aspirin; Brain Ischemia; CpG Islands; DNA Methylation; Follow-Up Studies; Genetic Association Studie

2016
To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:10

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cardiovascular Agents; Disability Evaluation; Dise

2016
miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40.
    Journal of translational medicine, 2016, 07-13, Volume: 14, Issue:1

    Topics: Aspirin; Atherosclerosis; Brain Ischemia; CD40 Antigens; Cell Proliferation; Female; Flow Cytometry;

2016
Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:10

    Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Biomarkers; Blood Glucose; Blood Pressure; Br

2016
Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy.
    Acta pharmacologica Sinica, 2016, Volume: 37, Issue:11

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Asian People; Aspirin; ATP Binding Cassette Tr

2016
Statin and Aspirin Pretreatment Are Associated with Lower Neurological Deterioration and Platelet Activity in Patients with Acute Ischemic Stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Hyd

2017
Successful drug-coated balloon angioplasty and single anti-platelet therapy to treat an ischaemic stroke patient with haemorrhage and acute coronary syndrome.
    Acute cardiac care, 2016, Volume: 18, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Brain; Brain Ischemia; Coronary Angiography;

2016
Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen?
    The Journal of heart valve disease, 2016, Volume: 25, Issue:2

    Topics: Aged; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Blood Coagulation; Brain Ischemia; Femal

2016
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease.
    Texas Heart Institute journal, 2016, Volume: 43, Issue:6

    Topics: Aged; Aspirin; Brain Ischemia; Chi-Square Distribution; Disease-Free Survival; Drug Resistance; Fema

2016
Secondary Prevention of Childhood Arterial Ischemic Stroke.
    Journal of child neurology, 2017, Volume: 32, Issue:5

    Topics: Aspirin; Belgium; Brain Ischemia; Child; France; Guideline Adherence; Health Care Surveys; Humans; P

2017
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
    Journal of the neurological sciences, 2017, Feb-15, Volume: 373

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat

2017
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
    Clinical journal of the American Society of Nephrology : CJASN, 2017, 02-07, Volume: 12, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther

2017
Neuroprotective effect of triflusal and its main metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), in the postischemic brain.
    Neuroscience letters, 2017, 03-16, Volume: 643

    Topics: Animals; Anti-Inflammatory Agents; Aspirin; Brain; Brain Ischemia; Cytokines; Infarction, Middle Cer

2017
Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting.
    Postgraduate medical journal, 2017, Volume: 93, Issue:1103

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Brain Ischemia; Clopidogrel; Female; Genetic Varia

2017
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
    JAMA cardiology, 2017, 05-01, Volume: 2, Issue:5

    Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combinati

2017
Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases.
    Neurological research, 2008, Volume: 30, Issue:4

    Topics: Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Down-Regulation; Female; Humans; Lysophospholi

2008
Current practice of antithrombotic treatment in ischemic stroke: a survey among Hungarian neurologists.
    Ideggyogyaszati szemle, 2008, May-30, Volume: 61, Issue:5-6

    Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Prescriptions;

2008
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Chest, 2008, Volume: 133, Issue:6 Suppl

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici

2008
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.
    Arthritis and rheumatism, 2008, Aug-15, Volume: 59, Issue:8

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An

2008
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
    Atherosclerosis, 2009, Volume: 204, Issue:2

    Topics: Adult; Aged; Arachidonate Lipoxygenases; Aspirin; Brain Ischemia; Case-Control Studies; Cyclooxygena

2009
ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy.
    European journal of neurology, 2008, Volume: 15, Issue:12

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Dr

2008
Aspirin attenuates cerebral ischemic injury in diabetic rats.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2009, Volume: 117, Issue:4

    Topics: Animals; Aspirin; Blood Glucose; Brain Ischemia; Cerebral Infarction; Diabetes Mellitus, Experimenta

2009
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
    Journal francais d'ophtalmologie, 2008, Volume: 31, Issue:8

    Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary B

2008
High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cell Size; Female; Giant Cell Art

2009
Prevention strategies of cardioembolic ischemic stroke in Chagas' disease.
    Arquivos brasileiros de cardiologia, 2008, Volume: 91, Issue:5

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Chagas Cardiomyopathy; Epidemiologic Methods; Female; Hemor

2008
[Celiac disease and ischemic stroke].
    Revue neurologique, 2009, Volume: 165, Issue:11

    Topics: Adult; Aspirin; Brain Ischemia; Celiac Disease; Female; Humans; Platelet Aggregation Inhibitors; Str

2009
Resistance to acetylsalicylic acid in patients after ischemic stroke.
    Polskie Archiwum Medycyny Wewnetrznej, 2008, Volume: 118, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Drug Resistance; Female; H

2008
Facts and controversies of aspirin and clopidogrel therapy.
    American heart journal, 2009, Volume: 157, Issue:3

    Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dos

2009
Neuroprotective effects of Kangen-karyu on spatial memory impairment in an 8-arm radial maze and neuronal death in the hippocampal CA1 region induced by repeated cerebral ischemia in rats.
    Journal of pharmacological sciences, 2009, Volume: 109, Issue:3

    Topics: Animals; Aspirin; Brain Ischemia; Cell Death; Disease Models, Animal; Dose-Response Relationship, Dr

2009
[Guidelines for the general management of patients with acute ischemic stroke].
    Acta neurologica Taiwanica, 2008, Volume: 17, Issue:4

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Inpatients; Stroke; Taiwan; Ti

2008
Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin.
    Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Cerebral Arteries; Dipyridamole; Drug Therapy, Combination; Female; H

2009
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
    Annals of internal medicine, 2009, Mar-17, Volume: 150, Issue:6

    Topics: Age Factors; Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cost of Illness; Female; Gastro

2009
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients.
    Neurology, 2009, May-26, Volume: 72, Issue:21

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Follow-Up Stu

2009
Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients.
    Journal of the neurological sciences, 2009, Jun-15, Volume: 281, Issue:1-2

    Topics: Adolescent; Adult; Aged; Aspirin; Brain Ischemia; Female; Humans; Logistic Models; Male; Middle Aged

2009
Moyamoya disease in an 8-year-old boy presenting with weakness.
    Pediatric emergency care, 2009, Volume: 25, Issue:5

    Topics: Anti-Inflammatory Agents; Aspirin; Attention Deficit Disorder with Hyperactivity; Brain Ischemia; Ch

2009
Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
    Journal of the neurological sciences, 2009, Sep-15, Volume: 284, Issue:1-2

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; Fibrinol

2009
The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke.
    Acta neurologica Taiwanica, 2009, Volume: 18, Issue:2

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Drug Utilization; Female; Fibrinolytic Agents; Humans; Male; M

2009
Köhlmeier-Degos Disease (malignant atrophic papulosis) and neurologic involvement.
    Arquivos de neuro-psiquiatria, 2009, Volume: 67, Issue:3A

    Topics: Adult; Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Malignant Atrophic Papulosis; T

2009
Medical treatment of patients with intracranial atherosclerotic disease.
    Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2009, Volume: 19 Suppl 1

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb

2009
Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2010, Volume: 30, Issue:2

    Topics: Animals; Aspirin; Brain Ischemia; Cells, Cultured; Cerebrovascular Circulation; Cilostazol; Clopidog

2010
The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
    Journal of cardiovascular electrophysiology, 2010, Volume: 21, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Fibrinolytic Agents; Fol

2010
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
    Prescrire international, 2009, Volume: 18, Issue:104

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini

2009
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
    Stroke, 2010, Volume: 41, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh

2010
[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].
    Der Nervenarzt, 2010, Volume: 81, Issue:4

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Clopidogrel;

2010
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
    Current medical research and opinion, 2010, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema

2010
Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats.
    Human & experimental toxicology, 2011, Volume: 30, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Aspirin; Biphenyl Compounds; Brain I

2011
Is higher serum total cholesterol level associated with better long-term functional outcomes after noncardioembolic ischemic stroke?
    Archives of physical medicine and rehabilitation, 2010, Volume: 91, Issue:6

    Topics: Aged; Aspirin; Brain Ischemia; Cholesterol; Cohort Studies; Female; Fibrinolytic Agents; Follow-Up S

2010
Aspirin resistance and compliance with therapy.
    Cardiovascular therapeutics, 2011, Volume: 29, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Case-Control Studies;

2011
Treatment of acute ischemic stroke in patients with cerebral microbleeds: a decision analysis.
    QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:1

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Cerebral

2011
Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results.
    Stroke, 2010, Volume: 41, Issue:9

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; P

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
    Archives of internal medicine, 2010, Sep-13, Volume: 170, Issue:16

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com

2010
Is early antithrombotic therapy necessary after tissue mitral valve replacement?
    The Journal of heart valve disease, 2010, Volume: 19, Issue:4

    Topics: Aged; Aged, 80 and over; Animals; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Cattle; Ch

2010
Effect of enoxaparin and aspirin on hemodynamic disturbances after global cerebral ischemia in rats.
    Resuscitation, 2010, Volume: 81, Issue:12

    Topics: Animals; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Enoxaparin; Hemodynam

2010
[Reducing blood pressure, giving aspirin... What must (never) be done in V.a. stroke].
    MMW Fortschritte der Medizin, 2010, Oct-07, Volume: 152, Issue:40

    Topics: Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Heparin; Humans; Platelet Agg

2010
[New options in the therapeutic management of acute ischaemic stroke. Good results with combined i. v. and i. a. lysis and mechanical thrombectomy].
    Fortschritte der Neurologie-Psychiatrie, 2010, Volume: 78, Issue:11

    Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebral Angiography;

2010
[Aggregation activity of platelets in various periods of ischemic stroke].
    Kardiologiia, 2010, Volume: 50, Issue:8

    Topics: Aged; Aspirin; Blood Coagulation Disorders; Blood Coagulation Tests; Brain Ischemia; Female; Humans;

2010
Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels.
    Atherosclerosis, 2011, Volume: 214, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Down-Reg

2011
Aspirin non-responder status and early neurological deterioration: a prospective study.
    Clinical neurology and neurosurgery, 2011, Volume: 113, Issue:3

    Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Drug Resistance; Female; Humans; Male; Middle Aged; N

2011
Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
    Gender medicine, 2010, Volume: 7, Issue:6

    Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Blood Gluco

2010
Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors.
    American journal of therapeutics, 2012, Volume: 19, Issue:6

    Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Dose-Response Relationship

2012
Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan.
    Pharmacoepidemiology and drug safety, 2011, Volume: 20, Issue:3

    Topics: Aspirin; Brain Ischemia; Cross-Sectional Studies; Databases, Factual; Drug Prescriptions; Humans; In

2011
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
    JPMA. The Journal of the Pakistan Medical Association, 2010, Volume: 60, Issue:10

    Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-B

2010
Aspirin failure in patients presenting with acute cerebrovascular ischaemia.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:2

    Topics: Acute Disease; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Brain Ischemia; Drug Resistance;

2011
Apixaban in patients with atrial fibrillation.
    The New England journal of medicine, 2011, 06-16, Volume: 364, Issue:24

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemi

2011
Ischemic stroke in patients receiving aspirin.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Argentina; Aspirin; Brain Ischemia; Chi-Square Dis

2012
Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats.
    Stroke, 2011, Volume: 42, Issue:9

    Topics: Animals; Aspirin; Brain Ischemia; Cerebral Cortex; Cerebrovascular Circulation; Cilostazol; Endothel

2011
Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events.
    Stroke, 2011, Volume: 42, Issue:10

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Foramen Ovale, Patent;

2011
Acetylsalicylic acid, but not clopidogrel, inhibits therapeutically induced cerebral arteriogenesis in the hypoperfused rat brain.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2012, Volume: 32, Issue:1

    Topics: Animals; Aspirin; Brain Ischemia; Cell Line; Cerebral Angiography; Cerebrovascular Circulation; Chem

2012
Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Female; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio;

2013
Blind runner.
    Survey of ophthalmology, 2012, Volume: 57, Issue:5

    Topics: Adult; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Hum

2012
Low-molecular-weight heparin in atherosclerotic stroke: a surprising resurrection of anticoagulants?
    Stroke, 2012, Volume: 43, Issue:2

    Topics: Antifibrinolytic Agents; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Female; Humans; Intra

2012
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
    JAMA, 2011, Nov-16, Volume: 306, Issue:19

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure;

2011
Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Brain Ischemia; Clopidogrel; Dose-Response

2012
Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes.
    Journal of the neurological sciences, 2012, Apr-15, Volume: 315, Issue:1-2

    Topics: Adult; Aged; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporte

2012
Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Re

2013
Antiplatelet therapy for transient ischemic attack.
    Journal of clinical hypertension (Greenwich, Conn.), 2012, Volume: 14, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders;

2012
Clinical, neuroradiological and molecular features of a patient affected by pseudoxhantoma elasticum associated to carotid rete mirabile: case report.
    Clinical neurology and neurosurgery, 2012, Volume: 114, Issue:6

    Topics: Adult; Angiography, Digital Subtraction; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Artery D

2012
[Perioperative management of antiplatelet therapy in thoracic surgery. A survey of German hospitals].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2012, Volume: 83, Issue:6

    Topics: Arterial Occlusive Diseases; Aspirin; Attitude of Health Personnel; Brain Ischemia; Clopidogrel; Com

2012
[Management of acute ischemic stroke].
    Der Internist, 2012, Volume: 53, Issue:5

    Topics: Aspirin; Brain Ischemia; Decompressive Craniectomy; Humans; Stroke; Thrombolytic Therapy

2012
Trans fat, aspirin, and ischemic stroke in postmenopausal women.
    Annals of neurology, 2012, Volume: 72, Issue:5

    Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Confidence Intervals; Dietary Fats, Unsaturated; Fema

2012
Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke.
    Experimental neurology, 2012, Volume: 236, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Docosahexaenoic Acids; In

2012
Increase of toll-like receptor 4 but decrease of interleukin-8 mRNA expression among ischemic stroke patients under aspirin treatment.
    Clinical biochemistry, 2012, Volume: 45, Issue:16-17

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Female; Gene Expression Regu

2012
Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study.
    Lupus, 2012, Volume: 21, Issue:11

    Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Brain Ische

2012
Capsular warning syndrome caused by spontaneous middle cerebral artery dissection.
    CNS neuroscience & therapeutics, 2012, Volume: 18, Issue:8

    Topics: Angiography, Digital Subtraction; Aspirin; Atorvastatin; Brain Ischemia; Cerebral Angiography; Diffu

2012
Laboratory effect on platelet activity within 24 h of the first 300-mg oral dose of aspirin given in hospital during the acute phase of ischemic cerebral events.
    Cerebrovascular diseases (Basel, Switzerland), 2012, Volume: 33, Issue:6

    Topics: Acute Disease; Administration, Oral; Aged; Aspirin; Blood Platelets; Brain Ischemia; Female; Humans;

2012
Optimal platelet inhibition following acute ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2012, Volume: 33, Issue:6

    Topics: Aspirin; Brain Ischemia; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors

2012
Obesity and intracranial in-stent thrombosis.
    Journal of neurointerventional surgery, 2013, Sep-01, Volume: 5, Issue:5

    Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Aspirin; Body Mass Index; Brain Ischemia; C

2013
Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques.
    Journal of neurosurgery, 2012, Volume: 117, Issue:5

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combina

2012
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2013, Volume: 22, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br

2013
[Postoperative cortical blindness after right upper lung lobectomy].
    Revista espanola de anestesiologia y reanimacion, 2012, Volume: 59, Issue:3

    Topics: Anticoagulants; Aspirin; Blindness, Cortical; Brain Ischemia; Cerebellum; Cerebral Angiography; Colo

2012
Symptomatic patients with intraluminal carotid artery thrombus: outcome with a strategy of initial anticoagulation.
    Journal of neurosurgery, 2013, Volume: 118, Issue:1

    Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Artery Thrombosis; C

2013
Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia.
    Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:7

    Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Brain Ischemia; Drug Resistance; Female; Hum

2013
Guidelines for acute ischemic stroke treatment: part II: stroke treatment.
    Arquivos de neuro-psiquiatria, 2012, Volume: 70, Issue:11

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation

2012
Timing and mechanism of ischemic stroke due to extracranial blunt traumatic cerebrovascular injury.
    Journal of neurosurgery, 2013, Volume: 118, Issue:2

    Topics: Adult; Angiography, Digital Subtraction; Aspirin; Brain Ischemia; Cerebral Angiography; Cerebral Art

2013
Quality of acute ischemic stroke care in Thailand: a prospective multicenter countrywide cohort study.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Chi-Square Distribution; Combined Modality Therapy; D

2014
The influence of anti-platelet resistance on the development of cerebral ischemic lesion after carotid artery stenting.
    Yonsei medical journal, 2013, Mar-01, Volume: 54, Issue:2

    Topics: Aged; Aspirin; Brain Ischemia; Carotid Arteries; Drug Resistance; Female; Humans; Male; Middle Aged;

2013
Aspirin versus low-molecular-weight heparin for ischemic stroke in children: an unanswered question.
    Stroke, 2002, Volume: 33, Issue:8

    Topics: Aspirin; Brain Ischemia; Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Feasibil

2002
Time lag to diagnosis of stroke in children.
    Pediatrics, 2002, Volume: 110, Issue:5

    Topics: Adolescent; Age Factors; Aspirin; Brain Ischemia; Child; Emergency Medical Services; Episode of Care

2002
[Acetylsalicylic acid and ACE inhibitors in heart disease--a phenomenon in dogs and cats?].
    Vnitrni lekarstvi, 2002, Volume: 48, Issue:8

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Brain Ischemia; Drug Interactions; Human

2002
Ischaemic stroke in young people: a prospective and long-term follow-up study.
    Cerebrovascular diseases (Basel, Switzerland), 2003, Volume: 15, Issue:1-2

    Topics: Acenocoumarol; Adolescent; Adult; Anticoagulants; Aspirin; Brain Ischemia; Disability Evaluation; Ec

2003
[Neuroprotection by aspirin in cerebrovascular pathology].
    Anales de la Real Academia Nacional de Medicina, 2002, Volume: 119, Issue:2

    Topics: Adenosine Triphosphate; Algorithms; Amino Acid Transport System X-AG; Animals; Aspirin; Brain Ischem

2002
Smoking and the risk of hemorrhagic stroke in men.
    Stroke, 2003, Volume: 34, Issue:5

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Body Mass Ind

2003
Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.
    Stroke, 2003, Volume: 34, Issue:6

    Topics: Anticoagulants; Arterial Occlusive Diseases; Asia, Southeastern; Aspirin; Brain Ischemia; Dipyridamo

2003
Editorial comment: Low-dose or moderate-dose anticoagulation: dream or hope for stroke prevention?
    Stroke, 2003, Volume: 34, Issue:6

    Topics: Administration, Oral; Anticoagulants; Aspirin; Brain Ischemia; Clinical Trials as Topic; Dose-Respon

2003
Anti-beta2-glycoprotein I antibodies and ischemic stroke in a 20-month-old boy.
    Pediatrics, 2003, Volume: 112, Issue:1 Pt 1

    Topics: Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoantibodies; Bas

2003
Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome.
    Neurology, 2003, Jul-08, Volume: 61, Issue:1

    Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Brain Ischemia; Female; Follow-Up Studies

2003
Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke.
    Stroke, 2003, Volume: 34, Issue:10

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cohort Stu

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    The New England journal of medicine, 2003, Sep-11, Volume: 349, Issue:11

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2003
ESPRIT: safety and efficacy of oral anticoagulation--a rebuttal.
    Stroke, 2003, Volume: 34, Issue:10

    Topics: Administration, Oral; Anticoagulants; Aspirin; Brain Ischemia; Humans; International Normalized Rati

2003
Acetylsalicylic acid reduces perfusion deficit in ischemic injured brain in rats.
    Neuroreport, 2003, Sep-15, Volume: 14, Issue:13

    Topics: Animals; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Disease Models, Animal; Fibrinolytic

2003
Should I start all my ischaemic stroke and TIA patients on a statin, an ACE inhibitor, a diuretic, and aspirin today?
    Journal of neurology, neurosurgery, and psychiatry, 2003, Volume: 74, Issue:11

    Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Brain Ischemia; Humans; Hydroxymethylglutaryl-CoA

2003
[Protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion in rats].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2003, Volume: 38, Issue:8

    Topics: Animals; Aspirin; Brain Ischemia; Disease Models, Animal; Epoprostenol; Male; Malondialdehyde; Neuro

2003
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
    Stroke, 2003, Volume: 34, Issue:12

    Topics: Antigens, CD; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Clopidogrel; Cross-Over Studies;

2003
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
    Stroke, 2004, Volume: 35, Issue:2

    Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitaliz

2004
High-dose aspirin is neuroprotective in a rat focal ischemia model.
    Brain research, 2004, Feb-20, Volume: 998, Issue:2

    Topics: Animals; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Male; Neuroprotective Agents; Ra

2004
Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke.
    Platelets, 2004, Volume: 15, Issue:1

    Topics: Adenosine Diphosphate; Aged; Anticoagulants; Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia;

2004
[Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice].
    Deutsche medizinische Wochenschrift (1946), 2004, Mar-19, Volume: 129, Issue:12

    Topics: Adult; Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Arteries; Clopidogrel; Drug The

2004
[Management of stroke in a ward of internal medicine. Limits and prospects].
    Recenti progressi in medicina, 2004, Volume: 95, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia;

2004
Risk factors and in-hospital outcomes in stroke and myocardial infarction patients.
    BMC public health, 2004, Jul-05, Volume: 4

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Croa

2004
There is no evidence that the benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
    Stroke, 2004, Volume: 35, Issue:10

    Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Pro

2004
Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack.
    British journal of haematology, 2004, Volume: 126, Issue:6

    Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Cell Size; Dose-Response Relationship, Drug; Female;

2004
Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.
    Neurology, 2004, Sep-14, Volume: 63, Issue:5

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biomarkers; Brain Infarction; Brain Ischemia; Coho

2004
Antiplatelet drug discontinuation is a risk factor for ischemic stroke.
    Neurology, 2004, Nov-09, Volume: 63, Issue:9

    Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stroke

2004
Ischaemic stroke in progressive systemic sclerosis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2004, Volume: 25, Issue:4

    Topics: Aspirin; Brain Ischemia; Dysarthria; Female; Humans; Infarction, Middle Cerebral Artery; Magnetic Re

2004
[Effects of aspirin on lowering plasma level of lysophosphatidic acid in cerebral ischemic patients].
    Zhonghua yi xue za zhi, 2004, Nov-17, Volume: 84, Issue:22

    Topics: Aged; Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Infant; Lysophospholipids; Male;

2004
Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
    The American journal of medicine, 2005, Volume: 118, Issue:2

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Peripheral Vascular

2005
Prevalence of aspirin resistance measured by PFA-100.
    International journal of cardiology, 2005, May-11, Volume: 101, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Cross-Sectional Studies; Drug Resistance; Female; Humans; Male; Middl

2005
Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke.
    The American journal of geriatric pharmacotherapy, 2004, Volume: 2, Issue:4

    Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Follow-Up S

2004
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
    Stroke, 2005, Volume: 36, Issue:7

    Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex

2005
Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units.
    Scottish medical journal, 2005, Volume: 50, Issue:2

    Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Brain Ischemia; Chemopre

2005
Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats.
    Neurological research, 2005, Volume: 27, Issue:5

    Topics: Animals; Antioxidants; Antipyrine; Aspirin; bcl-2-Associated X Protein; Blotting, Western; Brain Ede

2005
Clinical trials in giant cell arteritis.
    Current rheumatology reports, 2005, Volume: 7, Issue:4

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dose-Response Relationship, Drug; Giant Cell Arte

2005
Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke.
    Archives of neurology, 2005, Volume: 62, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Coronary Artery Disea

2005
Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
    Prescrire international, 2005, Volume: 14, Issue:78

    Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemo

2005
[Prophylaxis of stroke].
    Praxis, 2005, Jul-27, Volume: 94, Issue:30-31

    Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi

2005
Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100.
    Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:4

    Topics: Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clinical Trials

2005
Stroke following Glenn anastomosis in a child with inherited thrombophilia.
    International journal of cardiology, 2006, Aug-28, Volume: 111, Issue:3

    Topics: Anastomosis, Surgical; Aspirin; Brain Ischemia; Child, Preschool; Fibrinolytic Agents; Heart Bypass,

2006
Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage.
    Neurology, 2005, Oct-11, Volume: 65, Issue:7

    Topics: Administration, Oral; Aged; Aspirin; Brain Ischemia; Causality; Cerebral Arteries; Cerebral Hemorrha

2005
Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress.
    Pathophysiology of haemostasis and thrombosis, 2005, Volume: 34, Issue:1

    Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Age Factors; Aged; Aspirin; Blood Platelets; Brain Ischemia;

2005
Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2.
    Stroke, 2006, Volume: 37, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Male; Middle

2006
Rebound inflammation and the risk of ischemic stroke after discontinuation of aspirin therapy.
    Archives of neurology, 2006, Volume: 63, Issue:2

    Topics: Aspirin; Brain Ischemia; C-Reactive Protein; Humans; Inflammation; Platelet Aggregation Inhibitors;

2006
Adherence to aspirin in secondary prevention of ischemic stroke.
    Cerebrovascular diseases (Basel, Switzerland), 2006, Volume: 21, Issue:5-6

    Topics: Adult; Aged; Ambulatory Care; Aspirin; Brain Ischemia; Female; Follow-Up Studies; Health Care Survey

2006
The risks and safety of clopidogrel in pediatric arterial ischemic stroke.
    Stroke, 2006, Volume: 37, Issue:4

    Topics: Adolescent; Aspirin; Brain Ischemia; Child; Child, Preschool; Clopidogrel; Cohort Studies; Drug Ther

2006
Effects of aspirin plus alpha-tocopherol on brain slices damage after hypoxia-reoxygenation in rats with type 1-like diabetes mellitus.
    Neuroscience letters, 2006, Jun-12, Volume: 400, Issue:3

    Topics: alpha-Tocopherol; Animals; Antioxidants; Aspirin; Brain Ischemia; Cells, Cultured; Diabetes Mellitus

2006
High prevalence of previous antiplatelet drug use in patients with new or recurrent ischemic stroke: Buffalo metropolitan area and Erie County stroke study.
    Pharmacotherapy, 2006, Volume: 26, Issue:4

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Hospitaliz

2006
Dipyridamole plus aspirin: the best regimen for stroke prevention after noncardioembolic focal cerebral ischemia.
    Cerebrovascular diseases (Basel, Switzerland), 2006, Volume: 22, Issue:1

    Topics: Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Human

2006
Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis.
    Neurology, 2006, May-09, Volume: 66, Issue:9

    Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Comorbidity; Disease Progression; Double-Blind Method

2006
Dissection of cervical arteries: Long-term follow-up study of 130 consecutive cases.
    Cerebrovascular diseases (Basel, Switzerland), 2006, Volume: 22, Issue:2-3

    Topics: Adult; Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Humans

2006
Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease.
    The Journal of laboratory and clinical medicine, 2006, Volume: 147, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Collagen; Dose-Response Re

2006
Previous use of aspirin and baseline stroke severity: an analysis of 17,850 patients in the International Stroke Trial.
    Stroke, 2006, Volume: 37, Issue:7

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Infarction; Cohort Studies; Confounding Factors, Epid

2006
Long-term outcome in patients with cervical-artery dissections: There is still a lot to know.
    Cerebrovascular diseases (Basel, Switzerland), 2006, Volume: 22, Issue:2-3

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Humans; Platelet Aggr

2006
Enhanced platelet activation by prolactin in patients with ischemic stroke.
    Thrombosis and haemostasis, 2006, Volume: 96, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Ischemic Attack, Tran

2006
ESPRIT trial.
    Lancet (London, England), 2006, Aug-05, Volume: 368, Issue:9534

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Dipyridamole; Drug Interactions; G

2006
ESPRIT trial.
    Lancet (London, England), 2006, Aug-05, Volume: 368, Issue:9534

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Dose

2006
Viscosity, hemostasis and inflammation in atherosclerotic heart diseases.
    Clinical hemorheology and microcirculation, 2006, Volume: 35, Issue:1-2

    Topics: Aged; Aspirin; Blood Viscosity; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Diabetes Compl

2006
The significance of incomplete stent apposition in patients undergoing stenting of internal carotid artery stenosis.
    AJNR. American journal of neuroradiology, 2006, Volume: 27, Issue:7

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Arteries; Carotid St

2006
Does prior aspirin use reduce stroke mortality?
    The neurologist, 2006, Volume: 12, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female; Fibrinolytic A

2006
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
    Arthritis and rheumatism, 2006, Volume: 54, Issue:10

    Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Dose-

2006
Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2007, Volume: 27, Issue:6

    Topics: Animals; Antioxidants; Aspirin; Benzoates; Brain Ischemia; Cells, Cultured; Excitatory Amino Acid An

2007
Clinical trials and dipyridamole formulation selection.
    Cerebrovascular diseases (Basel, Switzerland), 2007, Volume: 23, Issue:1

    Topics: Aspirin; Brain Ischemia; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dipyridamole; Drug

2007
Effects of triflusal and aspirin in a rat model of cerebral ischemia.
    Stroke, 2007, Volume: 38, Issue:2

    Topics: Animals; Aspirin; Brain Ischemia; Disease Models, Animal; Drug Therapy, Combination; Male; Rats; Rat

2007
Emerging therapies: ESPRIT.
    Stroke, 2007, Volume: 38, Issue:4

    Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Dipyridamole; Drug Therapy,

2007
TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents.
    Current neurovascular research, 2007, Volume: 4, Issue:1

    Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Cells, Cultured; Clopidogrel; Dipyridamole; Fem

2007
Interaction between magnesium sulfate and acetylsalicylic acid in the MASH trial.
    Stroke, 2007, Volume: 38, Issue:5

    Topics: Aspirin; Brain Ischemia; Central Nervous System Agents; Drug Interactions; Humans; Magnesium Sulfate

2007
[The management of stroke in Phnom Penh, Cambodia].
    Bulletin de la Societe de pathologie exotique (1990), 2007, Volume: 100, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Calcium Channe

2007
Cerebral ischemia probably related to isotretinoin.
    The Annals of pharmacotherapy, 2007, Volume: 41, Issue:6

    Topics: Adult; Aspirin; Brain Ischemia; Dermatologic Agents; Dipyridamole; Heparin; Humans; Isotretinoin; Ma

2007
dl-3n-butylphthalide prevents stroke via improvement of cerebral microvessels in RHRSP.
    Journal of the neurological sciences, 2007, Sep-15, Volume: 260, Issue:1-2

    Topics: Animals; Aspirin; Benzofurans; Brain; Brain Ischemia; Cerebral Arteries; Cerebrovascular Circulation

2007
Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats.
    Methods and findings in experimental and clinical pharmacology, 2007, Volume: 29, Issue:4

    Topics: Animals; Antioxidants; Aspirin; Brain Ischemia; Disease Models, Animal; Drug Therapy, Combination; E

2007
Ischemic stroke and peripheral arterial thromboembolism in a patient with Crohn's disease: a case presentation.
    Journal of the neurological sciences, 2008, Mar-15, Volume: 266, Issue:1-2

    Topics: Anticoagulants; Aspirin; Blood Cell Count; Blood Coagulation; Bone Marrow; Brain Ischemia; Crohn Dis

2008
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
    Ugeskrift for laeger, 2007, Oct-01, Volume: 169, Issue:40

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents;

2007
Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.
    Acta neurologica Scandinavica, 2008, Volume: 117, Issue:4

    Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Electronic Data Processing; Female; Humans; Ischemic

2008
Can aspirin resistance be clinically predicted in stroke patients?
    Clinical neurology and neurosurgery, 2008, Volume: 110, Issue:2

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Cohort Studies; Drug Resistance; Female; Humans; Male; Middle

2008
Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia.
    Experimental neurology, 2008, Volume: 210, Issue:2

    Topics: Analysis of Variance; Animals; Aspirin; Brain Ischemia; Cerebral Infarction; Disease Models, Animal;

2008
Comment on "hyperresponsiveness of platelets in ischemic stroke" by Fateh-Moghadam et al.
    Thrombosis and haemostasis, 2008, Volume: 99, Issue:1

    Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Epine

2008
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
    Stroke, 2008, Volume: 39, Issue:5

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru

2008
The balance between stroke prevention and bleeding risk in atrial fibrillation: a delicate balance revisited.
    Stroke, 2008, Volume: 39, Issue:5

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation Factors; Brain Ischemia; Cerebral He

2008
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
    Ugeskrift for laeger, 2008, Mar-31, Volume: 170, Issue:14

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin;

2008
Cilostazol shows promise as an alternative to aspirin for patients with ischaemic stroke.
    The Lancet. Neurology, 2008, Volume: 7, Issue:6

    Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Data Interpretation, Statistical; Dose-Res

2008
Effects of an electrical field and its polarity on an abnormal part of the body or organ representation point associated with a diseased internal organ, and its influence on the Bi-Digital O-Ring Test (simple, non-invasive dysfunction localization method)
    Acupuncture & electro-therapeutics research, 1982, Volume: 7, Issue:4

    Topics: Acupuncture Therapy; Adult; Aspirin; Brain Ischemia; Child; Coronary Disease; Electric Stimulation T

1982
[Current status of medical treatment].
    Minerva medica, 1980, Jul-31, Volume: 71, Issue:29

    Topics: Aminophylline; Animals; Anticoagulants; Aspirin; Barbiturates; Brain Ischemia; Cerebrovascular Disor

1980
Treatment of cerebral ischemia.
    Comprehensive therapy, 1981, Volume: 7, Issue:4

    Topics: Aspirin; Brain Ischemia; Carotid Arteries; Dicumarol; Dipyridamole; Endarterectomy; Heart Murmurs; H

1981
Diagnosis and management of ischemic stroke. Part I.--Threatened stroke and its management.
    Current problems in cardiology, 1983, Volume: 8, Issue:5

    Topics: Anticoagulants; Arrhythmias, Cardiac; Aspirin; Brain Ischemia; Carotid Artery Thrombosis; Cerebral A

1983
Changes of the levels of antithrombin III in patients with cerebrovascular diseases.
    Thrombosis research, 1983, Jul-15, Volume: 31, Issue:2

    Topics: Adult; Aged; Antithrombin III; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorde

1983
Role of propranolol and aspirin in decreasing platelet aggregation in occlusive cerebrovascular diseases.
    The Journal of the Association of Physicians of India, 1983, Volume: 31, Issue:9

    Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation; Platelet Count; Propranolol

1983
[Optimal dose of aspirin in ischemic cerebrovascular disorders].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1983, Volume: 72, Issue:11

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Female; Humans; Male; Middle Aged; Platelet Aggregation

1983
[Preventive medical treatment of cerebral ischemic accidents related to atherosclerosis].
    La Revue du praticien, 1984, Apr-12, Volume: 34, Issue:21 Pt 2

    Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Female; Humans; Hypertension; Male; Middle Aged; Platelet

1984
[Fibrinolytic agents, anticoagulants and anti-platelet agents in the management of ischemic cerebrovascular disorders].
    Nihon rinsho. Japanese journal of clinical medicine, 1982, Volume: 40, Issue:10

    Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Endopeptidases; Humans; Ischemic Attack, Transie

1982
Platelet aggregation in focal cerebral ischemia -a clinical study.
    Acta neurologica Scandinavica, 1982, Volume: 65, Issue:3

    Topics: Adult; Aged; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male

1982
[Platelet function inhibition and anticoagulation in coronary, cerebral and peripheral arterial occlusive disease. 2. Secondary prevention].
    Fortschritte der Medizin, 1982, May-13, Volume: 100, Issue:18

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; M

1982
[Anti-platelet aggregation therapy and ischaemic cerebral accidents due to atheroma (author's transl)].
    La Nouvelle presse medicale, 1982, May-01, Volume: 11, Issue:20

    Topics: Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; Humans; Platelet Aggregation

1982
[Cerebral ischemia as a complication of mitral valve prolapse].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1982, Nov-10, Volume: 102, Issue:31

    Topics: Adult; Anticoagulants; Aspirin; Brain Ischemia; Female; Humans; Male; Mitral Valve Prolapse

1982
Platelet hyperaggregability in ischemic cerebrovascular disease and effects of aspirin.
    Thrombosis and haemostasis, 1982, Oct-29, Volume: 48, Issue:2

    Topics: Arteries; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Humans; Ischemic Attack, Transi

1982
Therapy of ischemic cerebrovascular disease.
    Annals of internal medicine, 1980, Volume: 93, Issue:5

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Arteries; Cerebrovascular Disorders; Endarterectomy

1980
[Ischemic cerebro-vascular accidents: usefulness of anticoagulant and antiaggregating agents (author's transl)].
    Revue medicale de Bruxelles, 1981, Volume: 2, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Humans; Plat

1981
Shortened megakaryocyte-platelet regeneration time in patients with ischemic cerebrovascular disease.
    Thrombosis research, 1981, Mar-15, Volume: 21, Issue:6

    Topics: Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Humans; Megakaryocytes;

1981
Platelet aggregation induced by arachidonic acid and thromboxane generation in patients with hypertension or cerebrovascular disease.
    Prostaglandins and medicine, 1981, Volume: 7, Issue:6

    Topics: Adolescent; Adult; Aged; Arachidonic Acids; Aspirin; Blood Platelets; Brain Ischemia; Female; Humans

1981
[Multicenter studies in the USA and Canada: thrombocyte function inhibitor in ischemic cerebrovascular diseases].
    Lakartidningen, 1980, Jan-30, Volume: 77, Issue:5

    Topics: Aspirin; Blood Platelets; Brain Ischemia; Canada; Female; Humans; Male; Sulfinpyrazone; United State

1980
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
    Minerva cardioangiologica, 1980, Volume: 28, Issue:10

    Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human

1980
US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices.
    Stroke, 1995, Volume: 26, Issue:9

    Topics: Aspirin; Attitude of Health Personnel; Brain Ischemia; Carotid Arteries; Cerebral Angiography; Cereb

1995
Essential thrombocytemia and ischemic stroke: report of six cases.
    Italian journal of neurological sciences, 1994, Volume: 15, Issue:7

    Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Magnetic Resonance Imaging

1994
Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
    Journal of neurosurgery, 1995, Volume: 82, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Cerebral Infarction; Female

1995
Childhood stroke at three years of age with transient protein C deficiency, familial antiphospholipid antibodies and F. XII deficiency--a family study.
    Neuropediatrics, 1994, Volume: 25, Issue:6

    Topics: Antibodies, Antiphospholipid; Aspirin; Basal Ganglia; Brain Ischemia; Child, Preschool; Diagnosis, D

1994
Amaurosis fugax: prognosis and the role of acetylsalicylic acid.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 1994, Volume: 29, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Blindness; Brain Ischemia; Cerebrovascular Disorders; Female; Foll

1994
Effects of viscosity and oxygen content on cerebral blood flow in ischemic and normal rat brain.
    Journal of the neurological sciences, 1994, Volume: 124, Issue:1

    Topics: Animals; Aspirin; Autoradiography; Blood Volume; Brain Chemistry; Brain Ischemia; Cerebrovascular Ci

1994
Development of aspirin resistance in persons with previous ischemic stroke.
    Stroke, 1994, Volume: 25, Issue:12

    Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular D

1994
Diaspirin crosslinked hemoglobin (DCLHb): effect of hemodilution during focal cerebral ischemia in rats.
    Artificial cells, blood substitutes, and immobilization biotechnology, 1994, Volume: 22, Issue:3

    Topics: Animals; Aspirin; Blood Substitutes; Blood Volume; Brain Ischemia; Cerebral Infarction; Cerebrovascu

1994
Safety of combination aspirin and anticoagulation in acute ischemic stroke.
    The Annals of pharmacotherapy, 1994, Volume: 28, Issue:4

    Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Stud

1994
[20,000 kg aspirin and 45 pages British Medical Journal].
    Nederlands tijdschrift voor geneeskunde, 1994, May-14, Volume: 138, Issue:20

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Coronary Disease; Hu

1994
Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability?
    Stroke, 1994, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Disorders; Brain Ischemia; Cerebral Infar

1994
Effect of anti-platelet therapy (aspirin + pentoxiphylline) on plasma lipids in patients of ischaemic stroke.
    Indian journal of physiology and pharmacology, 1993, Volume: 37, Issue:2

    Topics: Adult; Aged; Aspirin; Blood Chemical Analysis; Brain Ischemia; Drug Therapy, Combination; Female; Hu

1993
Effect of policosanol on cerebral ischemia in Mongolian gerbils: role of prostacyclin and thromboxane A2.
    Prostaglandins, leukotrienes, and essential fatty acids, 1993, Volume: 49, Issue:3

    Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Brain Ischemia; Drug Synergism; Epoprostenol; Fatty

1993
Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.
    Stroke, 1994, Volume: 25, Issue:2

    Topics: Adult; Age Factors; Aged; Analysis of Variance; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female

1994
Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators.
    Neurology, 1993, Volume: 43, Issue:1

    Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Male;

1993
Focal cerebral ischemia in rats. Effect of hypervolemic hemodilution with diaspirin cross-linked hemoglobin versus albumin on brain injury and edema.
    Anesthesiology, 1993, Volume: 78, Issue:2

    Topics: Albumins; Animals; Aspirin; Brain Edema; Brain Injuries; Brain Ischemia; Cross-Linking Reagents; Hem

1993
Ischemic stroke, Part 2: Optimal treatment and prevention.
    Geriatrics, 1993, Volume: 48, Issue:3

    Topics: Aged; Aspirin; Brain Edema; Brain Ischemia; Cerebral Infarction; Heparin; Humans; Recurrence; Risk F

1993
[Myocardial infarction and cerebrovascular accident complicating papillary elastofibroma of the mitral valve].
    Presse medicale (Paris, France : 1983), 1995, Oct-14, Volume: 24, Issue:30

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Fibroma; Heart Neoplasms; He

1995
Low-molecular-weight heparin for the treatment of acute ischemic stroke.
    The New England journal of medicine, 1996, May-23, Volume: 334, Issue:21

    Topics: Acute Disease; Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Nadroparin; Platelet Aggregatio

1996
Effect of KBT-3022, a new cyclooxygenase inhibitor, on experimental brain edema in vitro and in vivo.
    European journal of pharmacology, 1996, Feb-22, Volume: 297, Issue:3

    Topics: Animals; Arachidonic Acid; Aspirin; Brain; Brain Edema; Brain Ischemia; Cyclooxygenase Inhibitors; G

1996
[Stroke in young people].
    Revista de neurologia, 1996, Volume: 24, Issue:126

    Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Child; Dipyridamole; Female; Humans; Male; Middle Aged;

1996
[Antiaggregant treatment for cerebral ischemia: ticlopidine versus aspirin].
    Revista de neurologia, 1996, Volume: 24, Issue:126

    Topics: Aged; Aspirin; Brain Ischemia; Carotid Arteries; Female; Humans; Male; Platelet Aggregation Inhibito

1996
US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke. Medical therapy in patients with carotid artery stenosis.
    Stroke, 1996, Volume: 27, Issue:9

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Cerebrovascular Disorders; Data Collectio

1996
CAPRIE trial.
    Lancet (London, England), 1997, Feb-01, Volume: 349, Issue:9048

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P

1997
CAPRIE trial.
    Lancet (London, England), 1997, Feb-01, Volume: 349, Issue:9048

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P

1997
CAPRIE trial.
    Lancet (London, England), 1997, Feb-01, Volume: 349, Issue:9048

    Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Costs; Humans; Platelet Aggregation Inhibitors; Randomize

1997
Early outcome in acute ischemic stroke is not influenced by the prophylactic use of low-dose aspirin.
    Journal of the neurological sciences, 1997, Volume: 145, Issue:1

    Topics: Aged; Aspirin; Brain Ischemia; Cause of Death; Cerebral Hemorrhage; Cerebrovascular Disorders; Femal

1997
[Dosage of acetylsalicylic acid in cerebral ischemia].
    Der Internist, 1997, Volume: 38, Issue:3

    Topics: Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Pla

1997
Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals.
    Neurology, 1997, Volume: 48, Issue:6

    Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia

1997
[Anticoagulation in cerebral ischemia?].
    Ugeskrift for laeger, 1997, May-19, Volume: 159, Issue:21

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Brain Ischemia; Humans

1997
Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
    Journal of the neurological sciences, 1997, Sep-01, Volume: 150, Issue:1

    Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Humans; Platelet Aggregation Inhib

1997
Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study.
    Neurological research, 1997, Volume: 19, Issue:4

    Topics: Aged; Angina Pectoris; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Studies; Female; F

1997
Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial.
    Lancet (London, England), 1997, Aug-09, Volume: 350, Issue:9075

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Hemorrhage; Heparin; Humans; Platelet Aggregation Inhibitor

1997
Does daily aspirin diminish severity of first-ever stroke?
    Archives of neurology, 1997, Volume: 54, Issue:11

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Case-Cont

1997
Thrombolytic therapy as early management of ischemic stroke.
    American family physician, 1998, Jan-01, Volume: 57, Issue:1

    Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Fibrinolytic

1998
Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocyt
    Circulation, 1998, Feb-03, Volume: 97, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders;

1998
Differences in medical and surgical therapy for stroke prevention between leading experts in North America and Western Europe.
    Stroke, 1998, Volume: 29, Issue:2

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Endar

1998
[Acetylsalicylic acid in ischemic insult].
    Deutsche medizinische Wochenschrift (1946), 1998, Feb-27, Volume: 123, Issue:9

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Myocardial Infarction; P

1998
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
    Clinical therapeutics, 1998, Volume: 20 Suppl B

    Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa

1998
[Neuroprotective action of aspirin].
    Anales de la Real Academia Nacional de Medicina, 1997, Volume: 114, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Brain Ischemia; Cerebrovascular Di

1997
Subarachnoid molecular hemoglobin after subarachnoid hemorrhage in rats: effect on the area of hypoperfusion.
    Journal of neurosurgical anesthesiology, 1998, Volume: 10, Issue:3

    Topics: Analysis of Variance; Anesthetics, Inhalation; Animals; Antipyrine; Aspirin; Blood; Blood Substitute

1998
Detection of microemboli distal to cerebral aneurysms before and after therapeutic embolization.
    AJNR. American journal of neuroradiology, 1998, Volume: 19, Issue:7

    Topics: Aneurysm; Anticoagulants; Aspirin; Basilar Artery; Brain Ischemia; Carotid Artery Diseases; Carotid

1998
Antipyretic therapy in acute stroke.
    Lancet (London, England), 1998, Aug-29, Volume: 352, Issue:9129

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Heparin; Humans; Pr

1998
NSA supports low-dose aspirin.
    The Nurse practitioner, 1999, Volume: 24, Issue:2

    Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; United States; United States Food

1999
Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin.
    Journal of neurology, neurosurgery, and psychiatry, 1999, Volume: 66, Issue:2

    Topics: Aspirin; Brain Ischemia; Humans; Meta-Analysis as Topic; Risk

1999
Treatment of acute ischemic stroke: where are we?
    Neurologia (Barcelona, Spain), 1999, Volume: 14, Issue:1

    Topics: Animals; Aspirin; Brain Damage, Chronic; Brain Ischemia; Calcium Channel Blockers; Cerebral Hemorrha

1999
Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysis.
    PharmacoEconomics, 1997, Volume: 12, Issue:6

    Topics: Aspirin; Brain Ischemia; Costs and Cost Analysis; Dipyridamole; Health Care Costs; Humans

1997
Craniofacial pain followed by scalp necrosis and stroke. An unusual presentation of the primary antiphospholipid syndrome.
    Journal of neurology, 1999, Volume: 246, Issue:2

    Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D

1999
Neuroprotective effects of acetylsalicylic acid in an animal model of focal brain ischemia.
    Neuroreport, 1999, Feb-05, Volume: 10, Issue:2

    Topics: Animals; Aspirin; Brain; Brain Ischemia; Cerebral Infarction; Male; Neuroprotective Agents; Rats; Ra

1999
Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone?
    Journal of neurology, neurosurgery, and psychiatry, 1999, Volume: 66, Issue:5

    Topics: Aspirin; Brain Ischemia; Cerebral Arteries; Humans

1999
Aspirin reduces experimental cerebral blood flow in vivo.
    Neurological research, 1999, Volume: 21, Issue:5

    Topics: Animals; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Depression, Chemical; Female; Male; R

1999
Comparison of standard and alternative prehospital resuscitation in uncontrolled hemorrhagic shock and head injury.
    The Journal of trauma, 1999, Volume: 47, Issue:5

    Topics: Animals; Aspirin; Blood Substitutes; Brain Injuries; Brain Ischemia; Cerebrovascular Circulation; Em

1999
Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone.
    Journal of neurology, neurosurgery, and psychiatry, 1999, Volume: 67, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Brain Ischemia; Humans; Secondary Preventio

1999
Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone.
    Journal of neurology, neurosurgery, and psychiatry, 1999, Volume: 67, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Brain Ischemia; Enzyme Inhibitors; Humans;

1999
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
    The American journal of medicine, 1999, Volume: 107, Issue:6

    Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; C

1999
Does prior use of aspirin affect outcome in ischemic stroke?
    The American journal of medicine, 2000, Feb-15, Volume: 108, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Female; Humans; Male; Middle

2000
Ask the doctor. Recently I read that aspirin can actually increase a person's risk for a stroke by causing bleeding in the brain. I have atrial fibrillation and my doctor wants me to take a blood thinner - if not warfarin, then at least aspirin. I've alre
    Harvard heart letter : from Harvard Medical School, 2000, Volume: 11, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Humans; Platelet Aggregation Inhi

2000
Alert to physicians: possible interaction of aggrenox and adenosine.
    Journal of the American College of Cardiology, 2000, Volume: 36, Issue:4

    Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action Preparati

2000
Systemic lupus erythematosus associated with moyamoya syndrome.
    Lupus, 2000, Volume: 9, Issue:8

    Topics: Adolescent; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Artery, Internal; Carotid Stenos

2000
Which patients with an ischemic stroke are likely to be helped or harmed by early aspirin treatment?
    The Journal of family practice, 2000, Volume: 49, Issue:10

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Humans; Randomized Controlle

2000
Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
    Stroke, 2001, Volume: 32, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Pressure; Brain Ischemia; Ce

2001
Heparin and aspirin in stroke.
    Lancet (London, England), 2001, Jan-20, Volume: 357, Issue:9251

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Heparin, Low-Molecular-Weight; Humans

2001
ASA or low-molecular-weight heparin in the initial management of acute ischemic stroke complicating atrial fibrillation?
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Feb-06, Volume: 164, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I

2001
Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat.
    Neuroscience letters, 2001, Apr-20, Volume: 302, Issue:2-3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Astrocytes; Brain; Brain Injur

2001
Acetylsalicylic acid reduces ischemia-induced proliferation of dentate cells in gerbils.
    Neuroreport, 2001, Apr-17, Volume: 12, Issue:5

    Topics: Animals; Antimetabolites; Aspirin; Brain Ischemia; Bromodeoxyuridine; Carotid Artery, Common; Cell D

2001
CURE--clopidogrel's major advance.
    International journal of clinical practice, 2001, Volume: 55, Issue:3

    Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Plate

2001
[Antibodies to phospholipids and ischemic disorders of cerebral circulation in young age].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1997, Volume: 97, Issue:6

    Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antibodies, Antiphospholipid; Anticoagulants; Anti

1997
Neuroprotective effect of aspirin by inhibition of glutamate release after permanent focal cerebral ischaemia in rats.
    Journal of neurochemistry, 2001, Volume: 79, Issue:2

    Topics: Adenosine Triphosphate; Animals; Aspirin; Brain; Brain Ischemia; Cerebral Infarction; Excitatory Ami

2001
The effect of vasodilators on aspirin-induced antagonism of t-PA thrombolysis.
    Neurological research, 2001, Volume: 23, Issue:7

    Topics: Animals; Antihypertensive Agents; Aspirin; Atenolol; Brain Ischemia; Cerebrovascular Circulation; Dr

2001
[High or middle dose tinzaparin versus aspirin for the treatment of cerebral ischemic accident].
    Presse medicale (Paris, France : 1983), 2001, Nov-03, Volume: 30, Issue:32

    Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Tinzaparin

2001
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.
    The New England journal of medicine, 2001, Dec-13, Volume: 345, Issue:24

    Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Echocardiography, Transesophageal; Female; Follow-Up Stu

2001
Inhibition of glutamate release via recovery of ATP levels accounts for a neuroprotective effect of aspirin in rat cortical neurons exposed to oxygen-glucose deprivation.
    Stroke, 2002, Volume: 33, Issue:1

    Topics: Adenosine Triphosphate; Animals; Aspirin; Biological Transport; Brain; Brain Ischemia; Cell Death; C

2002
Oral anticoagulant therapy for the prevention of stroke.
    The New England journal of medicine, 2001, Nov-15, Volume: 345, Issue:20

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Humans; International Normalized Ratio; Platelet Aggregatio

2001
Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation.
    Proceedings of the National Academy of Sciences of the United States of America, 2002, Feb-05, Volume: 99, Issue:3

    Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspirin; Blood Pressure; Brain; Brain Is

2002
Resuscitation from severe hemorrhagic shock after traumatic brain injury using saline, shed blood, or a blood substitute.
    Shock (Augusta, Ga.), 2002, Volume: 17, Issue:3

    Topics: Animals; Aspirin; Blood Substitutes; Blood Transfusion; Brain; Brain Injuries; Brain Ischemia; Carbo

2002
Warfarin or aspirin for recurrent ischemic stroke.
    The New England journal of medicine, 2002, Apr-11, Volume: 346, Issue:15

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Data Interpretation, Statistical; Hemorrhage; Humans; Plate

2002
Warfarin or aspirin for recurrent ischemic stroke.
    The New England journal of medicine, 2002, Apr-11, Volume: 346, Issue:15

    Topics: Anticoagulants; Aorta; Aspirin; Brain Ischemia; Echocardiography, Transesophageal; Humans; Platelet

2002
Warfarin or aspirin for recurrent ischemic stroke.
    The New England journal of medicine, 2002, Apr-11, Volume: 346, Issue:15

    Topics: Administration, Oral; Anticoagulants; Aspirin; Brain Ischemia; Hemorrhage; Humans; International Nor

2002
Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain.
    The Journal of clinical investigation, 2002, Volume: 109, Issue:8

    Topics: Adenosine Triphosphatases; Animals; Antigens, CD; Apyrase; Aspirin; Brain Ischemia; Disease Models,

2002
Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?
    Stroke, 2002, Volume: 33, Issue:6

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Data Interpretation, Statistical; Embolism; Endpoint Determ

2002
[Serotonin content in the thrombocytes and the effect of acetylsalicylic acid on its rate of liberation in ischemic stroke].
    Klinicheskaia meditsina, 1979, Volume: 57, Issue:9

    Topics: Absorption; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Dose-R

1979
Trials of antiplatelet drugs: some methodological considerations.
    Revue d'epidemiologie et de sante publique, 1979, Sep-18, Volume: 27, Issue:2

    Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Drug Therapy, Combination; Fem

1979
Focal cerebral ischemia in rats: effect of hemodilution with alpha-alpha cross-linked hemoglobin on CBF.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 1992, Volume: 12, Issue:6

    Topics: Animals; Aspirin; Brain; Brain Ischemia; Cerebrovascular Circulation; Cross-Linking Reagents; Diseas

1992
[Changes in EEG and higher nervous activity of rats during cerebral anti-ischemic protection by acelysin].
    Biulleten' eksperimental'noi biologii i meditsiny, 1992, Volume: 113, Issue:3

    Topics: Animals; Anti-Infective Agents; Aspirin; Brain; Brain Ischemia; Conditioning, Classical; Drug Combin

1992
Why test antiplatelet therapy in acute ischaemic stroke and how can this be done?
    Postgraduate medical journal, 1992, Volume: 68 Suppl 2

    Topics: Acute Disease; Aspirin; Brain Ischemia; Clinical Trials as Topic; Heparin; Humans; Platelet Aggregat

1992
[Anti-ischemic protection of the brain using water-soluble form of aspirin-acelisin].
    Biulleten' eksperimental'noi biologii i meditsiny, 1992, Volume: 113, Issue:2

    Topics: Animals; Aspirin; Brain Ischemia; Rats; Rats, Inbred Strains; Solubility; Time Factors

1992
Platelet activity and stroke severity.
    Journal of the neurological sciences, 1992, Volume: 108, Issue:1

    Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Calcium; Cardiovascular Agents; Collagen; Disease Su

1992
Cerebral ischemia associated with anticardiolipin antibodies.
    Acta neurologica Scandinavica, 1992, Volume: 85, Issue:6

    Topics: Adult; Aged; Antiphospholipid Syndrome; Aspirin; Autoantibodies; Brain Ischemia; Cardiolipins; Cereb

1992
[Drug treatment of ischemic disturbances of circulation in the brain].
    Duodecim; laaketieteellinen aikakauskirja, 1990, Volume: 106, Issue:20

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Ticlopidine

1990
[Ulcer prevention in therapy with low-dose acetylsalicylic acid?].
    Deutsche medizinische Wochenschrift (1946), 1991, Jun-21, Volume: 116, Issue:25

    Topics: Aspirin; Brain Ischemia; Coronary Disease; Drug Therapy, Combination; Histamine H2 Antagonists; Huma

1991
[Treatment of acute manifestation of hemichorea with aspirin. A case report].
    Acta medica Austriaca, 1991, Volume: 18, Issue:4

    Topics: Aged; Aged, 80 and over; Anesthesia, General; Aspirin; Brain Ischemia; Carotid Stenosis; Chorea; Cor

1991
Effects of triflusal and acetylsalicylic acid on microthrombi formation in experimental brain ischemia.
    Experimental pathology, 1991, Volume: 41, Issue:1

    Topics: Animals; Aspirin; Brain Ischemia; Cerebral Arteries; Intracranial Embolism and Thrombosis; Male; Pla

1991
Spasm of the near reflex associated with cerebrovascular accident.
    Australian and New Zealand journal of ophthalmology, 1990, Volume: 18, Issue:4

    Topics: Accommodation, Ocular; Aged; Aspirin; Atropine; Brain Ischemia; Cerebral Infarction; Diplopia; Femal

1990
Mechanism of stroke in patients taking aspirin.
    Neurology, 1990, Volume: 40, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Infarction; Cerebrovascular Disord

1990
Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum.
    European neurology, 1985, Volume: 24, Issue:4

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Dicumarol; Dipyridamole; Drug Therapy, Combination; Female;

1985
Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia.
    Stroke, 1989, Volume: 20, Issue:12

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Blood P

1989
[The effectiveness of antiplatelet therapy in ischemic cerebrovascular attacks in the chronic stage].
    Ceskoslovenska neurologie a neurochirurgie, 1989, Volume: 52, Issue:5

    Topics: Aspirin; Brain Ischemia; Dipyridamole; Female; Hemiplegia; Humans; Male; Middle Aged; Pentoxifylline

1989
Effect of low dose acetylsalicylic acid upon plasma thromboxane B2 levels and platelet aggregation in ischemic stroke patients.
    Clinica chimica acta; international journal of clinical chemistry, 1989, Oct-16, Volume: 184, Issue:3

    Topics: Adenosine Diphosphate; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Mal

1989
Risk associated with heparin withdrawal in ischaemic cerebrovascular disease.
    Journal of neurology, neurosurgery, and psychiatry, 1989, Volume: 52, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Heparin;

1989
Individually controlled aspirin in the long-term treatment of patients with chronic arterial diseases.
    Angiology, 1989, Volume: 40, Issue:5

    Topics: Adenosine Diphosphate; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease;

1989
[Antiplatelet effects of combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia].
    Rinsho shinkeigaku = Clinical neurology, 1989, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Humans;

1989
Low dose aspirin and its antithrombotic effect in ischaemic stroke patient.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1989, Volume: 72, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Administration Schedule; Female; Human

1989
[Ditazol in the therapy of ischemic cerebrovascular diseases. Clinical results and laboratory experiments (22-to-34-month clinical follow-up)].
    Minerva medica, 1985, Oct-20, Volume: 76, Issue:40

    Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Brain Ischemia; Collagen; Epinephrine; Female; Humans;

1985
[Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months)].
    Minerva medica, 1985, Oct-27, Volume: 76, Issue:41

    Topics: Adenosine Diphosphate; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Isoxsuprine; Male; Oxa

1985
Mitral valve prolapse and thromboembolic disease in pregnancy: a case report.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1988, Volume: 27, Issue:1

    Topics: Adult; Aspirin; Brain Ischemia; Contraceptives, Oral; Dipyridamole; Drug Therapy, Combination; Embol

1988
Whole blood platelet function in acute ischemic stroke. Importance of dense body secretion and effects of antithrombotic agents.
    Stroke, 1989, Volume: 20, Issue:1

    Topics: Acute Disease; Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Dipyridam

1989
[Pharmacological and therapeutic features of cerebral ischemic conditions].
    La Ricerca in clinica e in laboratorio, 1988, Volume: 18 Suppl 2

    Topics: Aspirin; Blood Flow Velocity; Blood Viscosity; Brain Ischemia; Cerebrovascular Circulation; Combined

1988
[Alternating hemiplegia in childhood. Clinical report and single photon emission computed tomography study].
    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1988, Volume: 136, Issue:8

    Topics: Acetazolamide; Aspirin; Brain Ischemia; Cerebral Cortex; Child, Preschool; Chloral Hydrate; Drug The

1988
Effect of acetylsalicylic acid on urinary excretion of prostaglandin E in stroke patients.
    Prostaglandins, 1986, Volume: 32, Issue:6

    Topics: Arginine Vasopressin; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Humans; Inappropria

1986
Validation of cognitive and functional assessment instruments in vascular dementia.
    International journal of psychiatry in medicine, 1987, Volume: 17, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Dementia; Double-Blind Method; Female; Humans; Mal

1987
Comparison of the effect of acetylsalicylic acid on platelet function in male and female patients with ischemic stroke.
    Thrombosis research, 1987, Aug-01, Volume: 47, Issue:3

    Topics: 6-Ketoprostaglandin F1 alpha; Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Brain Ischemia;

1987
[Remote development of transient ischemic attack, reversible ischemic neurologic deficit and infarct with minimum residual damage. Prospective study of 149 patients treated medically].
    Medicina clinica, 1987, Sep-12, Volume: 89, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Infarction; Female

1987
Studies of platelet hyperactivity in patients with ischemic cerebrovascular diseases: IV. Determination of the optimal dosage of aspirin by measuring plasma salicylate level.
    Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association, 1987, Volume: 86, Issue:9

    Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Female; Humans; Male; Middle Aged; Salicylates; Sali

1987
[Extra-intracranial bypass operation. Morphologic studies of the feasibility of intervention and concomitant medication].
    Fortschritte der Medizin, 1986, Apr-30, Volume: 104, Issue:17

    Topics: Adult; Aspirin; Blood Vessel Prosthesis; Brain Ischemia; Cerebral Revascularization; Combined Modali

1986
Effect of incremental doses of aspirin on bleeding time, platelet aggregation and thromboxane production in patients with cerebrovascular disease.
    European journal of clinical investigation, 1985, Volume: 15, Issue:6

    Topics: Adult; Aged; Aspirin; Bleeding Time; Brain Ischemia; Cerebrovascular Disorders; Dose-Response Relati

1985
Peripheral vascular disease: treatment and referral of the elderly. Part II.
    Geriatrics, 1985, Volume: 40, Issue:7

    Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular

1985
[Medical treatment of ischemic cerebrovascular disease].
    Duodecim; laaketieteellinen aikakauskirja, 1985, Volume: 101, Issue:22

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Infarction; Humans; Ischemic Attack, Transient; Pl

1985